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 Stroke is currently the second leading cause of death worldwide. The quest 
for understanding pathophysiological roles of stroke and looking for effective stroke 
treatments remains an urgent priority. I therefore explored a number of novel ways 
that are shown to improve stroke outcome.   
 Previous clinical study showed that stroke patients with poor clinical 
outcome correlated with high plasma cysteine (cys) level. Surprisingly, the similar 
association was not found with any of the excitotoxic neurotransmitter amino acids. 
This association was found to be related to the production of hydrogen sulphide (H2S) 
from cys by the action of cystathionine β-synthase (CBS). In this thesis (Chapter 3), I 
present data demonstrating that high level of H2S is detrimental to cell survival in 
both in vitro and in vivo experiments. In addition, H2S production is increased under 
ischemic conditions through up-regulation and activation of CBS. The inhibition of 
CBS was found to significantly enhance cell survival. Moreover, I demonstrated that 
a novel α-hydrazino acid analogue of cystathionine, a selective CBS inhibitor, 
improved cell survival in neuroblastoma cells and reduced infarct volume in stroke 
animals. It is concluded that CBS inhibition is a viable approach for the treatment of 
acute ischemic stroke.   
 NF-κB signalling activates several pro-inflammatory target genes. 
Andrographolide is a diterpenoid lactone isolated from a traditional medicinal herb 
and found covalently bind to the p50 subunit of the NF-κB, thus selectively inhibit 
NF-κB signalling. In Chapter 4, I present data demonstrating that andrographolide 
can reduce infarct volume by up to approximately 50%, probably through the 
attenuation of microglia and NF-κB activation, therefore reduced tumour necrosis 
factor (TNF)-α, interleukin (IL)-1β and prostaglandin (PG)E2 level in the ischemic 




 Leukotriene B4 (LTB4) is known as a potential chemokine that exerts pro-
inflammatory effects. In Chapter 5, I present data demonstrating that plasma LTB4 
level was found higher in ischemic stroke patients than normal control subjects. 
Moreover, high plasma LTB4 level was found correlated with poor stroke outcome in 
acute ischemic stroke patients. Using a rat thromboembolic stroke model, LTB44 
synthesizing enzymes including 5-lipoxygenase and LTA4 hydrolase were found 
elevated. Administration of LTB4 via intracarotid approach increased infarct volume 
in a rat transient ischemic model. Therefore, pharmacological inhibition of LTB4 
production may be a potential therapeutic approach for the treatment of ischemic 
stroke.    
 MOAP-1 has been identified to be a BAX-associating protein. The role of 
MOAP-1 in promoting caspase-dependent cell death has been studied by the 
molecular biology approach. Therefore, the in vivo physiological role of MOAP-1 is 
not understood. In Chapter 6, I present data demonstrating a potential role of MOAP-
1 in ischemic injury using MOAP-1
 
knockout mice. The present results suggested that 
MOAP-1 knockout animals showed smaller infarct volume and better functional 
outcome than wild type animals. These results were consistent with the in vitro stroke 
experiments using primary neuronal culture and genetic modified SH-SY5Y cells. In 
conclusion, both our in vitro and in vivo data demonstrated that MOAP-1 is an 










LIST OF TABLES 
 
Table 1.1. Summary of potential pharmcotherapy for acute ischemic stroke 
treatment in preclinical and clinical studies ...................................... 33 
Table 3.1.  H2S neurotoxic and neuroprotective effects in in vitro and in vivo 
studies ............................................................................................... 70 
Table 4.1.  Neurological score of andrographolide treated rats ........................ 128 
Table 4.2. OX-42 positive staining semi-quantification. ................................. 130 
Table 4.3. ED-1 positive staining semi-quantification .................................... 132 
Table 5.1.  Coronary risk factors, stroke subtypes, recanalization status at  
 24 h, modified ranking scale (MRS) and general profiles of  



















LIST OF FIGURES 
 
Figure 2.1. Rat tMCAO model with 100 min occlusion and 22 h 20 min 
reperfusion ........................................................................................ 41 
Figure 2.2.  Rat thromboembolic model .............................................................. 42 
Figure 2.3.  Mice tMCAO model ......................................................................... 44 
Figure 2.4. Measurement of infarct volume ........................................................ 46 
Figure 3.2.  Cellular localization of CBS in the rat cerebral cortex ..................... 77 
Figure 3.3.  Time course for CBS protein expression after pMCAO ................... 79 
Figure 3.4.  Immunofluorescent staining for CBS after pMCAO ........................ 80 
Figure 3.5. Effects of OGD on CBS expreeion in primary cultures of cortical 
astrocytes .......................................................................................... 81 
Figure 3.6. HPLC measurement for cys and hyc level in stroke patient serum 
samples ............................................................................................. 82 
Figure 3.7. HPLC measurement for cys and hcy level in pMCAO and tMCAO 
rat plasma samples ............................................................................ 83 
Figure 3.8. CBS-overexpressing (CBSOE) SH-SY5Y cells ............................... 84 
Figure 3.9. The effects of OGD on cell viability and LDH release SH-SY5Y 
CBSOE cells under normal, low and high substrate conditions ....... 86 
Figure 3.10. Comparison of endogenous and exogenous H2S effect in primary 
astrocytes .......................................................................................... 87 
Figure 3.11. Dose dependent effects of various cys and hcy concentrations on 
SHSY5Y CBSOE cells in 6OHDA, rotenone and OGD induced  
 cell death ........................................................................................... 90 
Figure 3.12. ROS production after OGD, rotenone and 6-OHDA insults under 
vehicle or high substrates condition .................................................. 91 
Figure 3.13. Inhibition of mitochondria complex III and SH-SY5Y CBSOE  
XVIII 
 
  cell viability in high substrates conditioned medium after  
  reoxygenation.................................................................................... 92 
Figure 3.14.  Design of L,L-cystathionine analogues ............................................ 94 
Figure 3.15. Inhibition of cystathioinine analogues against CBS using radioactive 
assay .................................................................................................. 95 
Figure 3.16. Saturated α-hydrazino acid cystathionine analogue inhibited CBS 
enzyme activity in ex vivo and in vitro assay .................................... 96 
Figure 3.17.  Administration of saturated α-hydrazino acid analogue into tMCAO 
rats ..................................................................................................... 97 
Figure 3.18.  OX-42 and ED-1 expression after saturated α-hydrazino acid 
analogue treatment. ........................................................................... 98 
Figure 3.19. Inhibitory efficacy of GABA transaminase activity by AOAA or 
saturated α-hydrazino acid analogue. .............................................. 100 
Figure 3.20. Post-treatment of saturated α-hydrazino acid analogue in tMCAO  
 rats. .................................................................................................. 101 
Figure 3.21.  Saturated α-hydrazino acid analogue inhibition on CSE. ............... 102 
Figure 3.22 Proposed mechanism of action and outcome that H2S plays a  
 role as an electron donor during aerobic and anaerobic condition . 109 
Figure 4.1 Chemical structure of andrograhpolide ........................................... 116 
Figure 4.3.  Time course effect of andrographolide on primary astrocyte cell 
survival against H2O2 induced oxidative stress ............................... 123 
Figure 4.4. Dose dependent effect of andrographolide against H2O2 induced 
oxidative stress on primary astrocytes. ........................................... 124 
Figure 4.5. GSH content in primary astrocyte cultures when treated with 
andrographolide against 0.2 mM H2O2 induced oxidative stress. ... 125 
Figure 4.6.  Andrographolide effect against H2O2 induced ROS production. .... 125 
Figure 4.7.  Andrographolide effect on SH-SY5Y human neuroblastoma cells 
against sodium dithionite induced oxygen deprivation................... 126 
XIX 
 
Figure 4.8. Andrographolide effect to pMCAO stroke rats. ............................. 127 
Figure 4.9. Immunohistochemistry staining of OX-42 in pMCAO rats  
 peri-infarct cortex.. ......................................................................... 129 
Figure 4.10.  Immunohistochemistry staining of ED-1 in pMCAO rats  
 peri-infarct cortex ........................................................................... 131 
Figure 4.11.  Andrographolide at 0.1 mg/kg 1 h post-stroke treatment reduced  
 the elevation of IL-1β in pMCAO ipsilateral hemisphere .............. 133 
Figure 4.12. Andrographolide at 0.1 mg/kg 1 h post-stroke treatment reduced  
 the elevation of TNF-α in pMCAO ipsilateral hemisphere ............ 133 
Figure 4.13. Andrographolide at 0.1 mg/kg 1 h post-stroke treatment reduced  
 the elevation of PGE2 in pMCAO ipsilateral hemisphere.. ............. 134 
Figure 4.14.  Andrographolide at 0.1 mg/kg 1 h post-stroke treatment inhibited  
 p65 subunit translocation to nucleus.. ............................................. 135 
Figure 5.2.  Stroke patient LTB4 level before and after tPA treatment and 
correlation of LTB4 level to MRS score ......................................... 149 
Figure 5.3. Time course and expression of cortical 5-LO, ED-1, OX-42 and 
GFAP after thromboembolic stroke ................................................ 150 
Figure 5.4. Time course and expression of striatal 5-LO, ED-1, OX-42 and 
GFAP  after thromboembolic stroke ............................................... 151 
Figure 5.5.  Immunofluorescence staining of 5-LO and LTA4 hydrolase after 
thromboembolic stroke ................................................................... 152 
Figure 5.6.  Immunofluorescence double staining for 5-LO, LTA4 hydrolase  
 or MPO in ipsilateral cortex or striatum at 24 h thromboembolic 
stroke.  ............................................................................................. 153 
Figure 5.7. Plasma and cortical LTB4 level after thromboembolic stroke.  ...... 154 
Figure 5.8. Administration of LTB4 in tMCAO model. .................................... 155 
Figure 6.3.  MOAP-1, RASSF-1A, Trim39, TNF-R1 and Bax expression  
 in the mouse brain. .......................................................................... 170 
XX 
 
Figure 6.4.  Immunofluorescent staining of MOAP-1 in mouse brain. .............. 171 
Figure 6.5. MOAP-1 overexpressed SH-SY5Y and cell viability under OGD 
condition. ........................................................................................ 172 
Figure 6.6. Wild type and MOAP-1 KO primary cortical neurons subjected to 
OGD condition ................................................................................ 174 
Figure 6.7.  Infarct volume and time spent on rotarod of wild type WT and 
MOAP-1 KO tMCAO mice ............................................................ 175 
Figure 6.8.  Protein expression of RASSF-1A, Trim39, TNFR-1 and Bax in 
MOAP-1 KO mice cerebral cortex ................................................. 177 
Figure 6.9. TNF-α, MOAP-1, Trim39, RASSF-1A, Bax, NeuN protein level  
  after tMCAO  in both wild type and MOAP-1 KO C57BL/6 mice  
  cerebral cortex................................................................................. 178 


















LIST OF ILLUSTRATIONS 
 
Figure 1.1. Type of stroke ..................................................................................... 2 
Figure 1.2. Atherosclerotic plaque development................................................... 6 
Figure 1.3.  Schematic diagram of extrinsic and intrinsic coagulation systems ..... 7 
Figure 1.4. Summary of the impact of damage caused ischemic pathological 
events following times ...................................................................... 11 
Figure 1.5. Cascade of ischemic injury ............................................................... 24 
Figure 3.1.  Endogenous source of H2S................................................................ 64 
Figure 4.2. Canonical NF-κB signaling pathway .............................................. 117 
Figure 5.1.   Leukotriene biosynthesis ................................................................ 140 
Figure 6.1.  MOAP-1 and its binding domains .................................................. 162 













LIST OF ABBREVIATION 
·OH Hydroxyl free radical 
12-HETE 12-hydroperoxyeiocosatetraenoic acid  
12-oxo-LTB4 12-oxo leukotriene B4 
15-HETE 15-hydroperoxyeiocosatetraenoic acid  
20-oxo-LTB4 20-oxo leukotriene B4 
3-MP 3-mercaptopyruvate  
3MST 3-mercaptopyruvate sulfurtransferase 
5-HPETE 5-hydroperoxy-eiocosatetraenoic acid  
5-LO 5-lipoxygenase  
5-methylTHF 5-methyletetrahydrofolate  
6-OHDA 6-hydroxydopamine  
AA Arachidonic acid  
AAASPS African American Antiplatelet Stroke Study 
ADP Adenosine diphosphate  
ADT 5-(4-methoxyphenyl)-3H-1, 2-dithiole-3-thione  
AIF Apoptosis-inducing factor  
ALIAS Albumin in Acute Stroke 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AOAA  Aminooxyacetic acid  
APC/C
dh1
 Anaphase-promoting complex  
APOE
-/-
 Apolipoprotein E knockout  
APP Amyloid precursor protein  
ASA Acetylsalicylic acid  
ATP Adenosine triphosphate 
Aβ β-amyloid  
BLT1 receptor LTB4 receptor type I  
BLT2 receptor LTB4 receptor type II 
CAD Caspase-activated deoxyribonuclease  
CAPRIE Clopidogrel versus Aspirn in Patients at Risk of Ischaemic Event 
CAT Cysteine aminotransferase 
CAT Catalase 
CATS Canadian American Ticlopidine Study  
CBS Cystathionine β-synthase 
CCA  Common carotid artery  
CCL Chemokine ligand 2  
CHO Chinese hamster ovary cells  
CNS Central nervous system  
COX Cyclooxygenase  
cPLA2 Cytosolic phospholipase A2  
CSE Cystathionine γ-lyase  
CSF Cerebrospinal fluid  
CXCL8 Chemokines like CXC ligand 8  
Cys  Cysteine  
XXIII 
 
CysLT Cysteinyl or peptidyl leukotrienes  
DD Death domain  
DED Death effector domain  
DIAS Desmoteplase in Acute Ischemic Stroke trial 
DISC Death inducing signalling complex  
DTT Dithiotreitol 
ECA Dxternal carotid artery  
ECCS-AIS Edaravone citicoline comparative study in acute ischemic stroke  
ES Embryonic stem  
FAST-MAG Field Administration of Stroke Therapy-Magnesium  
FBS Fetal bovine serum  
FLAP 5-LO activating protein  
GFAP Glial fibrillary acidic protein  
GPx Glutathione peroxidase 
GSH Glutathione 
H2O2 Hydrogen peroxide  
H2S Hydrogen sulfide  
HA Hydroxylamine 
HBSS Hank's blank salt solution  
Hcy Homocysteine  
HEK 293 Human embryonic kidney 293  
HMG-CoA Hydroxymethylglutaryl-cenzyme A  
HS
-
 Hydrosulfide anion  
i.c.v. Intracerebroventricular 
i.p.  Intraperitoneal  
ICA  Internal carotid artery  
ICAD Inhibitor of caspase-activated DNase 
ICAM-1 Intercellular adhesion molecule-1 








IL-2 Interleukin-2   
IL-5 Interleukin-5  
IL-6 Interleukin-6 
IL-8 Interleukin-8 
iNOS Inducible nitric oxide synthase  
IP-10 IFN-γ-inducible protein-10  
KATP Adenosine triphosphate-sensitive potassium  
LDH Lactate dehydrogenase 
LDL Low-density lipoprotein  




LTA4 Leukotriene A4 
LTA4H LTA4 hydrolase  
LTB4 Leukotriene B4 
LTC4 Leukotriene C4 
LTCS4 LTC4 synthase  
LTD4 Leukotriene D4 
LTE4 Leukotriene E4 
LTs Leukotrienes  
Mac-1 Macrophage-1 antigen  
MAdCAM-1 Mucosal vascular addressing cell adhesion molecule 1  
MCP-1 Monocyte chemoattractant protein-1  
MEFs Murine embryonic fibroblasts 
MHCII Major histocompatibility complex class II 
MI Myocardiac infarction  
MINOS Minocyclin to Improve Neurological Outcome in Stroke  
MIP-1α Macrophage inflammatory protein-1 α  
MMP-9 Matrix metalloproteinase-9 
MOAP-1 Modulator of apoptosis 1  
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MPTP Mitochondrial permeability transition pore  
MTHFR Methylene-tetrahydrofolate reductase  
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide  
Na2S Sodium sulfide  
NADPH Nicotinamide adenine dinucleotide phosphate  
NaHS Sodium hydrosulfide  
NeuMAST Neuroprotection with Minocycline Therapy for Acute Stroke 
Recovery Trial  
NeuSTART Neuroprotection with Statin Therapy for Acute Recovery Trial  
NF-κB Nuclear factor kappa-B  
NINDS National Institute of Neurological Disorders and Stroke 
NMDA N-methyl-D-aspartate 
NO Nitric oxide  
NOS Nitric oxide synthase  
NOX Nicotinamide adenine dinucleotide phosphate oxidase 
O2·
-
 Superoxide radical anion  





PARP Poly(ADP-ribose) polymerase 
PD Parkinson's disease  
PECAM  Platelet endothelial cell adhesion molecule-1  
PLP Pyridoxal 5'-phosphate  
PMNs Polymorphonuclear neutrophils  











RNAi  RNA interference  
ROS  Reactive oxygen species 
rtPA Recombinant tissue plasminogen activator 
S
2-
 Sulfur anion  
SAH Subarachnoid hemorrhage  
SAINT Stroke–Acute Ischemic NXY Treatment  
SAM S-adenosyl-L-methionine  
SBD-F 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonic acid ammounium  
SMC Smooth muscle cells  
SN Substatia nigra  
SNP Single nuclear polymorphism  
SOD Superoxide dismutase 
SQR Succinate-coenzyme Q reductase  
STAT Stroke Treatment with Ancrod Trial  
TASS Ticlopidine Aspirin Stroke Study  
TCA Trichloroacetic acid  
TCEP Tris(2-carboxyethyl)phosphine  
TGF-β Transforming growth factor - β  
tMCAO  Transient middle cerebral artery occlusion   
TNFR1 Tumor necrosis factor-α receptor 1  
TNF-α Tumor necrosis factor-α  
TTC Triphenyltetrazolium chloride  
TWEAK Tumor necrosis factor like weak inducer of apoptosis  
UCP2 Uncoupling protein 2  
VCAM-1 Vascular cell adhesion molecule-1 
VCAM-1 vascular cell adhesion molecule-1 
vitamin C Ascorbic acid  
vitamin C ascorbic acid  
vitamin E α-tocophenol  
vitamin E α-tocophenol  
WARSS Warfarin Aspirin Recurrent Stroke Study  
WARSS Warfarin Aspirin Recurrent Stroke Study  




LIST OF PUBLICATION AND AWARDS 
 
Research article  
 
1) Chan SJ, Chai C, Lim Tw, Yamamoto M, Lo EH, Lai MKP, Wong PTH. 
(2015) Cystathioine β-synthase inhibition is a potential therapeutic approach 
to treatment of acute stroke. ASN Neuro, 7(2)  
2) Chan SJ, Wong WSF, Wong PTH and Bian JS (2010). Neuroprotective 
effects of andrograhpolide in a rat model of permanent cerebral ischemia. 
British Journal of Pharmacology, 161(3) 
3) Zhao H, Chan SJ, Ng YK, Wong PTH (2013). Brain 3 mercaptopyruvate 
sulfurtransferase (3MST): Cellular localization and downregulation after 
acute stroke. Plos one, 3(6) 
4) Wong SY, Chan SJ, Wong WSF, Wong PTH and Lai MKP (2014).  
Andrograhpolide attenuates interleukin-1β-stimulated upregulation of 
chemokine CCL5 and glial fibrillary acidic protein in astrocytes. 
Neuroreport, 25(12) 
5) Li K, Yamamoto M, Chan SJ, Chaim MY, Qin W, Wong PTH, Yim EKFY, 
Tang BZ and Liu Bin (2014). Organic dots with aggregation-induced 
emission for tracking bone marrow stromal cell in the rat ischemic stroke 










1) S. J. Chan, J. Huang, C. Chai, V. C. K. Yu, P. T. H. Wong, 2014, The role of 
modulator of apoptosis (MOAP-1) in acute ischemic stroke, Journal of 
neurochemistry/ 12th Biennial Meeting of the Asian-Pacific Society for 
Neurochemistry, 130 (Suppl. 1) 
2) S. J. Chan, T. W. Lim, C. Chai, S. Q. Koh, M. Yamamoto, M. K. P. Lai, P. 
T. H. Wong, 2014, Is cystathionine beta synthase a viable therapeutic target 
for acute ischemic stroke?, Journal of neurochemistry/ 12th Biennial Meeting 
of the Asian-Pacific Society for Neurochemistry, 130 (Suppl. 1) 
3) S. J. Chan, M. P. Ng, P. T. H. Wong, R. C. Seet, 2014, The roles of 5-
lipoxyoxygenase and leukotriene B4 in the pathology of ischemic stroke, 
Journal of neurochemistry/ 12th Biennial Meeting of the Asian-Pacific 
Society for Neurochemistry, 130 (Suppl. 1) 
4) S. J. Chan, C. Chai, H. Kimura, M. K. P. Lai, P. T. H. Wong, 2014, 
Cystathionine beta-synthase overexpression decreased cell survival after 
oxygen glucose deprivation, ournal of neurochemistry/ The 11th Biennial 
Meeting of the Asian-Pacific Society for Neurochemistry / 55th Annual 
Meeting of the Japanese Society for Neurochemistry, 123 (Suppl. 1) 
5) H. Zhao, S. J. Chan, M. Yamamoto, M. Lai, P. T. H. Wong, 2014, 
Expression of hydrogen sulfide producing enzymes in the ischemic brain, 
ournal of neurochemistry/ The 11th Biennial Meeting of the Asian-Pacific 
Society for Neurochemistry / 55th Annual Meeting of the Japanese Society 






Oral presentation  
1) S. J. Chan, M. P. Ng, P. T. H. Wong, R. C. Seet, 2014, The roles of 5-
lipoxyoxygenase and leukotriene B4 in the pathology of ischemic stroke, 
Asian-Pacific Society for Neurochemistry 2014, Kaohsiung, Taiwan 
 
Awards  
1) Gold award for oral presentation award competition, Asian-Pacific Society 
for Neurochemistry (APSN) 2014, Kaohsiung, Taiwan 
2) Silver award for Tokuji Ikenaka Price for the best poster presentation, Asian 
Pacific Society for Neurochemistry (APSN) 2014, Kaohsiung, Taiwan 
3) Postgraduate student travel award for 12
th
 Meeting of the Asian-Pacific 
Society for Neurochemistry (APSN) conference 2014 
4) Student grant for participating 1
st
 Human Brain Project (HBP) summer school 
2014, Alpbach, Austria  
5) Student grant for participating ISN-APSN Advanced School 2014,  
Kaohsiung, Taiwan 
6) Student grant for participating ISN-APSN Advanced Neuroscience  2013, 
Singapore 










Chapter 1: Introduction  
1.1. Stroke incident  
 Stroke is the second leading cause of death and is known as the major leading 
cause of disability worldwide (Kim et al., 2013). In every year, estimate 795,000 
people experience a new or recurrent stroke. Among all, approximately 610,000 are 
first attack and 185,000 are recurrent attack (Go et al., 2014; Kochanek et al., 2011). 
Stroke remains an epidemic. On average, stroke occurs at every 40 seconds in United 
States. Moreover, someone will die of a stroke in every 4 min (Go et al., 2014). 
Economically, it remains one of the major burdens worldwide. Approximately $36.5 
billion was spent on stroke related treatment in 2010 (Go et al., 2014). With the 
increasing age of the population worldwide, the incidence of stroke is predicted to 
grow. The most common type of stroke is atherothrombotic brain infarction, which 
accounts for 61% of all strokes while embolic stroke accounts for 22%. Among all 
the stroke incidents, 87% are ischemic, 10% are intracerebral hemorrhagic strokes 
and 3% are subarachnoid haemorrhage stroke (Go et al., 2014). Women have higher 
stroke prevalence than men. According to GCNKSS and NINDS, estimate around 
55,000 more women have a stroke than men each year. More precisely, women have 
a higher lifetime risk of stroke but lower age-adjusted stroke incidence. Age-adjusted 
stroke incidence percentage differs among ethnicity, for instants white males accounts 
for 2.4%, white females accounts for 3.3%, black males accounts for 4.5% and 4.4% 
for black female, 2% for Asian, 5.9% for American Indian/Alaska native. Blacks, has 
38% greater risk of stroke incident than whites based on the Heart and Stroke 
Statistical Update (Go et al., 2014). The prevalence of stroke in Singapore is 
estimated at 4.1%, higher compared with published global stroke rate of 3.65% by the 
World Health Organization (Venketasubramanian et al., 2005). This looming 
epidemic of stroke in Singapore is concurrent with the increasing population 
prevalence of cigarette smoking, hypertension, hyperlipidaemia, physical inactivity 
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and diabetes mellitus, as well as an increasing average age of the global population. 
Genetic factors alone less likely contribute to the cause (Venketasubramanian et al., 
2005).  
1.2. Classification of stroke 
 Stroke can be classified into ischemic and haemorrhagic stroke. Ischemic 
stroke is characterized by low blood supply to a region of the brain while 
haemorrhagic stroke is characterized by blood accumulation within the closed cranial 
cavity (Caplan, 1989).  
 
Figure 1.1. Type of stroke. Ischemic stroke occurs when blood clot stops the 
cerebral blood flow to an area of the brain; whereas hemorrhagic stroke occurs when 
rupture of the blood vessels occurs and blood leaks into cranial cavity. Figure adapted 
from: Heart and Stroke Foundation. (2008).  
 
1.2.1. Ischemic stroke  
 Brain ischemia can be further classified into three main types, the 
thrombotic stroke, embolic stroke, or systemic hypoperfusion. Local in situ 
obstruction of artery leads to thrombotic stroke. Generally, thrombolytic stroke 
occurs due to arteriosclerosis. Nevertheless, embolic stroke is caused by blood clot 
dislodges from original site and travels to certain brain region, therefore leads to in 
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situ obstruction of an artery. Finally, circulatory problem leads to systemic 
hypoperfusion (Hafstrom et al., 1981).  
1.2.1.1. Thrombotic stroke and atherosclerosis 
 Thrombotic stroke can be classified as large and small vessels diseases. Large 
vessel thrombotic stroke occurs when blood clot forms in extracranial (common and 
internal carotid arteries) or intracranial arterial system (circle of Willis and branches). 
Small vessel thrombotic stroke occurs when blood clot forms at intracerebral arterial 
system that specifically arise from the distal vertebral artery, the basilar artery, the 
middle cerebral artery (MCA) stem and the arteries of the circle of Willis (Ay et al., 
2005).  
 Atherosclerosis is the most common pathological features for ischemic 
stroke. The pathogenesis of atherosclerosis is summarized in Figure 1.2. The disease 
mechanisms elicited by low-density lipoprotein (LDL), normally in combination with 
risk factors such as cigarette smoking, hypertension and diabetes mellitus (Bentzon et 
al., 2014). LDLs accumulate in the arterial intima and further modified by oxidation 
and aggregation. This modification stimulates innate and adaptive immune response 
and further induces smooth muscle cells or endothelial cells to express adhesion 
molecules, for instance intercellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1) and chemoattractants (Steinberg et al., 2010). The 
increase expression of adhesion molecules, chemoattractants and growth factors 
therefore interact with receptors on monocytes and eventually stimulate their homing, 
migration and differentiation into macrophages and dendritic cells (Subramanian et 
al., 2014). The recruited macrophages secrete pro-inflammatory cytokines such as 
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) and reactive oxygen 
species (ROS) that further modified LDLs as well as other mediators such as 
plasminogen activators, cathepsins, and matrix metalloproteinases (MMPs) (Stoger et 
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al., 2012; Tabas, 2010). MMPs degrade sub-endothelial basement membrane and 
hence further promote the loss of endothelium (Rajavashisth et al., 1999). The 
adaptive immune system recognizes the modified LDL and recruits immune cells 
including T helper 1 cells and possibly B cells. Immune cells secrete pro-
inflammatory cytokines that accentuate vascular inflammation (Hansson et al., 2009). 
The monocytes invade and cross the blood vessel into the intima. Monocytes 
eventually proliferate and differentiate into macrophages. Form cells are formed 
when macrophages take up the lipoproteins. Cells die with time and the isolated lipid 
pools will grow into confluent necrotic cores (Lusis, 2000). Neovessels are then 
formed and this provides an alternative entry for monocytes and immune cells. The 
plaque neovessels are fragile and leaky. Local plasma protein and erythrocytes invade 
the leaky neovessels, thereby causes inter plaque bleeding, expands necrotic core and 
enhances inflammation (Bentzon et al., 2014). Furthermore, the rupture of thin 
fibrous cap is a common source of plaque haemorrhage. Rupture frequently occurs at 
lesion edge that contains smooth muscle cells (SMCs). Ruptured caps are usually 
heavily infiltrated by foam cells which secrete proteolytic enzymes such as MMPs 
and further potentiate degradation of extracellular matrix (Lusis, 2000). In order to 
heal the rupture site, repaired collagen (type III) mediates thrombus organization and 
hence increases plaque volume that contributes to the progression of 
atherothrombosis (Bentzon et al., 2014). Atherosclerotic plaques and vascular 
stenosis result in the reduction of distal blood flow. Reduced of blood flow enhances 
the formation of thrombi therefore often causes embolization. It is formed in situ 
when the body's coagulation system is activated. Prothrombin can be activated by 
extrinsic and intrinsic system of coagulation (Figure 1.3). Extrinsic system of 
coagulation is tissue or endothelial injury released tissue factors that cause both 
platelet activation and activation of the blood serine protease coagulation factors 
(such as factor V and VII). Tissue factor forms a complex with factor VIIa and such 
complex converts intrinsic factor X to Xa. Factor Xa activates the prothrombinase 
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complex (composed of factor Va, Ca++ and phospholipids) and therefore catalyzes the 
conversation of prothrombin to form thrombin. Intrinsic factor X is formed when 
factor XII is activated. This triggers the coagulation cascade, in which a series of 
blood-clotting factors are subsequently activates factor X. The final step of 
coagulation process is the conversion of fibrinogen to insoluble polymers, namely 
fibrin, by thrombin. The fibrin form a network of fibres that entangled platelets and 
erythrocytes and form clot. As such, the amount of circulating fibrinogen and 
prothrombin pose an important role in clot formation. In addition to sudden growth of 
thrombus, thus further creates stenosis and thrombotic occlusion at the injury site 











Figure 1.2. Atherosclerotic plaque development. (A) Normal artery is formed by a 
monolayer of endothelial cells. (B). Atherosclerosis progression is elicited when low-
density lipoprotein (LDL) accumulates in the arterial intima, further modified by 
oxidation and aggregation. (C). Next, the adaptive immune response is stimulated and 
induces endothelial cells and smooth muscle cells to express adhesion molecules 
(VCAM-1, ICAM-1 and selectins). (D). The increase expression of adhesion 
molecules stimulates the homing and migration of monocytes and dendritic cells. 
Monocytes differentiate into macrophages and uptake lipids yielding foam cells. 
Smooth muscle cells (SMC) migrate, proliferate and synthesize extracellular matrix 
proteins such as collagen and elastin. (E). Matrix metalloproteinases (MMPs) degrade 
sub-endothelial basement components. Macrophages/SMCs die and lipid derived 
from the dead cells accumulates in the plaque and forms necrotic core that is covered 
by fibrous cap. (F). Fibrous cap is ruptured and causes blood coagulant and tissue 
factors release thereby trigger thrombus formation. Figure adapted from Orbay et al. 





Figure 1.3. Schematic diagram of extrinsic and intrinsic coagulation systems. 
Figure re-adapted from Orbay (Orbay et al., 2013). 
1.2.1.2. Embolism  
 Embolic strokes can be categorised as: (1). Cardiac as the known source; (2). 
A possible cardiac or aortic source based on transthoracic and/or transesophageal 
echocardiographic findings; (3). Arterial as the known source; (4). Unknown source 
in which tests for embolic sources are negative (Caplan, 1993). Understanding the 
source of the composition of the embolus is crucial to determine the treatment for 
patients (Caplan, 2002). The onset of embolic stroke is usually precipitous and as 
maximal at the start, that infers the dissimilarity to thrombolysis. Secondly, embolism 
forms in multiple site within different vascular territories and the main source arises 
from left ventricular thrombus or left atrial appendage (Caplan, 1993). The symptoms 
can be present with stuttering and fluctuating symptoms. This could be due to the 
clearance of embolic caused by thrombolysis or migration to other parts. Such 
syndrome normally clears within 24 h after stroke. Silent infarction would occur in 
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this case and the area of infarction is relatively smaller thus give rise to the symptoms 
(Flemming et al., 2004). This process is regarded as transient ischemic attack due to 
embolism.  
1.2.1.3. Systemic hypoperfusion 
 Systemic hypoperfusion is defined as global reduce of blood flow. It can be 
caused by cardiac pump failure due to cardiac arrest or arrhythmia, pulmonary 
embolism, acute myocardial ischemia, pericardial effusion or bleeding. The 
symptoms of systemic hypoperfusion is varied from thrombosis and embolism, 
whereby most affected patients have the evidence of circulatory compromise and 
hypotension such as pallor, sweating, tachycardia, severe bradycardia and low blood 
pressure. Since the brain suffers from global reduction of blood flow, the neurologic 
signs are typically bilateral. Despite, occasional asymmetric neurologic signs are 
present due to the pre-existing asymmetrical craniocerebral vascular occlusive disease 
(Caplan, 2002).  
1.2.2. Haemorrhagic stroke  
 Brain haemorrhage is sub-classified into intracerebral haemorrhage (ICH) 
or subarachnoid haemorrhage (SAH). ICH is defined as direct bleeding into the 
brain parenchyma with formation of a focal haematoma (Caplan, 1992); while SAH is 
defined as bleeding into the cerebrospinal fluid within the subarachnoid space 
surrounding the brain (Caplan, 1992).  
1.2.2.1. Intracerebral haemorrhage (ICH) 
 ICH accounts for 10% of all strokes. Etiology study showed that ICH is more 
common among Chinese and Japanese ancestry and American blacks (Caplan, 1992). 
Commonly, bleeding from capillaries, arterioles or small arteries attributes to ICH 
(Caplan, 1992). Different from SAH, the bleeding is found directly in the brain and 
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forms a localized hematoma. The accumulation of blood occurs over a short period of 
time, normally in min or hours (hs), eventually spreading into the cerebrospinal fluid 
(CSF) in the ventricular system or once the build-up pressure fails in containment 
(Fisher, 1971). The cause of ICH was mainly due to vascular malformations, 
traumatic haematomas (trauma), bleeding diathesis and amyloid angiopathy (Fisher, 
1971). Chronic hypertension may lead to the damage and rupture of arteries thereby 
causes ICH. However, half of the patients with spontaneous ICH do not have history 
of hypertension. Moreover, cases that associate with acute rises in blood pressure or 
cranial blood flow are most often related to amphetamines, cocaine, exposure to 
extreme cold, trigeminal nerve stimulation, post carotid endarterectomy, post heart 
lesion or transplantation (Caplan et al., 1992). The neurological symptoms of ICH, 
compare with embolism and SAH, normally begin slowly and are not maximal at 
onset. The symptoms normally increase gradually over min or few hours. Normally, 
symptoms begin with headache, vomiting and a decreased level of consciousness and 
develop into life-threatening phase when the hematoma enlarges. The increase of 
pressure and edema formation is normally caused by the accumulation of blood. 
These increase the chance of mortality and morbidity (Fisher, 1971). 
1.2.2.2. Subarachnoid haemorrhage (SAH) 
 SAH accounts for only 5% of stroke (van Gijn et al., 2007). Epidemiology 
study reports that incidence of SAH is higher in Finland and Japan at around 20 per 
100,000 person per years (Linn et al., 1996). Most of the SAH occurs in young 
patients (2000). Around 85% of the SAH are caused by the ruptured aneurysm; 
whereas 10% are caused by non-aneurysmal peri-mesencephalic haemorrhage. The 
remaining 5% are caused by uncommon factors including tumours, cocaine abuse, 
anticoagulant drugs, sickle cell diseases, inflammatory lesions of cerebral arteries, 
spinal cord vascular lesions and non-inflammatory intracerebral lesions (Linn et al., 
1996). The risk factors SAH are hypertension, cigarette smoking, alcoholism, and 
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genetic factors. Nonetheless, genetic factors are relatively rare (Feigin et al., 2005; 
Ruigrok et al., 2001). The pathogenesis is characterized by the rupture of the 
aneurysm, leaks into the CSF, spreads in CSF and eventually causes the increase of 
intracranial pressure. Continuous bleeding is fatal or causes deep coma. In contrast, in 
non-aneurysmal cases, bleeding may continue over a period of time (Linn et al., 
1996). SAH is featured clinically by a sudden headache. The headache that is caused 
by SAH is generally diffuse and extreme suffering. It normally lasts up to 1 or 2 
weeks, or even longer. Vomiting is usually occurs spontaneously after the onset of 
stroke (Linn et al., 1996).  
1.3. Ischemic cascade  
 Brain has the highest consumption of energy than other organs. During the 
event of stroke, oxygen, glucose and energetic required for ionic gradients 
homeostasis are reduced (Martin et al., 1994). Ischemic brain injury arises from a 
multimodal cascade of pathological events that evolve over time and space (Dirnagl 
et al., 1999b). The ischemic cascades subsequently cause the reduction of adenosine 
triphosphate (ATP), glutamate release and excitotoxicity, free radicals generation 
from mitochondria, inflammatory components stimulation, damage of lipid 
membrane sand finally trigger both necrotic and apoptotic cell death (Dirnagl et al., 






Figure 1.4. Summary of the impact of damage caused ischemic pathological 
events following times. The onset of ischemic stroke triggers excitotoxicity in the 
very early phase and facilitates the following cell death events including peri-infarct 
depolarization, inflammatory response and finally apoptosis. X axis illustrates the 
period of the event and y axis illustrates the impact of the each elements on the final 
outcome. Figure re-adapted from Dirnagl et al. (Dirnagl et al., 1999). 
 
1.3.1. Excitotoxicity  
 Failure in blood supply cuts off the energetic supply particularly oxygen and 
glucose to the brain hence impairs the physiological homeostasis of ionic gradients. 
For instance, it causes the loss of membrane potential and depolarisation of neurons 
and glia. Subsequently, the voltage dependent and receptor dependent calcium 
channels are activated and amino acids including glutamate are released into the 
extracellular space (Dirnagl et al., 1999a). The increase of extracellular glutamate 
activates ionotropic N-methyl-D-aspartate (NMDA) receptor and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, thus promotes Ca2+ 
and Na+ influx. The excessive Ca2+ influx activates the downstream phospholipases, 
proteases, and endonucleases that function to degrade cell membrane and proteins, 
enhances mitochondrial Ca2+ overload and impair ATP production (Nakka et al., 
2008). Furthermore, Ca2+ overload leads to positively feedback mechanism that 
promotes the increase of glutamate in extracellular space and leads to excitotoxicity. 
Moreover, the increase of Na+ influx aggravates cell swelling and edema (Dirnagl et 
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al., 1999a). Excitotoxicity is an executioner that facilitates tissue damage during 
cerebral ischemia. It triggers intracellular signalling pathways, promotes the pro-
inflammatory gene expression, programme cell death apoptosis and acute cell death 
necrosis (Dirnagl et al., 1999a). Therefore, inhibition of excitotoxicity is crucial and 
prime strategies to alleviate stroke treatment.  
1.3.2. Free radicals generation  
 Brain tissue has high lipid contents. As such, it is relatively more susceptible 
to free radical damage than other organs in the body. Cerebral ischemia and cerebral 
reperfusion stimulate the generation of ROS. ROS includes of nitric oxide (NO), 
superoxide radical anion (O2·-), hydrogen peroxide (H2O2) and hydroxyl free radical 
(·OH) (Uttara et al., 2009). In addition, when NO and O2· interact with each other, a 
powerful radical species is produced, namely oxidant peroxynitrile (ONOO-) (Beetsch 
et al., 1998; Nishino et al., 1991). ROS is tightly regulated by endogenous anti-
oxidant system, including anti-oxidative enzymes such as catalase (CAT), glutathione 
peroxidase (GPx) and superoxide dismutase (SOD) or non-enzyme anti-oxidants such 
as α-tocophenol (vitamin E), ascorbic acid (vitamin C) and glutathione (GSH) (Mehta 
et al., 2007; Nita et al., 2001). During stroke and cerebral reperfusion, the elevation 
of ROS leads to several detrimental effects to brain injury including damage of 
membrane lipids by peroxidation of unsaturated fatty acids, damage of nucleic acid, 
impair of gene and gene repair activity (Dirnagl et al., 1999a). Moreover, ROS 
disrupts mitochondrial electron transport chain and facilitates endoplasmic reticulum 
(ER) stress thus induces necrotic and apoptotic cell death in brain after cerebral 
ischemia (Dirnagl et al., 1999a).  
1.3.3. Inflammation 
 Inflammatory events are initiated rapidly after the onset of cerebral ischemia 
(Becker, 1998; Hallenbeck, 1996; Zheng et al., 2004). A few hours after the onset of 
13 
 
ischemic stroke, inflammatory cells and mediators start accumulating in the ischemic 
hemisphere. Subsequently, ROS is generated owing to the energy depletion or 
reperfusion from spontaneous recanalization or compensation by the collateral 
circulation. The increase of ROS thereby activates endothelial cells, leukocytes 
including granulocytes, monocytes/macrophages, lymphocytes in the peripheral 
vascular system as well as astrocytes and microglia in the central nervous system 
(CNS) (Danton et al., 2003; Emsley et al., 2002).  
1.3.3.1. Endogenous inflammatory cells  
 The brain was thought as an immunoprivilege site with no or little immune 
cells until the late 20th century. Microglia, the resident macrophages and astrocytes 
are the most abundant cells in the CNS. They are responsible for the spontaneous 
immune response after ischemic attack. Morphologically, microglia change from 
ramified structure to amoeboid when activated by cerebral ischemia. Activated 
microglia express CD11b, F4/80 and Iba-1 therefore share same markers with 
macrophages. As such, activated microglia are regarded as macrophages like immune 
cells in the brain (Taylor et al., 2013). Previous reports suggested 60 min after 
ischemic attack, microglia located in the ischemic core significantly increased the 
number of their processes (Morrison et al., 2013). Moreover, microglia activation is 
sensitive to cerebral blood reperfusion, for example, Iba1+ microglia are present at 3.5 
to 12 h after cerebral blood flow reperfusion (Ito et al., 2001). Similar to 
macrophages, microglia have M1, which is the classically activated phenotype, or a 
M2, which is the alternatively activated phenotype. M1 microglia contribute to the 
release of a variety of pro-inflammatory mediators for instances TNF-α, inducible 
nitric oxide synthase (iNOS), IL-1β, interleukin-18 (IL-18) and chemokine ligand 2 
(CCL2) after stimulation by ischemic injury or reperfusion (Patel et al., 2013). 
Furthermore, they present CD80, CD86 and major histocompatibility complex class 
II (MHCII) once activated and present antigens to T cells (Taylor et al., 2013). 
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Interestingly, M2 microglia were found to involve in neuroprotection and repaired by 
up-regulation of neurotrophic factors (Patel et al., 2013).  
 Astrocytes are another endogenous immune cells that involve in the secretion 
of various inflammatory mediators (Benveniste, 1998). Once activated, increased 
expression of glial fibrillary acidic protein (GFAP) can be found in astrocytes (Pekny 
et al., 2005). Thus, activated astrocytes can be characterized by specific structural and 
functional change and such process is known as "reactive gliosis". Activated 
astrocytes are involved in the production of several inflammatory factors and 
chemokines. Inflammatory factors includes of interleukin-1, -6, -10 (IL-1, -6 and -
10), interferon-α,-β (IFN-α and -β), colony-stimulating factors, TNF-α, transforming 
growth factor-β (TGF-β), and chemokines; whereas chemokines includes of 
RANTES, interleukin-8 IL-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), 
and interferon-γ (IFN-γ)-inducible protein-10 (IP-10), iNOS and tumor necrosis 
factor like weak inducer of apoptosis (TWEAK) (Dong et al., 2001; Donohue et al., 
2003). 
1.3.3.2. Circulatory inflammatory cells   
 Circulating leukocytes migrate to the ischemic brain tissues and adhere to the 
blood vessel walls spontaneously upon ischemic stroke or after reperfusion of blood 
flow. Neutrophils infiltrate to the ischemic brain from circulatory system from 30 min 
to a few hours after the onset of stroke and peak from day 1 to 3 (Hallenbeck, 1996; 
Jin et al., 2010). Neutrophils generally play negative role in ischemic brain 
pathogenesis. They facilitate tissue injury mainly due to the delayed post-ischemic 
hypoperfusion. This is normally caused by the obstruction of neutrophils in 
microvessels. Neutrophils in microvessels release vasoconstrictive mediators and 
cause the dysfunction of vasoreactivity of cerebral arteries. This further worsens the 
release of cytotoxic enzymes, free oxygen radicals and products of phospholipids 
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cascade (Hartl et al., 1996). ICAM-1 is the adhesion molecule involves in the access 
of neutrophils to the brain through the endothelial walls. Mice that were immuno-
depleted with neutrophils showed a 3-fold reduction in infarct volume, improved of 
ipsilateral cortical cerebral blood flow and neurological deficit compared with 
tMCAO control mice (Connolly et al., 1996). Furthermore, ICAM-1 knockout mice 
demonstrated around 4-fold reduction in infarct volume and improvement of function 
outcome (Connolly et al., 1996). CXC ligand 8 (CXCL8)/ IL-8, as chemokines, 
attracted leukocytes activation and accumulation (Campbell, 2004). Study showed 
that by blocking CXCL8, it inhibited polymorphonuclear neutrophils (PMNs) 
infiltration by 40% in permanent ischemic stroke model and 54% in transient 
ischemic stroke model (Garau et al., 2005). Blocking of neutrophils infiltration by 
CXCL8 blocker protected brain from ischemic damage at 44% in transient ischemic 
rat stroke model without interfering with brain chemokine level (Garau et al., 2005). 
Moreover, Suriano et al. showed that mice deficient with macrophage-1 antigen 
(Mac-1), which is a mediator functions in facilitating adhesion and transendothelial 
migration, had a 26% reduction in infarct volume when compared with wild type 
tMCAO mice (Soriano et al., 1999).  
 Macrophages are important inflammatory leukocytes. They infiltrate from the 
blood to the brain during ischemic damage (Shichita et al., 2012). Macrophages 
infiltration was reported significantly increased from 12 to 24 h and peaked at day 3 
after reperfusion (Clausen et al., 2008). They aggravate stroke damage by producing 
various inflammatory cytokines for instances, IL-1β, TNF-α and IL-23 (Clausen et 
al., 2008). Nevertheless, T lymphocytes was found increased in pMCAO animal 
model after neutrophils at relatively late post occlusion, which is at 72 and 96 h 
(Stevens et al., 2002). In a clinical study, Nadareishvili and co-workers showed that 
the increase of stroke recurrent and death correlated with the lymphocytes elevation 
in the circulatory system (Nadareishvili et al., 2004). This provides more insight 
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evidences that blocking lymphocytes infiltration could potentially alleviate 
inflammatory damage to ischemic stroke. Becker and co-workers demonstrated that 
blocking of lymphocytes adhesion to endothelium by treating animals with anti-α4 
ameliorated the ischemic injury (Becker et al., 2001). Taken together, these studies 
implicated that inhibition of leukocytes infiltration could bring beneficial outcome to 
ischemic stroke.  
1.3.3.3. Adhesion molecules, cytokines and chemokines  
 Adhesion molecules are crucial for leukocytes infiltration from the 
circulatory system to the brain parenchyma. Leukocytes are known to gain access to 
the brain through the endothelial wall via 3 major steps, rolling, adhesion and 
transendothelial migration of leukocytes (Wang et al., 2007a). Once activated by 
ischemic injury, adhesion molecules such as P-selectin, E-selectin, and L-selectin, the 
immunoglobulin superfamily such as ICAM-1,2 and VCAM-1, platelet endothelial 
cell adhesion molecule-1 or PECAM and the mucosal vascular addressing cell 
adhesion molecule 1 or MAdCAM-1 and integrins (CD11a-c) mediate neutrophils 
infiltration (Wang et al., 2007a). Several studies have demonstrated that the elevation 
of adhesion molecules were detrimental to ischemic stroke. For instances, P-selectin, 
E-selectin, ICAM-1 and VCAM-1 protein and mRNA level was found increase in 
ischemic stroke animals (Blann et al., 1999; Huang et al., 2000; Okada et al., 1994; 
Wang et al., 1995; Wang et al., 1994). Mice with P-selectin overexpression showed 
larger infarct volume and by treating animals with inhibitors or antibodies against P- 
or E-selectin deficient mice showed to improve stroke outcome in several research 
studies (Connolly et al., 1997; Huang et al., 2000; Lehmberg et al., 2006; Mocco et 
al., 2002). Similarly, several studies showed that blocking of VCAM-1 or ICAM-1 
with antibodies, antisense oligonucleotides or inhibitors led to neuroprotection 
(Bowes et al., 1993; Chopp et al., 1996; Kanemoto et al., 2002; Kitagawa et al., 
1998; Vemuganti et al., 2004; Zhang et al., 2003). Increase of VCAM-1 and ICAM-1 
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was found in ischemic stroke patient plasma and cerebral spinal fluid. The elevation 
was also shown to correlate with bad stroke outcome (Ehrensperger et al., 2005; 
Selakovic et al., 2003; Simundic et al., 2004). Moreover, in the autopsied brains of 
the stroke patients, the VCAM-1 expression was documented to be higher in 
astrocytes and cerebral vasculatures (Blann et al., 1999). Despite paramount animal 
studies suggesting the positive outcome by inhibiting adhesion molecules in 
experimental stroke animals, no clinical trials were successful so far. For instance, 
anti-ICAM therapy with Enlimomab in phase III clinical trial did not show beneficial 
effect to ischemic stroke but exacerbated the stroke outcome in patients (2001). 
 Chemokines are a family of regulatory polypeptides serve as a crucial role in 
regulating the migration of leukocytes to the ischemic tissue (Wang et al., 2007). 
Chemokines can be divided into 4 groups, which are C, CC, CXC and CX3C based 
on the binding specificity to the receptors of G-protein coupled receptors superfamily 
(Biber et al., 2006; Wang et al., 2007a). Some important chemokines include of 
MCP-1 and macrophage inflammatory protein-1 α (MIP-1α) was found activated in 
animal experimental stroke models (Pang et al., 2001; Yamagami et al., 1999). 
Chemokine affects blood brain barrier (BBB) permeability. This is supported by 
previous reports that the administration of MCP-1 increased the permeability of both 
in vitro and in vivo BBB by alteration in tight junction protein for around 17-fold 
(Stamatovic et al., 2005). In addition, evidences suggested MIP-1α and MCP-1 
played a deleterious in stroke. Chen and co-workers showed that ischemic injury was 
exacerbated by the recruitment of inflammatory cells in an in vivo MCAP-1 
overexpressing rat brains (Chen et al., 2003).  
 Endogenous inflammatory cells and peripheral immune cells produce 
cytokines such as IL-1, TNF-α, IL-6, IL-10 and TGF-β. Among all, IL-1 and TNF-α 
appear to serve pro-inflammatory responses while IL-6, IL-10 and TGF- β possess 
anti-inflammatory roles (Allan et al., 2001). Both TNF-α and IL-1β were found 
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spontaneously elevated after ischemic stroke. IL-1 β mRNA level was found elevated 
within 15-30 min after ischemic stroke and protein level elevated as a few hours later 
(Buttini et al., 1994; Davies et al., 1999). Biphasic expression of IL-1β was 
documented after reperfusion of cerebral blood flow (Haqqani et al., 2005), which 
was elevated at 1 and 6-24 h after reperfusion. IL-1β plays deleterious role to stroke. 
This was supported by the study that the addition of IL-1β aggravated ischemic 
damage (Yamasaki et al., 1995). Moreover, TNF-α was found increased 
spontaneously after ischemic attack. It was documented that TNF-α increased initially 
at 1-3 h after ischemic and peaked again at 24 - 36 h (Offner et al., 2006). Study 
revealed that the administration of recombinant TNF-α protein after stroke, 
aggravated stroke outcome (Barone et al., 1997a). In contrast, the inhibition of TNF- 
α ameliorated stroke damage (Nawashiro et al., 1997). As such, similar to IL-1β, 
TNF-α contributes to inflammatory damage during ischemic injury.  
1.3.3.4. Other inflammatory mediators 
 The roles of nitric oxide synthase (NOS), arachidonic acid (AA) and MMP in 
ischemic stroke have been widely studied. NO is an important mediator in the brain 
and functions as a neurotransmitter or gasotransmitter. Furthermore, it plays an 
important role in regulating vascular tone and host defence (Wang et al., 2007a). 
After the onset of ischemic stroke, the mRNA, protein and enzymatic activity of 
iNOS and the production of NO were found elevated (Iadecola et al., 1995a). 
Deletion of iNOS in mice showed smaller infarct and better functional outcomes 
when subjected to MCA occlusion (Zhao et al., 2000). Iadecola et al. showed that 
pharmacological inhibition of iNOS in rats ameliorated the ischemic brain injury by 
reducing around 30% of infarct volume (Iadecola et al., 1995b).  
 The AA cascade is initiated when ischemic damage stimulates the release of 
phospholipase A2 (PLA2) (Adibhatla et al., 2006). Evidence from PLA2 knockout 
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mice showed smaller infarct volume and less development of brain edema (Bonventre 
et al., 1997). AA can be metabolized into two different pathways, namely 
cyclooxygenase (COX) and lipoxygenase (LOX) pathways. COX and LOX pathways 
will be further discussed in detail later in chapter 5. Cerebral ischemia is 
characterized by the breakdown of BBB thereby leading to leukocyte infiltration and 
degradation of the basal lamina (Mehta et al., 2007). Zinc dependent MMPs for 
instances MMP-2 and MMP-9 are involved in the degradation of basal lamina during 
ischemic injury (Fukuda et al., 2004). Thrombolysis by tPA treatment during 
ischemic stroke may facilitate haemorrhagic conversion possibly due to the disruption 
of BBB following MMP-9 activation (Kelly et al., 2006). MMP-9 compares with 
MMP-2 appears to play more important role in aggravating stroke outcome.  Asahi et 
al. reported that mice deficient of MMP-9 showed better stroke outcome. 
Nonetheless, such beneficial effects did not observe in MMP-2 deficient mice (Asahi 
et al., 2000; Asahi et al., 2001).  
1.3.4. Necrotic and apoptotic cell death 
 Reduction of cerebral blood flow evolves from an initial stage of reversible 
damage (Garcia et al., 1995a). Without further energy supply, tissue undergoes 
apoptotic or necrotic cell death eventually. Necrotic neurons are characterized as 
exhibiting pyknosis (nucleus shrinks and the chromatin condenses), karyorrhexis (the 
chromatin of the nucleus fades), karyolysis (the strunken nucleus fragments to 
complete dispersal) and cytoplasmic eosinophilia or loss of hematoxylin affinity 
(Farber et al., 1981). In contrast, apoptosis is an energy dependent programmed form 
of cell death which is characterized morphologically as cell shrinkage, membrane 
blebbing, chromatin condensation and DNA fragmentation eventually avoiding 




1.3.4.1. Necrosis  
 Necrosis is caused by sudden loss of osmotic homeostasis, shortage of 
nutrients and extreme physical or chemical injury in an area of a tissue. Necrotic cells 
swell as they take up water (Mehta et al., 2007). This subsequently causes the rupture 
of the membrane and leakage of cellular contents into the surrounding tissue thereby 
triggers the consequent inflammatory response (Mehta et al., 2007). The process of 
necrosis is not well understood yet. It is believed that the severity and duration of 
ischemia determine cells undergoing rapid necrotic death or slower apoptotic death 
(Mehta et al., 2007).  
1.3.4.2. Apoptosis 
 The major apoptotic signalling pathways can be generally classified into 
extrinsic and intrinsic pathways.  
1.3.4.2.1. Intrinsic pathway/ mitochondrial mediated apoptosis   
 The production of free radicals, DNA damage, the disruption of 
mitochondrial function and growth factor deficiency following cerebral ischemia 
induce apoptosis (MacManus et al., 1997). Studies demonstrated that various cellular 
or biochemical pathways involve in mitochondrial-mediated apoptosis. Mitochondria-
mediated apoptosis is initiated by tBid and Bcl-2 family. Truncated Bid (tBid) is 
released once Bid is activated and this induces the release of cytochrome c from 
mitochondria (Budihardjo et al., 1999). Nevertheless, Bcl-2 family comprises of the 
anti-apoptotic proteins (Bcl-2 and Bcl-xL) and pro-apoptotic proteins (Bax, Bak, Bid 
and Bad) (Antonsson et al., 2001; Gross et al., 1999; Harris et al., 2000; Love, 2003). 
Pro-apoptotic Bcl-2 family proteins such as Bax and Bad are sequestered by 14-3-3 
proteins and Bcl-xL under normal physiological conditions. Upon cerebral ischemia, 
Bax and Bad undergo post-translational modification and are subsequently released 
from 14-3-3 protein or Bcl-xL. Bax thereby translocates to the outer mitochondria 
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membrane. Within the outer mitochondrial membrane, Bax, Bak or other BH3 
domain pro-apoptotic proteins forms channels that facilitates cytochrome c release 
from mitochondrial inter membrane space (Fujimura et al., 1998; Love, 2003). 
Cytochrome c release stimulates procaspase-9 to form apoptosome with apoptotic 
protease-activating factor 1 (APAF-1). This leads to the release of apoptogenic 
proteins such as caspase-9 (Love, 2003; Mehta et al., 2007; Nakka et al., 2008; Zhang 
et al., 2004a). Activated caspase-9 cleaves and activates downstream caspases 
(capase-3, -6 and -7) (Mehta et al., 2007; Nakka et al., 2008; Namura et al., 1998). 
Caspases are known as the executor in death mechanism (Nakka et al., 2008). They 
facilitate cell death mechanisms via the breakdown of cellular framework through the 
activation of caspase-activated deoxyribonuclease (CAD),  degradation the inhibitor 
of caspase-activated DNase (ICAD),  degradation of cytoskeletal or nuclear proteins, 
cleavage of DNA repair proteins such as poly(ADP-ribose) polymerase (PARP), 
degradation of anti-apoptotic proteins Bcl-2 and Bcl-xL and promotion of DNA 
fragmentation (Love, 2003; Zhang et al., 2004a). Multiple existing experimental 
evidences suggested that cerebral ischemic causes the activation of caspases. For 
examples caspase 3, pro-caspase 3 and PARP, were found up-regulated and activated 
in animal focal stroke model (transient and permanent models) and global cerebral 
ischemia. These studies were consistent with the clinical evidences observed in stroke 
patients (Davoli et al., 2002; Love et al., 2000a; Love et al., 2000b; Namura et al., 
1998; Ni et al., 1998; Niwa et al., 2001).  
 Furthermore, genetically inhibiting apoptosis is beneficial to ischemic stroke 
outcome. Endres et al. demonstrated the PARP-1 knockout mice showed significantly 
smaller infarct volume than the wild type control (Endres et al., 1997). In another 
study, transfection of PARP-transgene in PARP-1 knockout mice reversed the 
reduced brain infarct volume in a stroke model (Goto et al., 2002). The promising 
effect of PARP-1 inhibition to stroke outcome leads to the development of several 
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PARP-1 inhibitors such as FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-
pyridinyl)propyl]-4(3H)-quinazolinone (Iwashita et al., 2004), INO-1001 (Komjati et 
al., 2004), 3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone (Takahashi 
et al., 1999), 3-Aminobenzamide (3-AB)(Ding et al., 2001), 4-amino-1,8-
napthalimide (4-ANI) (Kabra et al., 2004) and 2-methyl-3,5,7,8-
tetrahydrothiopyrano[4,3-d)pyrimidine-4-one (DR2313) (Nakajima et al., 2005). 
These reports suggested that PARP-1 could be a potential therapeutic candidate for 
ischemic stroke treatment. 
1.3.4.2.2. Extrinsic pathway  
 Extrinsic pathway is also known as death receptors mediated apoptosis. It is 
activated when death receptors were stimulated by selectively binding of its cognate 
death ligands. Death receptors that are belong to tumor necrosis factor receptor 
(TNFR) super family include of Fas/CD95/Apo1, tumor necrosis factor-α receptor 1 
(TNFR1), DR4 and DR5. They have been known to share a homologous intercellular 
sequence known as death domain (DD). Binding of the death receptors to its cognate 
ligand causes the trimerization of receptors and interaction of the ligand with the 
receptor cytoplasmic DDs. Death domain allows recruitment of specific adaptors 
molecules and forms the death inducing signalling complex (DISC) (MacManus et 
al., 1997; Mehta et al., 2007). Procaspase-8 is therefore recruited to the adaptor 
molecule, recognized by its death effector domain (DED) and subsequently promotes 
auto-proteolysis to active form. Active caspase-8 activates the downstream death 
pathway targets such as procaspase-3 or action of Bid and eventually leads to 
neuronal death (Mehta et al., 2007).   
1.3.4.2.3 Caspase independent pathway  
 Depletion of ATP activates both caspase dependent and independent 
apoptotic pathways. One of the novel independent apoptotic pathway is apoptosis-
23 
 
inducing factor (AIF) mediated apoptosis pathway. AIF is a 67kDa protein, locates in 
the mitochondrial inner membrane space. It is released upon apoptotic signal. The 
release of AIF leads to cell death characterized by chromatin condensation and DNA 
fragmentation (Hong et al., 2004). AIF has been shown to involve in pathogenesis of 
cerebral ischemia. Plesnila et al. demonstrated that AIF translocation from 
mitochondria to nucleus occurred at 1 h after reperfusion (Plesnila et al., 2004). 
Moreover, Cregan et al. has demonstrated that administration of neutralizing 
antibodies against AIF reduced neuronal injury in Apaf-1 knockout neurons (Cregan 
et al., 2002). Taken together, AIF could be an important therapeutic target for 













Figure 1.5. Cascade of ischemic injury. Cerebral ischemia or cerebral blood flow 
reperfusion initiates a cascade of signalling pathways that leads to necrosis and 
apoptosis. The reduction of blood flow causes the energy deprivation, anoxic 
depolarization and thus leads to glutamate excitotoxicity. Glutamate excitotoxicity 
causes intracellular calcium overload and stimulates cytotoxic edema and necrosis. 
Moreover, calcium overload leads to mitochondrial collapse and triggers the release 
of reactive oxygen species (ROS) or cytochrome c release. Cytochrome c release 
thereby triggers caspases activation and leads to apoptosis. Free radicals 
accumulation leads to lipid peroxidation, proteolysis and DNA deamination and 
subsequently cellular apoptosis and necrosis. Nonetheless, reperfusion produces 
injury that augmenting BBB breakdown, leukocytes infiltration and subsequently 
arachidonic acid (AA) release, ROS production and triggers cell death mechanisms. 
Transcription factor, such as NF-κB pathways is activated and leads to further cell 
death pathway activations. Figure re-adapted from Nakka et al., and Wang et al., 
(Nakka et al., 2008; Wang et al., 2007a)  
 
1.4. Current treatment for acute stroke            
1.4.1. Intravenous tissue plasminogen activator  
 Intravenous recombinant tissue plasminogen activator (rtPA), alteplase at 0.9 
mg/kg of body weight, is the only FDA approved therapy for acute ischemic stroke 
since 1996. It was approved to be administered to ischemic stroke patients at the first 
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3 h after the onset of the symptoms. Subsequent analysis of the National Institute of 
Neurological Disorders and Stroke (NINDS) study together with another six 
randomized trials showed a favourable outcome when treatment was given between 3 
and 4.5 h (Hacke et al., 2008). There is estimated only 2% of stroke patients receive 
rtPA treatment despite the extension of thrombolysis therapeutic window to up to 4.5 
h after the onset of stroke. Primarily reason is due to the delayed admission to a 
stroke centre (Hacke et al., 2008).  
1.4.2. Endovascular stroke therapy  
 Physically retrieve of cerebral thrombi or by suction could remove the 
blocking thrombi in the cerebral artery and increase recanalization rate among 
ischemic stroke patients. This can be achieved by clot retrieval devices. Several FDA 
approved retrievers such as Microsnare (Gonzalez et al., 2007), Neuronet (Theiss et 
al., 2013), the Merci retriever (Becker et al., 2005) and the TREVO device (Prince et 
al., 2014) were tested clinically with good clinical outcome. Coupled the clot 
retriever devices with intra-arterial thrombolysis (Lewandowski et al., 1999) and 
fibrinolysis (Lee et al., 2010; Molina et al., 2005) demonstrated beneficial outcome 
clinically, especially in large vessel occlusion (Broussalis et al., 2012a).  
1.4.3. Current use of primary and secondary stroke prevention  
 Acetylsalicylic acid (ASA), also known as aspirin is a FDA approved 
antiplatelet agent for secondary ischemic stroke prevention. It inhibits irreversible 
platelet aggregation by blocking of cyclooxygenase (Catella-Lawson et al., 2001). 
Recommended doses for therapy is 75 - 150 mg daily and higher doses causes higher 
haemorrhage complication (Srivastava, 2010).  
 Ticlopidine is an adenosine diphosphate (ADP) receptor inhibitor and has 
been approved by FDA for secondary ischemic stroke prevention. It showed risk 
reduction of rates of stroke in Canadian American Ticlopidine Study (CATS) and 
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Ticlopidine Aspirin Stroke Study (TASS) at 250 mg twice daily (Gent et al., 1988; 
Harbison, 1992). Especially in CATS, ticlopidine showed significant reduction in the 
stroke recurrent, myocardiac infarction (MI) or vascular death in stroke patients (Gent 
et al., 1988). However, ticlopidine failed to show better outcome than aspirin in high-
risk group as demonstrated in the African American Antiplatelet Stroke Study 
(AAASPS) (Gorelick et al., 2003).  
Clopidogrel is a thienopyridine compound and is a FDA approved antiplatelet 
agent for secondary ischemic stroke prevention (Broussalis et al., 2012a). It is an 
analogue of ticlopidine and was found more effective than aspirin in the Clopidogrel 
versus Aspirin in Patients at Risk of Ischemic Event (CAPRIE) trial (1996). In 
addition, clopidogrel causes less gastrointestinal bleedings than aspirin. Despites the 
effectiveness of clopidogrel demonstrated in CAPRIE trial, several studies indicated 
poorer clinical outcome possibly due to clopidogrel resistance caused by patients with 
cytochrome P450 polymorphism (Kaur et al., 2013).  
Warfarin has been used for more than 20 years ago (Broussalis et al., 2012a). 
Substantial bleeding risk is the limitation of Warfarin even though it has 
demonstrated to be effective in preventing cardioembolic stroke in European Atrial 
Fibrillation Trial (Broussalis et al., 2012a). However, no different was found in 
clinical effectiveness in stroke as well as haemorrhage rate when compare warfarin 
with aspirin in the Warfarin Aspirin Recurrent Stroke Study (WARSS) (Hankey, 
2002). Intensive monitoring the risk of bleeding is required by warfarin therapy 
therefore makes antiplatelet drugs remain the primary choice for stroke prevention 
(Broussalis et al., 2012a).  
1.5. Promising ongoing therapeutics for acute ischemic stroke  
 The development of therapies for stroke evaluates from in vitro model, in 
vivo animal stroke studies and finally investigating the drug effectiveness in clinical 
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trials. Animal experiments provide several advantageous to study about the drug 
targets which include of the neurological outcome and physiological outcome, drug 
efficacy and metabolism as well as the underlying mechanisms in stroke 
pathophysiology (Sutherland et al., 2012). Drug targets that were found to be 
efficacious in experimental studies including targeting excitotoxicity, CNS 
inflammation, neuronal apoptosis, free radical damage, and calcium influx into cells 
(Sutherland et al., 2012). O’Collins et al. identified 1026 drug candidates for acute 
ischemic stroke treatment reported from 1957 to 2003 (O'Collins et al., 2006). 
However, most of the potential drug candidates failed to improve clinical outcome. 
One reason for the failure could be due to the complexity of the mechanism of 
pathophysiology of neuronal damage after ischemic stroke (Savitz et al., 2007). 
Therefore, compounds with a multimodal mode of action or several compounds target 
more than one pathways will be more preferable. 
 Several therapeutic strategies have been developed for the ischemic stroke 
treatment. Unfortunately, most of the agents could not achieve clinical success. Some 
promising ongoing studies including desmoteplase, tenecteplase, batroxobin, 
hypothermia, high dose human albumin therapy, magnesium therapy, minocycline, 
endaravone and statins are by far the most promising new therapeutic candidates for 
ischemic stroke treatment and are discussed below. A list of potential therapeutic 
candidates tested in clinical and preclinical trial is summarized in table 1.1 (Page 33-
34).  
1.5.1. Desmoteplase, tenecteplase and batroxobin 
 Desmoteplase, tenecteplase, ancrod and batroxobin are thrombolytic agent. 
Desmoteplase derived from vampire saliva is more fibrin-specific compare with rtPa. 
It is believed to be a safer thrombolytic agent than rtPA (Broussalis et al., 2012b). In 
the Desmoteplase in Acute Ischemic Stroke trial (DIAS), administration of 
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desmoteplase within 3-9 h after the onset of stroke was found to have better 
recanalization rate, better clinical outcome, low intracerebral bleeding (Hacke et al., 
2005). It also showed no neurotoxicity or effect on the BBB (Broussalis et al., 
2012b).  
 Tenecteplase has a longer half-life and greater fibrin specificity than 
alteplase. Tenecteplase functions to degrade the fibrin matrix of the thrombus 
(Broussalis et al., 2012b). A relatively lower dose of tenecteplase, 0.1-0.4 mg/kg was 
tested in the Phase II study. When treated within 3 h after stroke, no symptomatic 
intracerebral haemorrhage was observed. However, the following trial was 
prematurely terminated due to no significant effect when compare with rtPA 
treatment (Haley et al., 2010).  
 Different from desmoteplase and tenecteplase, Ancrod and batroxobin cleave 
fibrinogen rather than fibrin (Sacco et al., 2007). Ancrod is a pit viper venom was 
hypothesized to yield better efficacy and safety than other thrombolytic agents. 
However, in the Stroke Treatment with Ancrod Trial (STAT), ancrod showed lack of 
efficacy and revealed a trend of increased bleeding (Levy et al., 2009). In contrast, 
batroxobin, which is a thrombin-like snake venom enzyme demonstrated to have 
beneficial neurological functions to stroke (Gusev et al., 2006). Furthermore, 
batroxobin demonstrated effectiveness in reducing risk for stroke and transient 
ischemic stroke recurrence in patients when evaluated as a candidate for secondary 
stroke prevention (Xu et al., 2007) .  
1.5.2. Hypothermia 
 Mounting experimental evidences over the past 20 years consistently reported 
moderate hypothermia attributed to neuroprotection with appropriate therapeutic 
window for clinical application (Barone et al., 1997b; Corbett et al., 2000; Ginsberg 
et al., 1992; Huh et al., 2000). Hypothermia is neuroprotective against excitotoxicity, 
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free radical formation, the activation of protein kinase C (PKC) activity and the 
increase of cellular metabolism (Berger et al., 2002; Globus et al., 1995; Yenari et 
al., 2008). More importantly, hypothermia showed beneficial outcome for ischemic 
stroke. In the COOL AID I trial, the patients who were treated rtPA received 
hypothermia with surface cooling and intermittent ice water and whole-body alcohol 
rubs to cool down the core temperature to 32°C showed better functional outcome in 
modified Rankin Scale score compared with control (Krieger et al., 2001). 
Furthermore, shivering was found as a serious “dose limiting” factor that could affect 
clinical outcome in conscious patients. Thus oral buspirone at 30mg or intravenous 
meperidine at 0.4μg/ml were used clinically and showed significant temperature 
lowering outcome thus is believed to be able to improve the ischemic stroke outcome 
(Ginsberg, 2007). Several major trials for instance Controlled Hypothermia in Large 
Infarction and Cooling in Acute Stroke are currently planned and ongoing 
(Sutherland et al., 2012).  
1.5.3. High dose human albumin therapy 
 Several animal studies have shown that albumin treatment reduced stroke 
outcome in animal models significantly (Belayev et al., 1997; Belayev et al., 2001; 
Belayev et al., 1998). Study also suggested that albumin treatment up to 4 h post-
stroke reduced infarct volume significantly (Belayev et al., 2001). The underlying 
mechanism of neuroprotection was indicated through reducing brain edema, 
improving cerebral blood flow, inhibiting pathological platelet aggregation, 
antagonizing ROS, and maintaining vascular patency (Halliwell, 1988; Sutherland et 
al., 2012; Wayner et al., 1985). A pilot study that administrated 25% human albumin 
to stroke patients within 16 h of stroke onset was conducted (Palesch et al., 2006) 
(Ginsberg et al., 2006a). Positive outcome was demonstrated in the Albumin in Acute 
Stroke (ALIAS) trial showing that highest albumin doses confers 81% better outcome 
than the lower dose tiers. Based on the encouraging results, larger placebo-controlled 
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randomized multicentre phase III trial of ALIAS is planned and ongoing (Ginsberg et 
al., 2006b).  
1.5.4. Magnesium  
 Magnesium sulphate (MgSO4) has been long used clinically for the treatment 
for pre-eclampsia (Ginsberg, 2008). Compare to other potential acute stroke 
treatments, it is relatively inexpensive. Several preclinical ischemia studies indicated 
that magnesium could be an effective neuroprotectant (Izumi et al., 1991; Marinov et 
al., 1996; Westermaier et al., 2005). Yang et al. showed rats recovered from stroke 
when treated with 90 mg/kg of MgSO4 up to 6 h after stroke onset in autologous 
MCA thromboembolic model (Yang et al., 2000). The safety of magnesium was 
tested clinically in the Field Administration of Stroke Therapy-Magnesium (FAST-
MAG) Pilot Trial (Saver et al., 2004). The study was initiated since delayed time to 
delivery is one of the main factors that caused the failure of human neuroprotectant in 
clinical trials. The FAST-MAG Pilot Trial was performed by paramedics while 
sending stroke patients to the hospital. The FAST-MAG was a great success and 
showed feasibility and safety with no serious adverse effects. Intravenous 
administration of MgSO4 therapy showed to associate with beneficial functional 
outcome at 90 days. A larger phase III clinical trial is progressing after the promising 
outcome from FAST-MAG Pilot Trial (Sutherland et al., 2012) 
1.5.5. Endaravone and NXY-059 
 Endaravone and NXY-059 are both free radical scavangers. Endaravone was 
shown to be neuroprotective in pre-clinical animal studies on rat global, focal, 
transient MCA and mice MCA occlusion models (Amemiya et al., 2005; Nakajima et 
al., 2005; Watanabe et al., 1994; Zhang et al., 2005). Therapeutic window of 
endaravone among animal studies varies from only effective before 2 h to up to 6 h. 
Similarly, edaravone showed improved outcome on the MRS at 90 days in the 
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Edaravone Acute Infaction Study trial, with a therapeutic window of 72 h (Zhang et 
al., 2003). Moreover, edaravone attributed to beneficial outcome in stroke patients 
with small-vessel occlusion as shown in a small cohort of clinical study recruited 83 
patients (Nakase et al., 2011). As shown in the Edaravone – citicoline comparative 
study in acute ischemic stroke (ECCS-AIS) trial, edaravone treated group 
demonstrated significantly better neurological outcome at 3 months than citicoline 
(Mitta et al., 2012) suggesting the promising effect of edaravone in ischemic stroke 
treatment.  
NXY-059 is another antioxidant with promising neuroprotective effect to 
experimental ischemic stroke. It was first showed to have neuroprotective effect in 
several animal stroke models including rodent (Sydserff et al., 2002; Yoshimoto et 
al., 2002a; Yoshimoto et al., 2002b; Zhao et al., 2001b), rabbit (Lapchak et al., 
2002a; Lapchak et al., 2002b; Lapchak et al., 2004) and nonhuman primates 
(Marshall et al., 2003; Marshall et al., 2001) with an overall reduction of 43% in 
infarct volume (Macleod et al., 2008). In the animal preclinical trials, NXY-059 
showed to have a similar effective therapeutic window as rtPA (Marshall et al., 
2003). Therefore, it could be administered as a combinary therapy with rtPA. The 
Stroke–Acute Ischemic NXY Treatment (SAINT) I trial was relatively successful in 
which NXY-059 showed reducing disability in patients (Fisher, 2006). However, the 
SANIT II study that was more statistically powerful showed disappointing outcome 
(Diener et al., 2008). The potential reason for the clinical failure could be due to the 
enrolment therapeutic window of ischemic stroke and the type of the stroke for the 
study (Sutherland et al., 2012). Further investigation is highly warranted. 
1.5.6. Minocycline 
 Minocycline is a tetracycline antibiotic with a broad-spectrum of mechanism 
of action. It is a promising neuroprotectant for ischemic stroke by demonstrating 
32 
 
smaller infarct size in both transient and permanent MCA models (Koistinaho et al., 
2005; Nagel et al., 2008; Tao et al., 2013; Weng et al., 2007). The possible 
mechanism of action involves inhibiting of inflammatory responses, alleviation of 
activated microglia formation, attenuation of MMP and NO production and inhibition 
of apoptosis (Sutherland et al., 2012). Minocyclin has been commonly used as 
antibiotics for many years without safety concern. In the Minocyclin to Improve 
Neurological Outcome in Stroke (MINOS), minocyclin demonstrated its safety and 
was well tolerant with rtPA, at 10 mg/kg intravenously without causing severe 
haemorrhages encouraged the further ongoing trials (Fagan et al., 2010). Phase III 
Neuroprotection with Minocycline Therapy for Acute Stroke Recovery Trial 
(NeuMAST) is ongoing and aims to determine the beneficial effects of minocyclin in 
improving functional outcome (Sutherland et al., 2012).    
1.5.7. Statins  
 Statins or hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors function to lower cholesterol (Prinz et al., 2008). It previously showed to 
reduce the incidence of myocardial infarctions and stroke (Prinz et al., 2008). In the 
experimental preclinical trials, studies indicated that statin is a promising agent that 
can protect the brain from the progression of ischemic damage (Cimino et al., 2005; 
Kilic et al., 2005; Laufs et al., 2002; Prinz et al., 2008). Statin manifests its effects by 
increasing NO bioavailability. This can therefore promote cerebral blood flow 
perfusion, enhance endothelial function, anti-oxidative, anti-inflammatory and 
potentially atherosclerotic plaque stabilization properties (Sutherland et al., 2012). 
The clinical safety of lovastatin was determined in the Phase I Dose Escalation 
Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART) (Elkind 
et al., 2009). The primary outcome was quite promising and granted FDA approval 
for 72 h treatment after stroke at maximum dose of 8 mg/kg/day (Elkind et al., 2009). 
Phase II trial (NeuSTAT II) is currently progressing with the primary outcome to 
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determine the effectiveness of simvastatin in term of neurological outcome (with a 
therapeutic window up to 12 h after stroke) and secondary outcome to assess the 
haemorrhagic transformation of patients who receive combinatory treatment with 
rtPA (https://clinicaltrials.gov/ct2/show/NCT01073007). 










t-PA  Effective (O'Collins 
et al., 2006) 
Phase III: Effective 
(1995; Lee et al., 
2004) 
Desmoteplase Effective (Liberatore 
et al., 2003) 
Phase II ongoing 
(Hacke et al., 2008) 
Teneteplase Effective (Zhang et 
al., 2004b) 
Phase II/III ongoing 
(Haley et al., 2010) 
Batroxobin  Effective (Wu et al., 
2001) 
Effective ongoing  
(Xu et al., 2007; 
Zeng et al., 2009) 
2 Ca2+ channel 
blocker 
Nimodipine Effective (Horn et 
al., 2001) 
Ineffective  (O'Collins 









Edaravone Effective (Amemiya 
et al., 2005; 
Nakajima et al., 
2005; Watanabe et 
al., 1994; Zhang et 
al., 2005) 
Effective (Nakase et 
al., 2011) 
Statin  Effective (Prinz et 
al., 2008) 
Phase IV ongoing 
(Kaur et al., 2013) 
NXY-059 Effective 
(Yoshimoto et al., 
2002a; Yoshimoto et 
al., 2002b; Zhao et 
al., 2001; Lapchak et 
al., 2002; Marshall 
et al., 2001; Macleod 
et al., 2008) 
 
Phase III: Ineffective 
(Uttara et al., 2009) 
Tirilazad Effective (Sena et 
al., 2007) 
Ineffective (van der 






et al., 2000) 















et al., 1996) 
Phase II ongoing 
(Muir et al., 2004) 
CGS 19755 Effective(Miyabe et 
al., 1997) 
Phase III: Ineffective 
(Davis et al., 2000) 
Aptiganel  Effective (Schabitz 
et al., 2000) 
Phase III: Ineffective 
(Schabitz et al., 
2000) 
MK-801 Effective (Lyden et 
al., 2002) 
 - 





al., 1998) et al., 2005) 
YM872 Effective (Suzuki et 
al., 2003) 
Phase II ongoing 








Hypothermia Effective (Huh et al., 
2000) 
Phase III ongoing 






Effective (Belayev et 
al., 1999a; Belayev 
et al., 1999b; Liu et 
al., 2001; Remmers 
et al., 1999) 
Phase III ongoing 
(Ginsberg et al., 
2006) 
Minocyclin Effective (Huang et 
al., 2000; Weng et 
al., 2007; Tao et al., 
2013; Fagan et al., 
2010)  
Phase III ongoing 
(Ginsberg et al., 
2006) 
 
Table 1.1. Summary of potential pharmcotherapy for acute ischemic stroke 
treatment in preclinical and clinical studies. Table re-adapted from Kaur et al. 
(Kaur et al., 2013).  
 
1.6. Failure of neuroprotectant in clinical trials and future direction  
 To date, thousands of neuroprotectants have proven successful in 
experimental studies but failed to exert its effectiveness in clinical studies. As such, 
we have learned much from the failed trials in the past. Methodology for the current 
ongoing clinical trials is greatly improved. At the same time, stroke research has 
enhanced our understanding of the epidemiology and pathophysiology of stroke. The 
next step for the potential pharmacological development for ischemic stroke 
treatment will be focusing on the strategy for planning translational studies and 
efforts in connecting animal studies to clinical studies.  
The primary outcome for animal studies were always reduction in infarct 
size; whereas the primary outcome for clinical studies used outcome of disability and 
neurological deficits by Modified Rankin Scale (MRS) or Barthel Index, which may 
not be relevance to the behaviour studies in rodents. Employing of diffusion and 
perfusion MRI to the clinical trials have proven to bring beneficial outcome for 
translational studies, such as the Diffusion and Perfusion Imaging Evaluation for 
Understanding Stroke Evolution (DEFUSE) and Desmoteplase in Acute Ischemic 
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Stroke Trial (DIAS) (Savitz et al., 2007). These studies suggested that salvageable 
penumbra should be used as one of the parameter to determine the drug effects 
(Savitz et al., 2007).  
 Moreover, patients’ selection should match with animal models that the 
potential pharmacological candidates tested previously. The presence of brain infarcts 
in different brain regions, for instance cortex, white matter, or deep grey matter 
structures depends on where the ischemia event evolves. For instance, the most 
established and widely used animal models predominantly affect the striatum and 
cortex (Savitz et al., 2007). As such, clinical trial should recruit patients with infarcts 
that caused by MCA occlusion. Diffusion-weighted MRI, magnetic resonance 
angiography and perfusion computed tomography could be used to identify the 
location of the ischemia, the vascular occlusive lesion and the ischemic penumbra as 
such to select the appropriate patients for inclusion (Wintermark et al., 2006).   
 Furthermore, drugs that target multiple pathways or the cocktails of drugs 
targeting various ischemic pathophysiological pathways are getting greater attention 
in the future. This approach attempts to maximize treatment effects (Savitz et al., 
2007).   
Future clinical trials for neuroprotective agents should not recruit patients 
with thrombolytic treatment. This imposes complexity for the investigation on the 
potency of the drugs and determination for the specific drug effect (Savitz et al., 
2007). Finally, neurorestoration or agents that can stimulate CNS endogenous repair 
mechanisms have drawn much attention lately. Intriguing futuristic possibilities to 






1.7. Objective of the study   
 Currently, rtPA is the only FDA approved drug for the treatment of acute 
stroke. Ischemic stroke is a myriad, interconnected molecular mechanism leading to 
cell protection or cell death. A single neuroprotective agent working on one particular 
aspect of the ischemic pathological cascade may not be able to achieve substantial 
beneficial neurological outcome. It envisages that stroke treatments need to involve a 
multi-faceted approach with multiple drugs that target different pathways. Hence, the 
quest for understanding pathophysiological roles for stroke and looking for effective 
stroke treatments remains an urgent priority. In this work, I am looking for novel 
molecular candidates that show strong correlation to clinical stroke outcome and by 
targeting them, I am searching for new strategy to impede ischemic cascade to 
facilitate maximal therapeutic outcome.  
 In Chapter 3, I study the potential role of cystathionine β synthase (CBS) in 
acute ischemic stroke. It was previously found that high plasma cysteine (cys) level 
correlated with poor clinical outcome 3 months post-stroke in acute stroke patients 
(Wong et al., 2006). Surprisingly, such association was not observed with the 
excitotoxic amino acids acting on the glutamate receptors, namely glutamate, 
aspartate and glycine. Cys is the precursor of hydrogen sulfide (H2S) via the catalytic 
action of CBS. Therefore increase of cys level could cause an increase in H2S level 
after ischemic stroke. H2S could exacerbate stroke outcome (Qu et al., 2006). In the 
present study, I aim to ascertain that reduction of H2S production in cells leads to a 
reduction of cell death under ischemic conditions. Specifically, I employed cells 
transfected to overexpress CBS, primary astrocytes, and in vivo stroke models to 
provide supporting evidence to support the idea that inhibition of CBS may be a 
potential treatment approach for acute ischemic stroke. 
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 NF-κB signalling activates several pro-inflammatory NF-κB target genes, 
including TNF-α, IL-1α and β, IL-6, inducible nitric oxide synthase (iNOS), 
intercellular adhesion molecule 1 (ICAM-1), and matrix metallopeptidase (MMP) 9, 
key genes of eicosanoid metabolism which encodes for cytosolic phospolipase A2 
(cPLA2), cyclooxygenase 2 (COX-2), and microsomal prostaglandin E synthase 1, 
subsequently aggravate ischemic stroke injury. Andrographolide is a diterpenoid 
lactone isolated from a traditional medicinal herb Andrographis paniculata. It 
possesses potent anti-inflammatory activity and has been used for centuries for the 
treatment of inflammatory diseases. Andrographolide was previously reported to be 
able to bind covalently to the reduced cys 62 residue of the p65 subunit of the NF-κB, 
thus selectively inhibiting NF-κB signalling. Therefore, in Chapter 4, I aim to 
investigate the potential therapeutic effects of andrographolide on cerebral ischemia 
using in vitro ischemic stroke models and rat model with permanent middle cerebral 
artery occlusion (pMCAO).  
 Leukotriene B4 (LTB4) is known to have a variety of pro-inflammatory 
effects. Arachidonate5-lipoxygenase-activating protein (ALOX5AP) gene encodes5-
LO activating protein (FLAP) mutation has great predisposition to ischemic stroke. 
LTB4was synthesized from leukotriene A4 (LTA4) by LTA4 hydrolase, when FLAP 
and 5-LO catalyse the conversion of arachidonic acid (AA). However, the function 
of LTB4 in ischemic stroke and the correlation of LTB4 to ischemic stroke have not 
been studied. Our pilot clinical study showed that high plasma LTB4 levels in stroke 
patients were associated with poor stroke outcome. As such, in Chapter 5, I aim to 
ascertain if this association can be observed in a rat embolic stroke model. In 
addition, I will examine the expression of LTB4 synthesizing enzymes (5-LO and 
LTA4 hydrolase) in the brain and neutrophils, and to investigate if neutrophils 
activation enhances LTB4 synthesis and release.   
 Lastly, cerebral ischemia triggers two general pathways of apoptosis: the 
intrinsic pathway and extrinsic pathway. MOAP-1 has been identified as a BAX-
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associating protein. While the role of MOAP-1 in promoting caspase-dependent cell 
death has been only studied by in vitro molecular biology approach. The in vivo 
physiological role of MOAP-1 is not well understood. Therefore, I aim to investigate 
the potential role of MOAP-1 as an important apoptotic mediator in ischemic injury 

























Chapter 2: Materials and Methods  
2.1. Ethics statement 
All animal care and experimental procedures on animals in the thesis were 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
National University of Singapore. All efforts were made to minimize the suffering 
and number of rats in all experiments. Animals were housed under diurnal lighting, 
conditions and fed standard rat chow and water ad libitum. 
2.2. Permanent middle cerebral artery occlusion (pMCAO) on rats  
Cerebral ischemia was induced by permanently removal of left middle 
cerebral artery (MCA) with modification (Tamura et al., 1981). Male Sprague 
Dawley (SD) rats (270 - 330g) were randomly assigned into sham with vehicle 
control, pMCAO with vehicle control or pMCAO with drug treatment. Rats were 
anesthetized with ketamine (75 mg/kg, intraperitoneal) and xylazine (10 mg/kg, 
intraperitoneal). The animal was placed in a lateral position and a vertical 2 cm 
incision was made between the left orbit and the external auditory canal. The second 
incision was made on the superior and posterior margins of the temporalis muscle. 
The muscle was retracted and exposed the skull and zygoma. Zygoma was removed 
to expose the infratemporal fossa. A cranietomy was made using a dental drill at the 
junction between the medial wall and the roof of the infratemporal fossa. Next, the 
drilled skull was removed and MCA was exposed under a layer of dura. Dura was 
then removed carefully without damaging cerebral vasculatures by a modified 27G 1 
inch long needle. The MCA ran over the white band of myelinated fibres and two 
points of MCA were cauterised with a disposable cauteriser (Bovie Medical 
Corporation, USA), at the origin of MCA after myelinated fibres and at the point it 
intersects the inferior cerebral vein. After occlusion, the skin was sutured with 4-0 
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polypropylene monofilament. During operation, rat body temperature was maintained 
at 37°C until recovery from anaesthesia.   
2.3. Transient middle cerebral artery occlusion (tMCAO) on rats  
The proximal occlusion of MCA via the intraluminal suture techniques is the 
most commonly used model in experimental stroke research. It was initially 
developed in rats by Koizumi (Koizumi et al., 1986) and further modified by Longa 
(Longa et al., 1989). Male Wistar rats were anesthetized with isoflurane (1.5 unit) in 
a 30% oxygen and 70% nitrous oxide mixture. Laser Doppler sonography probe was 
used in the experiment to determine the relative cerebral blood flow (rCBF) which is 
crucial to confirm occlusion of MCA in the intraluminal suture techniques. A small 
temporal incision was made on the right scalp and the masseter muscle was 
dissociated from the edge of the skull. Next, the skull was thinned with a dental drill 
and a laser-Doppler sonography probe was mounted on the right parietal bone. The 
real time rCBF was monitored throughout the whole surgery. To induce cerebral 
ischemia, animal was placed in a supine position. Briefly, a 2 cm midline neck 
incision was made to expose the common carotid artery (CCA). The tissue and nerves 
surrounding the CCA was carefully dissected. The occipital artery was cauterised and 
tissues surrounding internal carotid artery (ICA) was carefully dissected to expose 
pterygopalatine artery. Pterygopalatine artery was permanently ligated with 7-0 silk 
suture. After exposing the external carotid artery (ECA), two ligations, one 
permanent and one temporary were made on ECA. Temporary ligation was placed in 
the bifurcation of CCA and ECA. An incision was made in between two ligations, 
and a small half incision was made on ECA for monofilament insertion. Next, a 4-0 
monofilament silicon coated filament was passed from ECA and inserted into ICA. 
The filament was advanced to around 19 to 20 mm from the CCA bifurcation and a 
sharp dropped of relative cerebral blood flow to 70% was observed to ensure the 
success of inducing MCA occlusion on rats. A 100 min occlusion was made followed 
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by reperfusion of cerebral blood flow by withdrawal of silicon-coated filament. A 
restoration of cerebral blood flow from 30% to around 70% should be observed. 
Finally, the skin was sutured with 4-0 polypropylene monofilament and animals were 
returned to their home cage when awaken from anaesthesia. Representative TTC 
staining and cerebral blood flow are shown in Figure 2.1.  
 
Figure 2.1. Rat tMCAO model with 100 min occlusion and 22 h 20 min 
reperfusion. (A). showed the TTC staining for rat tMCAO model at 24 h post-stroke. 
(B). The representative brain pictures after 0.1 M PBS perfusion, necrotic tissue 
appeared as relatively whitish in the right cortex. (C). The representative laser 
Doppler flowmetry before occlusion, during occlusion and after reperfusion.     
 
2.4. Thromboembolic stroke model on rats  
The thromboembolic stroke model was adapted from Zhang et al. (Zhang et 
al., 1997b) and Aoki et al. (Aoki et al., 2002). Male Wistar rats (270 to 300g) were 
anesthetized with isoflurane (1.5 unit) in a 30% oxygen and 70% nitrous oxide 
mixture. Briefly, femoral arterial blood from a donor rat was withdrawn by a PE-50 
tube and kept at room temperature for 2 h. Blood clot was transferred to 4°C and 
subsequently retained for 22 h. PE-50 tubing containing blood clot was cut into 3.5 
centimetre and transferred into a sterile saline, followed by several washed. The clot 
was subsequently transferred carefully to a modified PE-50 catheter. A surgical 
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incision was made as described in 2.3 (page 40). Upon completion of all ligations, 
surgical clips were applied to the CCA and ICA to stop the blood flow during incision 
on ECA. The sterile modified PE-50 catheter that contains the clot was inserted 
gently from the ECA into the distal ICA and the homologous clot finally occluded 
MCA. The catheter was withdrawn at 5 min after the clot was injected. Laser Doppler 
flowmetry (2 mm posterior, 5 mm lateral to bregma) was used to monitor the relative 
cerebral blood flow. Relative CBF with less than 20% of pre-ischemic baselines after 
injection of homologous clots and maintained for a period of 2 h without spontaneous 
recanalization was used as the inclusion criteria. Representative TTC staining and 
cerebral blood flow are shown in Figure 2.2. 
 
 
Figure 2.2. Rat thromboembolic model. (A). A 3.5 cm emboli was made as 
described above. (B). At 3 h after the emboli injection, clot was clearly seen in ICA 
and blocked cerebral blood flow to MCA. Emboli remained in the brain after 72 h. 
(C). The representative laser Doppler flowmetry before and after occlusion. Relative 
cerebral blood flow was monitored up to 2 h (D). The representative figure for TTC 






2.5. Transient middle cerebral artery occlusion (tMCAO) on mice  
 The operation procedure for tMCAO model was similar to rats tMCAO 
model. Six to eight weeks adult male C57BL/6 mice was used in the study. Laser-
Doppler sonography probe was mounted directly on the skull. Briefly, a 2 cm neck 
incision was made. Trachea was exposed by dissecting the soft tissues. Next CCA 
and ECA was carefully dissected without harming the vagal nerve. Next, ECA was 
ligated to 7-0 suture and second knot was made on ECA in the bifurcation of ECA 
and ICA. CCA was temporary ligated by a 4-0 silk suture and small vascular clip was 
applied on ICA. A small cut was made on ECA, therefore, the modified silicon coated 
7-0 polypropylene monofilament can be inserted into ECA and advancing into ICA. 
Different from rat tMCAO model, pterygopalatine artery was not ligated in mice 
tMCAO model. Next, silicon coated filament was further advanced into ICA until a 
significant drop of relative cerebral blood flow from 100% to around 15% was 
observed. Reperfusion was achieved upon withdrawal of silicon coated filament and 
restoration of relative blood flow detected by laser Doppler flowmetry. 




Figure 2.3. Mice tMCAO model.(A). C57BL/6 mice were used in the study. (B). 
The representative laser Doppler flowmetry before occlusion, after occlusion of CCA, 
during MCA occlusion for 90 min and reperfusion by removal of monofilament. (C). 
The representative TTC staining for tMCAO and pMCAO models on mice at 24 h 
post-stroke.     
 
2.6. Generation of MOAP-1 knockout mice  
 MOAP-1 knockout mice was kindly provided by Associate Professor Victor 
Chun-Kong Yu, Department of Pharmacy, National University of Singapore (NUS). 
Littermates up to F7 generation were used in the study. The knockout genotype was 
confirmed by PCR genotyping and western blotting.  
 
2.7. Evaluation of neurological score  
 The rat neurological outcome can be scored as listed below according to 




Score Behavioural outcome  
0 Rat is active and healthy without showing significant 
neurological sign. When lift the rat 1 m above the floor, 
forelimbs extend towards the floor.  
1 When lift the rat 1 m above the floor, forelimbs flex 
consistently. 
2 Only when the tail is pulled, rat circles spontaneously towards 
the contralateral side. Rat can move straight in an open field.  
3 Without pulling the tail and allow to move freely in an open 
field, rat circles spontaneously. 
4 Rat is weak, inactive, paralyzes to ipsilateral side and shows no 
spontaneous movement. 
5 Dead  
 
 
2.8. Rotarod  
 24 h after stroke, animals were assessed for motor functions by rotarod (TSE 
system, USA). During the assessments, animals were placed on the accelerating rod 
at a starting speed of 4 rpm. The rate of the rotating rod was accelerated from 4 - 400 
rpm within 240 s. The trials were repeated 3 times for an interval of 20 min. The 
latency to drop of each animals was measured. Average of the last two trials were 
calculated.   
  
2.9. Infarct volume assessment  
 The rats were euthanized at 3, 8 or 24 h after stroke. The whole brains were 
cut into 2 mm coronal sections using a brain-sectioning block (Zivic Miller, USA) 
and immediately stained by 2% 2,3,5-Triphenyltetrazolium chloride (TTC, Sigma, 
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USA) at room temperature for 15 min. Images for TTC stained brain sections were 
taken. The infarct volume was measured using the Image J (NIH, USA) with 
correction for brain oedema (Figure 2.4).  
 The true infarct volume (IV) was calculated as below,  
Equation 1: IV (mm3) = Σ [IA / (ASF)] * Thickness  
(thickness for rats  brains = 2 mm, thickness for mice = 1 mm; IA = infarct area) 
Equation 2: ASF (Average swelling factor) = (IH - NIH)/ (IH + NIH)/ N 
(N is the number of slides cut from brain. N = 8 for Chapter 4; N = 6 for Chapter 5; N 
= 7 for Chapter 6  
IH= infarct hemisphere; NIH=non infarct hemisphere 
Equation 3: Percentage of infarct volume = Σ IV/ Σ (NIH*Thickness)*100% 
 
Figure 2.4. Measurement of infarct volume. NIH: non-infarct hemisphere; IH: 
infarct hemisphere; IA: infarct area.  
 
 
2.10. Rat or mouse primary neuron culture  
Primary neuron was prepared from E17/18 pregnant Sprague Dawley rats or 
E15/16 pregnant C57BL/6 mice as described previously (Cheung et al., 2007) with 
minor modification. Poly-D-lysine coated plates were prepared one day in advance. 
Briefly, 0.1 mg/ml of sterile poly-D-lysine (Sigma, USA) was dissolved in autoclaved 
distilled water and filtered with 0.2 µM filter unit (Minisart, Sartorius stedim). Next, 
the poly-D-lysine was loaded onto tissue culture plates and incubated at 37ºC in 5% 
CO2 incubator overnight. Before seeding primary neuron onto poly-D-lysine coated 
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plates, poly-D-lysine solution was discarded and washed once with autoclaved 
distilled water. Tissue culture plates were further dried until primary neurons are 
ready for seeding. Surgical tools were autoclaved and oven dried until usage. Culture 
medium were prepared as followed,  
A. Solution 1 (Filtered and keep at 4°C) 
250 ml of the sterile Hank's blank salt solution (HBSS, Sigma, USA) solution 
1.94 ml 150 mM Magnesium sulfate (Sigma, USA) 
0.75 g Bovine Serum Albumin (Sigma, USA) 
 
B. Solution 2 (Filtered and keep at 37°C water bath)  
20 ml solution 1 
80 μl DNAse (Sigma, USA) 
4 mg Trypsin (Sigma, USA) 
 
C. Solution 3 (Filtered and keep at 4°C) 
20 ml solution 1 
200 μl 150 mM Magnesium sulfate (Sigma, USA) 
80 μl DNAse (Sigma, USA) 
10.4 mg trypsin inhibitor (Sigma, USA) 
 
D. Solution 4 (Filtered and keep at 4°C) 
16.8 ml solution 1 
3.2 ml solution 3 
 
Fetal rats or mice were removed from pregnant rats/mice and cerebral 
cortices were harvested under surgical microscope. Meninges of fetal rats or mice 
were removed with fine forceps and transferred to solution 1 in a 50 ml falcon tube 
(BD bioscience). The cortical cortex was centrifuged at 1000 rpm for 1 min at 15°C 
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and supernatant was discarded. Cell pellet was re-suspended in solution 2 and 
incubated in 37°C water bath for 5 min. Solution 4 was added into cells digested in 
solution 2 and centrifuged at 1000 rpm for 5 min at 15°C. Supernatant was discarded 
and pellet was gently re-suspended in solution 3 using a 10 ml serological pipette, 
followed by 5 ml serological pipette. The cells further centrifuged at 1000 rpm for 15 
min at 15ºC. Finally, the pellet was re-suspended in neurobasal medium (Gibco, Life 
technologies) supplemented with 1% penicillin/streptomycin (Gibco, Life 
technologies), 2.5% B27 (Gibco, Life technologies), 0.25% Glutamax (Gibco, Life 
technologies) and 10% fetal bovine serum (FBS, Gibco, Life technologies) and 
seeded in a cell density of 1 million cells per well in 6 well plate. Cells were then 
incubated at 37ºC in 5% CO2 incubator. Culture medium was changed 24 h later to 
neurobasal supplemented with 1% penicillin/streptomycin, 0.25% Glutamax, 2.5% 
B27. At Day 4, half medium was change to neurobasal supplemented with 1% 
penicillin/streptomycin, 0.25% Glutamax, 2.5% B27 with cytosine 
arabinoside (AraC, Sigma, USA) at final concentration of 1 µM. The mature cortical 
neurons were cultured until day 9-10 for use.  
2.11. Primary astrocyte culture from rats  
Primary astrocyte cultures were prepared from the cerebral cortices of 1-2 
day old Sprague-Dawley rat pups as described previously (Lu et al., 2008) with minor 
modifications. Briefly, the cerebral cortices were harvested and trypsinized with 
0.25% trypsin (Gibco, Life technologies) at 37°C. The cells were seeded onto 0.1 
mg/ml poly-D-lysine coated flask with DMEM/F12 (Gibco, Life technologies) 
medium supplemented with 10% FBS (Gibco, Life technologies) and 1% penicillin–
streptomycin (Gibco, Life technologies). The cultures were maintained at 37°C in a 
humidified atmosphere with 95% air/ 5% CO2. Culture medium was replaced 72 h 
later and changed medium twice weekly thereafter. At 10-12 days, the confluent 
cultures were shaken overnight to remove microglia and oligodendrocytes. The 
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remaining astrocyte monolayers were cultured until day 21 with change of medium 
twice weekly thereafter.   
2.12. Human neuroblastoma cells (SH-SY5Y) cell line, human embryonic kidney 
293 (HEK-293) and human embryonic kidney FT (HEK-FT) cell line  
Neuroblastoma SH-SY5Y, human embryonic kidney 293 (HEK-293) and 
human embryonic kidney FT (HEK-FT) cell lines were obtained from American 
Type Culture Collection (ATCC). Cells were maintained in DMEM/F12 (for SH-
SY5Y cells; Gibco, Invitrogen, USA) containing 10% fetal bovine serum (FBS, 
Gibco, Invitrogen, USA) and 1% penicillin–streptomycin (Gibco, Life technologies, 
USA) or DMEM (for HEK-293 or HEK-FT cells; Gibco, Life technologies, USA) 
containing 10% FBS (Gibco, Life technologies, USA) and 5% penicillin/streptomycin 
(Gibco, Life technologies, USA) at 37°C and incubated in a humidified atmosphere 
with 95% air/ 5% CO2. 
2.13. Cell viability assay  
 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) assay 
and lactate dehydrogenase (LDH) assay were employed to examine the cell viability. 
Briefly, upon completion of the experiments, old medium was discarded and replaced 
with cell culture medium with MTT (Sigma, USA) at a final concentration of 0.5 
mg/ml. The cells were incubated in MTT added medium at 37ºC for 2.5 h. After 2.5 h 
of MTT incubation, the medium containing MTT was removed and replaced with 
DMSO (Sigma, USA). Finally, the absorbance at 570 nm was measured with a 
reference wavelength at 630 nm by a microplate reader (Sunrise; TECAN) 20 min 
later. Moreover, cell viability was further confirmed by measuring the release of 
lactate dehydrogenase (LDH) in the culture medium by Cytotoxicity Detection Kit 
(Roche). Hundred percent cytotoxicity control was made by administering 2% Triton 
X-100 (Sigma, USA) cell medium to the control cells. Absorbance at 490 nm was 
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determined using a microplate reader (Sunrise; TECAN) after 30 min 
incubation. Percentage of LDH release was measured as [(experimental value - 
vehicle control)/ (100% cytotoxicity control - vehicle control)] × 100%. 
  
2.14. Immunohistochemistry  
 24 h after pMCAO, tMCAO or thromboembolic stroke, the rats were 
anaesthetized and perfused with 0.1 M phosphate buffer saline [16.6 g 
Na2HPO4.7H2O and 2.5 g NaH2PO4.2H20 and 8.9 g of NaCl in 1 L of deionised 
water, pH 7.2] followed by 4% paraformaldehyde [40 g dissolved in 0.1 M phosphate 
buffer, pH 7.2] through the heart. Brains were harvested and immersed in 4% 
paraformaldehyde for overnight at 4ºC, and then dehydrated in 10% sucrose at 4ºC 
overnight. Finally, the brains were cryopreserved at 20% sucrose at 4ºC. Coronal 
sections (30 µm) were cut using a cryostat and mounted onto glass slides 
(Matsunami, Japan) and air dried overnight. Brain slides were stored in -80°C until 
use. Upon staining, brain slides were air dried in room temperature for 30 min and 
permealized with 0.1% Triton-X (Sigma, USA, dissolved in 0.1 M phosphate buffer 
saline) for 10 min. Next, non-specific binding was blocked by incubating the section 
in 5% goat serum for 1 h and followed by interested primary antibodies 4ºC 
overnight. On the next day, the brain sections were washed three times with 0.1 M 
PBS. This was followed by incubation of brain sections with mouse/rabbit secondary 
antibody and streptavidin biotinyated horseradish peroxidase (HRP) complex (ABC 
kit, Vector Laboratories) at a concentration 1:200. Next, brain slices were washed 
three times with 0.1 M PBS and incubated in 1 X TBS buffer before the 
diaminobenzidine (DAB) experiment. In a fume hood, DAB-enhanced liquid 
substrates (Sigma Aldrich, USA) were loaded onto the brain sections for 5-10 
minutes. This was followed by five times washing of DAB stained brain sections for 
5 X of 1 X TBS buffer, methyl green counterstaining and a series of dehydration 
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process. Finally, sections were mounted with mounting medium and dried for 
overnight. Images of DAB stained brain sections were taken using a light microscope 
(Nikon Eclipse 80i, Japan).  
 Immunofluorescent staining was done as described in DAB methods except 
secondary used was fluorescent tag with anti-rabbit secondary antibody conjugated 
with Alexas 488 (Life technologies, USA) and anti-mouse secondary antibody 
conjugated with Alexas 555 (Life technologies, USA) for 1 h at room temperature. 
Nuclei was countered with diamidino-2-phenylindole dihydrochloride (DAPI, Sigma, 
0.5 µg/ml in 0.1 M phosphate buffer saline) for 5 min, followed by mounting with 
Pro-Long gold antifade fluorescent mounting medium (Life technologies, USA). 
Negative control was performed by probing sections with 0.1% Triton-X (Sigma, 
USA, dissolved in 0.1 M phosphate buffer saline) overnight. All the fluorescent 
images were captured using an Olympus FluoViewFV1000 (Olympus, Japan) laser 
scanning confocal microscope and images captured was processed by FV10-ASW1.7.  
2.15. Western blot  
2.15.1. Buffer preparation  
(A). 10 × PBS 
80 g NaCl 
2 g KCl 
14.4 g Na2HPO4 
2.4 g KH2PO4 
Dissolve in 1 L of deionised H2O  
(B). 1 × PBST  
Dilute 10 × PBS to 1 × PBS and adjust pH to 7.4  





(C). 10 x Running Buffer 
30.3 g (0.25 M) Tris Base 
144 g (1.92 M) Glycine 
10 g (1%) SDS or appropriate for concentrated stock 
add 1000 ml of deionised H2O  
(D). 1 x Running Buffer 
Dilute 10 x to 1 x  running buffer with deionised H2O  
pH will be around 8.3  
(E). 10 x Towbin’s Electrotransfer Buffer 
30.3 g Tris Base 
144 g Glycine 
add 1000 ml of deionised H2O  
(F). 1 x Towbin’s Electrotransfer Buffer 
100 ml 10 x Towbin’s Electrotransfer Buffer 
200 ml (20%) Methanol 
Mix with 700 ml of deionised H2O  










10% Seperating Gel 10 ml  
40% Acrylamide/Bis (29:1) (Biorad) 2.5 ml 
1.5M Tris (pH 8.8) (Sigma) 2.5 ml 
Deionised H2O 4.8 ml 
10% SDS (Sigma) 100 µl 
10% APS (Sigma) 100 µl 
TEMED (Biorad) 10 µl 
4% Stacking Gel 5 ml  
40% Acrylamide/Bis (29:1) (Biorad) 0.5 ml 
0.5M Tris (pH 6.8) (Sigma) 1.25 ml 
Deionised H2O 3.2 ml 
10% SDS (Sigma) 50 µl 
10% APS (Sigma) 50 µl 




10 ml of RIPA buffer (brain tissue samples, Cell signalling technologies) or 
CST lysis buffer (cell samples, Cell signalling technologies) was added with 1 tablet 
of protease inhibitor (Roche, Mannheim, Germany) and phosphatase inhibitor 
(Roche, Mannheim, Germany) before use. Brain tissues were thawed on ice and 
homogenized with 3 ml glass motor/pestle in RIPI buffer at 100 mg/ml. Cells were 
spun down by centrifugation after trypsinization and washed twice with cold PBS. 
The cells pellets were then re-suspended with 200 µl of CST buffer by passing though 
a 23G needle for five times. Homogenized brain tissue or cell samples were shaken 
on ice for 30 min for cell lysing. Finally, brain tissue or cell samples were centrifuged 
at 12,000 rpm at 4°C for 10 min and supernatant was stored at -80ºC until use. Total 
protein was determined by Bradford protein assay (Biorad, CA, USA) and mixed 
with 4 × laemmli buffer. Denaturation of proteins will be performed by heating up of 
total protein laemmli buffer mixture at 100°C for 5 min. Protein samples were stored 
at -80°C until use. Proteins were separated by 10% SDS/PAGE with running buffer 
(60 V for stacking, 30 min; 90 V for seperating, 3 h) and finally transferred onto a 
PVDF membrane (Amersham Biosciences, Buckinghamshire, UK) with wet transfer 
methods using towbin's electron transfer buffer (80 V for 90 min). Next, the non 
specific binding was blocked with 10% non-fat milk at room temperature. The 
membrane was then incubated with antibodies (dissolve in 5% BSA) at 4°C 
overnight, then washed and incubated in HRP-conjugated anti-rabbit or mouse IgG 
(Chemicon, Millipore Corporation) at room temperature for 1 h. Visualization was 
carried out using Luminata Forte or Crescendo western HRP substrate (Millipore 
Corporation, Billercia, MA, USA) and the chemiluminescence signals were detected 




2.16. Construction of rat CBS lentiviral expression vectors 
First strand cDNA was synthesized from PC12 cells total RNA using the 
RevertAid H Minus First strand cDNA Synthesis Kit (Fermentas/Thermo Scientific). 
CBS coding region was isolated by PCR from the cDNA using PrimeStar GXL DNA 
Polymerase (Clontech) with a SalI site-containing forward (5' CGCGTCGACCATG 
CCTTCAGGGACATCC 3') and BamHI site-containing reverse (GCGGATCCTA 
TTTCCGGGTCTGCTCAC) primers. Amplified product was digested with SalI and 
BamHI and inserted in-frame 3' to a myc-tag sequence in pL6mCWmycIE lentiviral 
vector to give pL6mCWmycCBSIE. pLenti6mCWmycIE was modified from 
pLenti6/V5-D-TOPO (Invitrogen) by reengineering the multiple cloning site, 
insertion of the cPPT and WPRE elements, and insertion of the N-terminal myc tag 
coding sequence and IRES-EGFP reporter cassette. Lentivirus packaging was 
performed in 293FT cells followed the manufacturer instruction (ViraPower™ 
Lentiviral Directional TOPO® Expression Kit, Invitrogen). Lentiviral particles were 
harvested from cell culture supernatant and used to transduce undifferentiated SH-
SY5Y cells when it reached 90% confluence in the presence of media containing 8 
μg/ml of Polybrene (Sigma Aldrich). Cell culture media was changed one day after 
transduction and Balsticidin S (10 μg/ml, Invitrogen) was used to select the CBS 
expressing SH-SY5Y. Expression of transgene was visualized by EGFP fluorescence. 
2.17. Oxygen glucose deprivation (OGD) 
OGD was achieved by incubating the SH-SY5Y cells in glucose free DMEM 
(Gibco, Life technologies) with 1% streptomycin/penicillin in a hypoxia chamber 
(1% O2/ 5% CO2/ 94% N2) for 24 h at 37˚C in a humidified incubator. OGD for 
primary cortical astrocyte culture was achieved by incubating the primary astrocytes 
in glucose free DMEM with 1% streptomycin/penicillin in a hypoxia chamber (5% 
CO2/ 95% N2) from 0.5 h to 8 h at 37˚C in a humidified incubator.  
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2.18. H2S synthesizing activity assay in cells  
H2S synthesizing activity in cells was measured according to Qu et al. (Qu et 
al., 2006). Briefly, cells were homogenized in 0.1 M potassium phosphate buffer, pH 
7.4 (0.45 ml) under varying concentrations of Cys and Hcy (total volume 0.5 ml). 
Blank was done by omitting the substrates. After incubation for 90 min at 37°C, Zinc 
acetate (Sigma, 1%, 0.25 ml)) was added into the reaction mixture and followed by 
the addition of tricholoracetic acid (Sigma, 10%, 0.25 ml). After centrifugation 
(13,000 rpm, 10 min) at 4°C, N-dimethyl-p-phenylenediamine sulfate (Sigma, 20 mM 
prepared in 7.2 M HCl, 0.133 ml) and FeCl3 (Sigma, 30 mM prepared in 1.2 M HCl, 
0.133 ml) were added to the supernatant. Absorbance at 670 nm was measured by a 
microplate reader (Sunrise; TECAN) 20 min later. Absorbance was converted to H2S 
concentration through a standard curve obtained by using NaHS as the standard. 
2.19. H2S synthesizing activity assay in brain tissue 
H2S synthesizing activity was performed in a reaction tubes fitted with air-
tight rubber septum. An 2 ml eppendorf tube contained a folded 2 cm × 2.5 cm filter 
paper (Whatman No. 1) was placed inside the reaction tubes. Five hundred microlitter 
of zinc acetate (1%, w/v; dissolved in 12% NaOH) was added into the eppendorf tube 
to trap the evolved H2S. Brain homogenate (300 µl., 50% w/v) in 50 mM potassium 
phosphate buffer (pH 6.8) was pre-incubated with vehicle control, or tested drug for 
10 min in 37°C water. The inhibitory reaction was temporary stopped by placing the 
reaction tube on ice and 10 mM of cysteine (Cys), 10 mM homocysteine (Hcy) and 2 
mM of pyridoxal 5'-phosphate (PLP) were added into the reaction mixture. The total 
volume was 1 ml. The reaction was initiated by incubating on 37°C water bath for 90 
min. Next, the reaction was stopped by injecting trichloroacetic acid (TCA, 0.5 ml, 
50% w/v) through the rubber septum to prevent the leaking of gas. After 1 h of 
incubation, 0.5 ml of N,N-Dimethyl-p-phenylenediamine sulphate (dissolved in 7.2 
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M HCl) and 0.5 ml of FeCl3 (dissolved in 1.2 M HCl) were added into the centre 
well. The centre well with trapped H2S were incubated in room temperature in dark. 
Absorbance at 670 nm was measured by a microplate reader (Sunrise; TECAN) 20 
min later. Absorbance was converted to H2S concentration through a standard curve 
obtained by using NaHS as the standard. 
2.20. High performance liquid chromatography (HPLC) 
2.20.1. Standard preparation 
 Individual stock solutions of D/L-hcy (Sigma, USA), L-cys (Sigma, USA), 
cysteinyl glycine (Sigma, USA) and glutathione (GSH, Sigma, USA) were dissolved 
in deionised H2O at appropriate concentration. Calibration curve were then 
constructed using 6 standard concentrations of the four aminothiols in 1 × PBS, pH 
7.4 and were run in triplicate. Internal standard used was cystamine dihydrochloride 
(Sigma, USA).  
 
2.20.2. Sample preparation 
 A mixture of 50 µl of stroke patients or animals serum or plasma samples, 25 
µl of cystamine dihydrochloride (Sigma, USA), and 25 µl of PBS at pH7.4 was 
incubated with 10 µl of 100 g/l tris(2-carboxyethyl)phosphine (TCEP, Sigma, USA) 
for 30 min at room temperature to reduce and release protein bound thiols. Next, 
deproteinization was achieved by adding 90 µl of 100g/L TCA (containing 1 mM 
EDTA, Sigma, USA) to the sample solution followed by centrifugation at 13,000g for 
10min. After centrifugation, 50 µl of the supernatant was added to an autosampler 
vial which contained 10 µl of 0.55 M NaOH; 125 µl of 0.125 M borate buffer 
(containing 4mM EDTA), pH 9.5; and 50 µl of 1 g/L 7-fluorobenzo-2-oxa-1,3-
diazole-4-sulfonic acid ammounium (SBD-F, Sigma, USA) in the borate buffer. The 
sample was then incubated for 60 min at 60°C. Aminothiols separation and 
determination was performed by using Shimadzu HPLC-fluorescence system.    
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2.20.3. Mobile phase and chromatographic conditions 
 The HPLC system consists of a Shimadzu system controller CBM-20A, 
solvent delivery unit LC-20A, auto-sampler SIL-20A, column oven CTO-20A, 
RF10AXL fluorescence detector with a 150W Xenon lamp. The detector was set at 
excitation and emission wavelengths of 385 nm and 515 nm respectively. Signal 
output was captured with the Shimadzu LC system software. Separation of the 
analytes was achieved with Ascentis C18 analytical column (Sigma, USA) at 29°C. 
The two mobile phases consisted of A: 1% acetic acid and B: HPLC grade 
acetonitrile. Aminothiols were separated over 10 min at a flow rate of 1ml/min, 
starting at 100% A (changed linearly over 5 min), followed by 90% : 10% A: B and 
reduced the concentration of A to 75% in gradient (increased of mobile phase B 
concentration to 25% respectively) over 5 min. The column was re-equilibrated for 
another 5 min before the starting of the next injection. The total run time for each 
sample was 15 min.     
2.21. Data analysis  
 All data are presented as mean ± SEM. Statistical significance was assessed 
with one-way ANOVA followed by a post hoc (Bonferroni) test for multiple group 
comparison. Differences with P value less than 0.05 were considered statistically 
significant. For neurological scores (Chapter 4), data were analyzed by the chi-square 









Chapter 3: Cystathionine β-synthase inhibition is a potential therapeutic 
approach to treatment of ischemic injury 
3.1.1. The discoveries of physiological role for H2S 
 Hydrogen sulfide (H2S) has been well known for the rotten egg smell. Its 
toxicity was first described in 1713 (Ramazzini et al., 1713). Since then, several 
reports on fatal intoxication by H2S has been documented (Burnett et al., 1977; Kabil 
et al., 2010; Kombian et al., 1993; Reiffenstein et al., 1992; Smith et al., 1979; 
Warenycia et al., 1989). At 3-10 ppm, H2S in the air appears unpleasant to human. At 
50 ppm, it irritates the eyes and respiratory tract. Above 500 ppm, H2S causes loss of 
consciousness, respiratory failure and eventually fatal to humans (Hu et al., 2011; Liu 
et al., 2012). It is believed that H2S attributes toxicity by activating of Ca2+ channels 
and Ca2+ dependent K+ channels (Kombian et al., 1993), reversibly inhibiting of 
cytochrome c oxidase (Hu et al., 2011) or inhibiting of carbonic anhydrase and 
monoamine oxidase (Liu et al., 2012). The physiological role of H2S in central 
nervous system (CNS) was first described in 1996 by Abe and Kimura (Abe et al., 
1996). Since then, like other gasotransmitters such as nitric oxide (NO) and carbon 
monoxide (CO), much attention has been drawn to H2S.  
3.1.2. Physical properties of H2S 
 H2S is a colour gas with a molecular weight of 34.08. It exists in gaseous 
form at room temperature and normal atmospheric pressure. In the mammalian body 
at physiological pH 7.4, approximately one third of H2S remains un-dissociated, 
while two third exists as hydrosulfide anion (HS-) while the rest appears as sulfur 
anion (S2-) (Reiffenstein et al., 1992). In the literature, the term free "H2S" is always 
refer to the sum of  HS-S2- and H2S (Reiffenstein et al., 1992).H2S is known to be able 
to penetrate cell plasma membrane freely due to its lipid solubility. Sodium 
hydrosulfide (NaHS) and sodium sulfide (Na2S) or the gaseous form of H2S have 
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been widely use as exogenous sources for H2S in laboratories (Hu et al., 2011). 
Former two sources of H2S, is known to rapidly dissociate when presences as a 
bolous thus do not reflect the physiological biosynthesis of H2S in vivo. Few slow-
releasing compounds have been recently developed for laboratories use, for example 
GYY4137 (Li et al., 2008) and S-diclofenac (Li et al., 2007).  
3.1.3. Endogenous source of H2S  
 H2S is endogenously expressed in several tissues, for instance heart, blood 
and brain (Tan et al., 2010). It was previously reported that H2S level in the brain was 
found to fall within a range of 50-160 µM (Goodwin et al., 1989; Warenycia et al., 
1989). Three enzymes have been known that contribute to endogenous production of 
H2S, namely cystathionine β-synthase (CBS, EC. 4.2.1.22), cystathionine γ-lyase 
(CSE, EC. 4.4.1.1) and 3-mercaptopyruvate sulfurtransferase (3MST, EC. 3.4.1.2). 
CBS and CSE are expressed in various tissues, including liver, heart, vasculature, 
brain, lymphocytes and kidney. CSE is the predominant H2S synthesizing enzyme in 
the cardiovascular system (Bian et al., 2006). Its mRNA level was reported in the 
myocardium (Geng et al., 2004), endothelial cells (ECs) (Yang et al., 2008) and 
smooth muscle cells (SMCs) (Zhao et al., 2001a). A novel study done by Rui Wang's 
group showed that mice deficient with CSE, developed hypertension spontaneously 
(Geng et al., 2004). These findings raised much attention on the role of H2S in 
vascular disease development. Moreover, CSE-/- mice was reported to develop lethal 
myopathy and were more susceptible to oxidative stress with cys deficient diet (Ishii 
et al., 2010). Taken together, these studies suggested that the physiological role of 
CSE in synthesizing H2S was found to be more profound in cardiovascular system. In 
the brain, CBS and 3MST are predominantly expressed (Shibuya et al., 2009b). 
3MST produces H2S in conjunction with cysteine aminotransferase (CAT, EC. 
2.6.1.3), in the presence of cys and α-ketoglutarate. CBS was regarded as the 
predominant enzyme contributes to H2S production in the brain previously. Until 
60 
 
Shibuya and colleagues found that H2S was produced at similar levels in both wild 
type and CBS-/- mice (Shibuya et al., 2009a). It is believed that 3MST produces H2S 
more efficiently than CBS (Shibuya et al., 2009a; Zhao et al., 2013). It could be due 
to the fact that 3MST can synthesize H2S from bound sulfane sulfure with higher 
efficiency than CBS (Shibuya et al., 2009a). Both CBS and CSE enzyme activity 
were found in adult mice brains. However, CBS enzyme activity is relatively higher 
in the brain than CSE by about 10-fold (Awata et al., 1995). In the following year, by 
Northen blot approach, Abe and Kimura found that CBS express in several brain 
regions. However, no significant CSE expression was detected (Abe et al., 1996). To 
support, they also found that high affinity CSE inhibitors did not suppress the 
production of H2S in the rat brain.  
 Cellular localization of CBS in the brain remains controversial. Robert et al. 
(Robert et al., 2003) used in situ hybridization and Northern blot to study the gene 
expression of CBS in the brain. Their results indicated that CBS expression was 
strongest in Purkinje cell layer and hippocampus. It was found declined in late 
embryonic stages but peaked after birth. Next, they used immunohistochemistry to 
investigate protein expression of CBS and found that most CBS localized in the cell 
bodies and neuronal process of Purkinje cells and Ammon's horn neurons. The 
localization of CBS in neuron was supported by Vitvitsky et al. by radiolabeling 
metionine and glutathione. Results showed that human astrocytes and neurons were 
both radiolabelled by isotopes (Vitvitsky et al., 2006). This further justified the 
possibility that CBS expressed in astrocyte as well as neuron. In contrast, Enokido et. 
al., by using double immunofluorescent approach, found that CBS was ubiquitously 
expressed in rat brain and mostly expressed in cerebellar molecular layer and 
hippocampal dentate gyrus, specifically localised in Bergmann glia and in astrocytes 
(Enokido et al., 2005). In postmodern human brain and human cell lines, Lee et al. 
found that CBS is expressed in the human brain and the CBS positive staining was 
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highly co-localized with astrocytes (Lee et al., 2009a). Lee and colleagues reported 
that culture astrocytes CBS enzymatic activity specific to H2S production is 7-fold 
higher than microglia, 10-fold higher than neuroblastoma cell SH-SY5Y and 11-fold 
higher than embryonic carcinoma cells NT-2, thus provided further evidences to 
support Enokido observation. The specific cellular localization of CBS in brain 
remains to be further confirmed.  
 Nonetheless, the concentration of H2S remains controversial. Conventionally, 
H2S concentration was found at micromolar concentration. Using gas 
chromatography with chemiluminescence sulfure detector, H2S concentration was 
detected to be around 14 ± 3 nM in eight mice brains (Furne et al., 2008). Ishigami 
and co workers developed a new method using small particles of silver to absorb H2S 
as Ag2S from the brain homogenates. Compare to the traditional H2S assay involves 
methylene blue, silver particle methods is more superior to avoid the possibility of 
measuring the acid labile sulfur (Ishigami et al., 2009). Using silver particle methods, 
Ishigami et al. detected H2S level in the brain was less than 9µM.  
3.1.4. Biosynthesis of H2S  
 Hcy is a sulfur-containing amino acid in the transulfuration pathway which is 
the demethylation product of dietary methionine (Gorelick, 2002). Hcy remethylation 
by methionine synthase is acted as a hcy removal pathway in which, a methyl group 
is removed from 5-methyl-tetrahydrofolate and methylated on hcy to form methonine 
(Stipanuk, 2004). The remethylation reaction is vitamin B12 dependent. 5-methyl-
tetrahydrofolate is a product of folic acid metabolism that uses methylene-
tetrahydrofolate reductase (MTHFR) (Gorelick, 2002). Hcy is converted to cys by 
CBS, which is a vitamin B6-dependent enzyme. Taken together, the defects of CBS, 
MTHFR, folic acid, B12 and B6 can lead to the up-regulation of hcy which is also 
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associated with cardiovascular disease and stroke (Gorelick, 2002). The biosynthesis 
of H2S is summarized in Figure 3.1 (page 64).  
 Folic acid in combination with vitamin B6 and B12 intake is able to reduce 
hcy level. Clinical trials using folic acid and vitamin B6 and B12 as treatment have 
been done worldwide. The Norweigian Vitamin Trial (NORVIT), the Western 
Norway B Vitamin Intervention Tiral (WENBIT) and Women’s Antioxidant and 
Folic Acid Cardiovascular Study (WAFCS) were not able to prove the beneficial 
effect of vitamin therapy on cerebrovascular events (Terwecoren et al., 2009). The 
most recent VITAmins TO Prevent Stroke (VITATOPS) trial which involves 8,164 
patients from 1998 to 2008, showed the vitamin treatment is safe for patients with 
recent stroke or transient ischemic stroke attack, however it does not prevent 
recurrent stroke (2010). Nevertheless, Heart Outcomes Preventaion Evaluation 2 
(HOPE2), which is a 5 years follow up trial involves 5,522 participants suggests that 
vitamin treatment could not reduce stroke severity or disability but at least reduce the 
risk of overall stroke (Saposnik et al., 2009). Most of the trials have failed as 
consequences. Is vitamin treatment be used and approved as a prevention for 
ischemic stroke remains unknown and the consistency of all failures in the clinical 
trial come to an unequivocal conclusion that vitamin treatment may not be a good 
approach for ischemic stroke therapy. Tons of evidences suggested that hcy could 
cause toxicity however the existent studies are done under the condition where the 
downstream mechanism of hcy is still present. Current clinical studies and meta 
analysis suggested that MTHFR polymorphism especially C677T (but not CBS) is 
associated with increased risk of ischemic stroke patients (Cronin et al., 2005; Kim et 
al., 2007; Linnebank et al., 2005; Sawula et al., 2009; Sazci et al., 2006). 
Furthermore, MTHFR C677T polymorphism showed significant correlation of 
elevated hcy with C677T polymorphism in ischemic stroke patients (Ho et al., 2006; 
Panigrahi et al., 2006; Sabino et al., 2009; Somarajan et al., 2011). Studies about 
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CBS polymorphism did not show significant correlation with ischemic stroke. One 
possibility could be due to the elevation of hcy that is caused by C677T 
polymorphism, favours the downstream metabolites accumulation and subsequently 
exerts toxic effect to neuron. As such, vitamin treatments could potentiate the 
conversion of hcy to downstream metabolites that is not favourable for ischemic 














Figure 3.1. Endogensous source of H2S. Endogenous H2S is produced by the action 
of cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE) and 3-
mercaptopyruvate sulfurtransferase (3-MST). (1). Activation of methionine by ATP 
in the presence of methionine S-adenosyl-transferase (MAT) to produce S-
adenosylmethionine (SAM). (2). SAM demethylation into S-adenosylhomocysteine 
(SAH). (3). Hydrolysis of SAH into homocysteine (hcy). (4). vitamin B6-derived 
pyridoxal-5'-phosphate–dependent CBS condenses serine and hcy to produce 
cystathionine. (5). Cystathionine is converted to cysteine (cys) and α-ketobutyrate by 
pyridoxal-5'-phosphate–dependentCSE. (6). Condensation of cys and hcy by CBS 
produces cystathionine and hydrogen sulfide (H2S). Kinetic study revealed that this 
reaction contributes more than 95% of the net H2S production by CBS. (7). 
Condensation of cys and hcy by CSE produces serine and H2S. This reaction 
contributes to 90% of the net H2S production by CSE. (8). Cysteine aminotransferase 
(CAT) catalyzes the transamination of cys to yield 3-mercaptopyruvate and further 
metabolised by 3-MST to produce sulfane sulfur and pyruvate. In the presence of 
reductants such as dithiotreitol (DTT) and glutathione (GSH), sulfane sulfure 
liberates H2S. (9). The transsulfuration pathways links to the GSH homeostasis in the 
brain. (10). 5-methyletetrahydrofolate (5-methylTHF) demetylation into THF while 
hcy remetylation into methionine by methionine synthase dependent on vitamin-B12 
derived methylcobalamin. (11). THF synthesizes 5,10-methyleneTHF through 
pyridoxal-5'-phosphate-dependent serine hydroxymethyltransferease. (12). Reduction 
of 5,10-methyleneTHF into 5-methylTHF catalyzed by 5,10-
methylenetetrahydrofolate reductase (MTHFR). Figure readapted from Durand et al. 






3.1.5. H2S in neurodegenerative diseases 
3.1.5.1. Ischemic stroke  
 High plasma cys level was found correlated to poor clinical outcome 3 
months post-stroke in acute stroke patients (Wong et al., 2006). In addition, cys level 
was found elevated in patients who had suffered from early stroke deterioration. 
Moreover, administration of cys dose dependently aggravated infarct volume of 
pMCAO stroke animals at 1.0 mmol/kg to 2.5 mmol/kg by intracerebroventricular 
(i.c.v.) administration and 10 mmol/kg by intraperitoneal (i.p.) administration 
respectively. In the study, cys surprisingly associated with ischemic stroke case 
clinically but such association was not found in glutamate, aspartate and glycine. This 
indicates that cys is more important amino acid in the cause of ischemic stroke 
pathogenesis than excitotoxic amino acids. Cys is the precursor of H2S. 
Hypothetically, the elevation of cys could cause the increase of H2S level after 
ischemic stroke. The study was followed up by injecting NaHS, a donar for H2S in 
experimental stroke animal model. When pre-administered NaHS at 0.18 mmol/kg to 
pMCAO animal, infarct volume was found significantly increased when compared 
with vehicle control (Qu et al., 2006). Nonetheless, the elevation of infarct volume 
effect was abolished by administration of MK-801 at 3 µmol/kg. As such, this 
suggests that H2S attributes the destructive effect to ischemic stroke via NMDA 
activation. CBS enzyme activity selective to H2S synthesis and H2S level were found 
increased in cortex of pMCAO stroke animals at 24 h. Loading of cys further 
increased H2S level in cortical tissues at 24 h after ischemic stroke. Administration of 
CBS inhibitors as well as CSE inhibitors, namely aminooxyacetic acid (AOAA), 
hydroxylamine (HA), β-cyanoalanine (β-CNA) and DL-propargylglycine (PAG) dose 
dependently reduced the infarct volume in pMCAO rats. Exceptional from others, 
AOAA showed inhibition of infarct volume progression at lower doses but not at 
higher doses. This may implicate that the AOAA is a non-selective inhibitors to CBS. 
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The underlying mechanism remains to be elucidated. Excitotoxicity by over 
stimulation on glutamate receptors occurs in stroke. Cheung et al. reported that H2S 
induced apoptosis in primary neuron at less than 200 µM of NaHS. However, NaHS 
at concentration greater than 200 µM induced necrosis in mature primary neuron 
when treated with 100 µM of glutamate (Cheung et al., 2007). As such, this study 
supports the possibility that H2S could play a neurotoxic effect during ischemic stroke 
injury. On contrary, in a transient middle cerebral artery occlusion (tMCAO) stroke 
model, H2S abolished injury caused by cerebral ischemia (Wang et al., 2014). In the 
study, Wang et al. administered H2S donar 5-(4-methoxyphenyl)-3H-1, 2-dithiole-3-
thione (ADT) at 3 h after reperfusion (Wang et al., 2014). They have found that ADT 
abolished BBB damage in tMCAO mice by suppressing post-ischemic inflammation-
induced MMP-9 and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
(NOX). Moreover, ADT reduced brain edema, increased blood H2S concentration, 
inhibited nuclear factor kappa-B (NF-κB) nuclear translocation thereby inhibited the 
expression of pro-inflammatory markers iNOS and IL-1β, enhanced the expression of 
anti-inflammatory markers arginase-1 and IL-10, decreased infarct volume and 
improved neurological deficits in tMCAO mice. These results conflicted with our 
previous reports on H2S exacerbated ischemic stroke outcome. Nevertheless, different 
ischemic stroke models were used in two studies, H2S donar administration before 
and after cerebral blood flow reperfusion could affect the stroke outcome differently. 
More studies on H2S role in permanent and transient ischemic stroke remains to be 
investigated.  
3.1.5.2. Parkinson's disease (PD) 
 PD is a neurodegenerative disease characterized by progressive loss of 
dopaminergic neurons in substantia nigra (SN). It was previously reported that 
plasma hcy levels elevated in PD patients treated with L-3,4-dihydroxyphenylalanine 
(Rozycka et al., 2013). On contrary, treating neuroblastoma cells with NAHS, dose 
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dependently reversed cell injury induced by rotenone, which is a toxin commonly 
used to establish in vitro and in vivo PD models (Hu et al., 2009). The report showed 
that NaHS prevented rotenone-induced p38 and JNK pathway thereby increased Bcl-
2/Bax levels, reduced mitochondrial membrane potential dissipation, cytochrome c 
release, capsase-9/3 activation and PARP cleavage. Other than rotenone, 1-Methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) were 
known as neurotoxin that can mediate selective damage to dopaminergic neurons and 
lead to parkisonism. Previous study indicated that MPTP inhibited endogenous 
synthesis of H2S in PC-12 (Tang et al., 2011a). Similar to rotenone, H2S reversed cell 
death induced by MPTP and 6-OHDA in PC-12 and SH-SY5Y cells respectively (Hu 
et al., 2010; Tang et al., 2011b; Tang et al., 2012). Mechanism of action that H2S 
exerts neuroprotective effect against parkinsonism model was shown to be caused by 
the activation of adenosine triphosphate-sensitive potassium (KATP) 
channel/PI3K/ATK/Bcl-2 pathways in PC-12 cells and PKCε/PI3K/AKT pathway in 
SH-SY5Y cells. H2S showed neuroprotective effects on several in vivo studies 
including MPTP, rotenone and 6OHDA induced PD models (Hu et al., 2010; Kida et 
al., 2011; Lu et al., 2012). Similar to MPTP treated PC12 cells, endogenous H2S level 
was markedly reduced in 6-OHDA induced PD rat model (Hu et al., 2010). Both 6-
OHDA and rotenone induced PD animal models were characterized by the loss of 
tyrosine-hydroxylase positive neurons and increase of pro-inflammatory factors with 
activation of NF-κB pathway. With NaHS treatment, the expression of the respective 
mediators for PD pathogenesis were reversed hence reflected in improvement of 
movement dysfunction and reduction of striatal neurons loss. MPTP treated animals 
when breathed in air containing 40 ppm H2S for 8 h/ day for 7 days, showed 
improvement in movement dysfunction, increase of tyrosine hydroxylase containing 
neurons in SN and striatum, potentially due to the anti-oxidative role of H2S thereby 
up-regulating antioxidant proteins including heme oxygenase-1 and glutamate-
cysteine ligase (Kida et al., 2011). The mechanism of action exerted by H2S in 
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improving parkinsonism in animal models were further confirmed by Lu et al. that it 
does not involve KATP channel by using Kir6.2-/- mice (Lu et al., 2012). In the study, 
Lu et al. demonstrated that systemic administration of NaHS to MPTP treated mice 
rescued dopaminergic neurons loss in SN compacta in both Kir6.2+/+ and Kir6.2-/- 
mice. This indicated that H2S might indirectly activate KATP channel (Lu et al., 2012). 
Interestingly, Lu et al. suggested that H2S enhanced mitochondrial uncoupling protein 
2 (UCP2) thereby reduced reactive oxygen species (ROS) production and functioned 
as an upstream mediators for KATP channel. Promising neuroprotective function 
exerted by H2S further entices the development for pharmacological agents targeting 
PD. Recently, a H2S-releasing L-Dopa drug was developed and found to be protective 
against 6-OHDA induced cell injury in SH-SY5Y cells as well as 6-OHDA induced 
PD animal model (Xie et al., 2012). The exciting neuroprotective role of H2S against 
PD remains to be further investigated and perhaps more efforts should be done in 
translating H2S releasing drugs into potential clinical usage in near future.   
3.1.5.3. Alzheimer's disease (AD) 
 AD is an irreversible, progressive neurodegenerative disorder that slowly 
destroys memory and logical thinking and eventually leads to defects in ability to 
handle normal life task. Pathologically, it is characterized by the presence of senile 
plaques and neurofibrillary tangles in the brain while the etiology remains unclear. 
Multiple evidences reported that chronic inflammation is one of the common 
mechanisms for AD pathogenesis (Akiyama et al., 2000; McGeer et al., 2010; Streit 
et al., 2004). Clinically, there is no direct evidence for H2S level in the AD patients' 
brain. However, indirect evidences showed that H2S level might decline in AD. For 
instance S-adenosyl-L-methionine (SAM) is known as a CBS activator, was found 
much reduce in AD human brains (Morrison et al., 1996). Secondly, Barbaux et al. 
discovered that CBS 844ins68 polymorphism was not commonly found in children 
with high IQ, when searching for correlation of functional polymorphisms in hcy/ 
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folate metabolism genes with mental disability (Barbaux et al., 2000). The brain of 
AD patients is characterized by the accumulation of β-amyloid (Aβ). Aβ25-35 induced 
cell death is commonly employed as in vitro AD model. Tang et al. showed that 
NaHS abolished cell death and apoptosis in Aβ25-35 treated PC12 (Tang et al., 2008). 
The improvement in cell survival exerted by NaHS was found caused by the 
preservation of MMP and attenuation of intracellular ROS generation after Aβ25-35 
treatment. Several groups have reported neuroprotective function of H2S in AD 
animal models (Fan et al., 2013; Giuliani et al., 2013; Xuan et al., 2012). Xuan et al. 
and Fan et al. induced AD on animals by injecting Aβ1-40 into dentate gyrus and 
hippocampus respectively. Xuan et al. showed that, administered of NaHS at 5 mg/kg 
daily restored cognitive impairment detected by Morris water maze, reduced neuronal 
apoptosis in CA1 subfield of the hippocampus with reduction of pro-inflammatory 
cytokines and alleviation of p38 MAPK and p65 NF-κB phosphorylation (Xuan et al., 
2012). Similar results were achieved by Fan et al. Fan et al. showed that 
administration of NaHS at 5.6 mg/kg daily rescued neuronal cell death in CA1 
hippocampal regions and suppressed release of pro-inflammatory cytokines with 
COX-2 and NF-κB inhibition (Fan et al., 2013). These observation was replicated by 
Giuliani et al. by using both Aβ1-40 induced AD models and 3 × Tg-AD mice (AD 
transgenic mouse harbouring human transgenes with amyloid precursor protein 
(APP)Swe, presenilin-1 (PS1)M146V and taup301L (Giuliani et al., 2013). They provided 
more AD pathological evidences by showing NaHS and Tabiano's spa water which is 
a spa-water with enriched of H2S contents, reduced phosphorylation of APP, PS1, 
Aβ1-42 and tau phosphorylation at Thr181, Ser396 and Ser202 in 3 × Tg-AD mice. 
Consistent with the previous two reports, Giuliani et al. showed anti-inflammatory 
roles of exogenous H2S by reducing pro-inflammatory cytokines and anti-apoptotic 
property by increasing Bcl-2 and decreasing Bax in AD transgenic mice. Moreover, 
downstream executioner caspase-3 level was found suppressed after exogenous H2S 
treatment. Consistently, available studies demonstrated exogenous supply of H2S 
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inhibited progression of AD pathogenesis. Nonetheless, there is no available evidence 
reported on the potential direct mechanism of action exerted by H2S on AD 
pathogenesis. As such, future studies should focus on studying potential direct role of 
H2S on AD pathogenesis and further validated the potential beneficial outcome of 
H2S producing agent in AD pre-clinical animal models. A summary for the in vitro 
and in vivo studies for H2S effect on neurodegenerative diseases are summarized in 
table 3.1.  
In vitro/ In 
vivo study 
Exogenous source 





60-300 (NaHS) Increased [Ca2+]i and induced 






0.1-1000 (NaHS) Reversed H2O2 induced cell injury. 
NaHS enhanced glutamate uptake 
function thereby reversed impaired 
GSH production, reduced ROS 
generation and suppressed ERK1/2 
activation.  





100-500 (NaHS) Increased [Ca2+]i, involves 
activation of calcium influx and 
calcium release from intracellular 
stores 






30-200 (NaHS) Protected neuron from glutamate 
induced oxytosis by increasing the 








< 200 (NaHS) 
 
200-1000 (NaHS) 
Induced apoptosis in glutamate 
induced excitotoxicity  
Induced necrosis in glutamate 







10-300 (NAHS) Attenuates LPS-induced 
inflammation in both primary 
microglia and BV-2 cells  








Improved cell viability in 6-OHDA 
treated cells; activation of AKT by 
PKCα, ε-dependent.  
(Tiong et 
al., 2010) 
100 (NaHS) and 
CBS 
overexpression 
Cytoprotective by elevated the 
Hsp90 protein level and suppressed 
6-OHDA induced ER stress  
(Xie et al., 
2012) 
1-300 (NaHS) Reversed rotenone induced cell 
death via regulation of mitoKATP 
channel/ p38- and JNK-MAPK 
pathway  
(Hu et al., 
2009) 




PC-12 cells  
toxicity via KATP/PI3K/AKT/Bcl-2 
pathway  
al., 2012) 
50-200 (NaHS) Protect against Aβ25-35 induced cell 









stroke model  
NaHS 0.9 mg/kg 
pretreatment (i.p.) 
NaHS 1.8 mg/kg 
pretreatment (i.p.) 
No significant effect on infarct 
volume after pMCAO rat stroke 
model 
 
Significantly increased infarct 
volume in pMCAO rat stroke 
model   
(Qu et al., 
2006) 
NaHS 0.85 mg/kg 
pretreatment (i.p.)  
NaHS 6.1mg/kg 
pretreatment (i.p.) 
Reduced rat hippocampal neuron 
injury induced by global cerebral 
ischemia-reperfusion  
 
Aggravated rat hippocampal neuron 
injury induced by global cerebral 
ischemia-reperfusion 
(Ren et al., 
2010) 
NaHS 0.85mg/kg  
post-treatment 3h 
after reperfusion  
Reduced mice tMCAO induced 
infarct volume and improved 
neurological deficit at 48 h after the 







NaHS 1.68 mg/kg  
and 5.6 mg/kg post-
treatment for 3 
weeks 
Reversed PD pathology and 
improved motor function 
dysfunction induced by rotenone 
and 6-OHDA in rats  
(Furne et 
al., 2008) 
40 ppm H2S gas for 
8h/ day for 7 days 
Improved in movement 
dysfunction, increased of tyrosine 
hydroxylase containing neurons in 
substantia nigra and striatum in 














NaHS 5mg/kg once 
daily for 3 days 
before surgery and 
thereafter 
continuously for 9 
days  
NaHS restored cognitive 
impairment, reduced neuronal 
apoptosis in CA1 subfield of the 
hippocampus in Aβ1-40 injection 




once daily for 3 
days before surgery 
and thereafter 
continuously for 3 
weeks 
Rescued neuronal cell death in CA1 
hippocampal regions in Aβ1-40 
injection into hippocampal rat AD 
model  
(Fan et al., 
2013) 
H2S enriched 
Tabiano's spa water 
Reduced phosphorylation of APP, 
PS1, Aβ1-42 and tau phosphorylation 
at Thr181, Ser396 and Ser202 in 











H2S and H2S synthesizing activity were found increased in the brain and 
blood of pMCAO animals at 24 h after the onset of stroke (Qu et al., 2006). H2S is 
recognized as the third gasotransmitter that play significant roles in modulating brain 
activity after NO and CO. In the brain, H2S is produced by the action of two key 
enzymes, namely the pyridoxal-5'-phosphate (PLP)-dependent CBS and the PLP-
independent 3MST. Previous report suggested that H2S mainly stored as bound 
sulfane sulfur and rapidly release when H2S stimulation by 3MST. However, in a 
recent study, Zhao et al. reported that 3MST was down-regulated in both the 
cortex and striatum following pMCAO, hence inconsistent with an increased 
production of H2S under ischemic conditions (Zhao et al., 2013 . Therefore, 
the focus is on CBS as the predominant enzyme responsible for H2S 
production in the brain.  
In the present study, CBS protein expression was examined. I hypothesize 
that CBS increase thus lead to the elevation of H2S observed in the brain after 
pMCAO at 24 h. Cys and hcy are known as the substrates for CBS to generate H2S. 
In both stroked rat and human plasma or serum samples, I examined the level of cys 
after ischemic injury. Finally, SH-SY5Y cell line was used as a model by artificially 
modifying enzyme and substrates conditions to mimic the observation achieved from 
the former two experiments, I postulate that CBS and cys as the substrate for both 
enzymes elevated after ischemic stroke thus attributes to the elevation of H2S. H2S is 
an upstream candidate that stimulates several downstream signalling pathways 
therefore inhibition of CBS or 3MST could be a potential therapeutic approach for 




3.2. Materials and Methods 
3.2.1. Cell culture  
 Neuroblastoma SH-SY5Y cell line was used in the study. Chapter 2, section 
2.12 (page 49).  
3.2.2. Primary culture of rat cortical astrocyte  
 Primary astrocyte cultures were prepared from the cerebral cortices of 1-2 
day old Sprague-Dawley rat pups as described in Chapter 2, section 2.11 (page 48).  
3.2.3. Construction of rat CBS lentiviral expression vectors 
 Methods are described in Chapter 2, section 2.16 (page 54).  
3.2.4. Oxygen glucose deprivation (OGD) 
 Methods are described in Chapter 2, section 2.17 (page 55). Cell viability was 
determined by MTT and LDH assay as described in Chapter 2, section 2.13 (page 
49).  
3.2.5. H2S synthesizing activity assay  
 H2S synthesizing activity in cells was measured according to Chapter 2, 
section 2.18 (page 55). H2S synthesizing activity in brain tissue was measured 
according to Chapter 2, section 2.19 (page 55). 
3.2.6. Permanent middle cerebral artery occlusion (pMCAO) model  
 Male Sprague Dawley rats six to eight weeks old were used in the study and 





3.2.7. Western blot 
Brains tissue from sham-operated control and pMCAO (3–72 h) rats were 
lysed and protein specimen was seperated by 10% SDS PAGE. The methods are 
described in Chapter 2, section 2.15 (page 51). Primary antibodies include CBS 
(1:1000, a gift from Professor Hideo Kimura from National Institute of Neuroscience, 
Japan), GFAP (1:5000, Sigma Aldrich) and β-actin (1:1000, Cell Signalling) were 
used in the study. Incubation of PVDF membrane with primary antibody was done at 
4°C overnight.  
3.2.8. Immunofluorescent staining  
 Rats were anaesthetized and perfused with 0.1 M phosphate buffer saline 
followed by 4% paraformaldehyde through the heart. Brains were removed and 
immersed in 4% paraformaldehyde overnight at 4˚C. Paraformaldehyde fixed brains 
were then cryoproected in 10% sucrose and eventually 20% sucrose at 4˚C until use. 
Coronal sections (30 μm) were made using a cryostat and mounted on glass slides 
(Matsunami, Japan). Immunofluorescent staining were described in Chapter 2, 
section 2.4 (page 41). Primary antibodies include CBS (1:200, a gift from Professor 
Hideo Kimura from National Institute of Neuroscience, Japan), GFAP (1:400, 
Chemicon, Millipore), OX-42 (1:200, Serotec) and NeuN (1:200, Chemicon, 
Millipore) were used in the study.  
3.2.9. Immunocytochemistry for primary cortical astrocytes 
 Primary astrocyte culture on poly-L-lysine coated glass coverslips were 
rinsed twice with PBS, pH=7.4 and fixed with 4% paraformaldehyde for 10 min. 
Fixed cells were made permeable by incubating in PBS containing 0.1% Triton-X for 
10 min. Cells were blocked with 10% goat serum for 1 h at room temperature and 
then incubated with primary monoclonal anti-GFAP (1:400, Chemicon, Millipore) 
antibody and anti-CBS (1: 200,a gift from Professor Hideo Kimura from National 
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Institute of Neuroscience, Japan) antibody at 4°C overnight. After washing with PSB, 
cells were incubated with Alexa 488-conjugated goat anti-rabbit (Molecular probes, 
USA) or Alexa 555 (Molecular probes, USA) for 1 h at room temperature and 
mounted with ProLong gold antifade reagent (Life technologies, USA). Fluorescent 
images were captured using QImaging (Canada) and images captured were processed 
by Image Pro insight (QImaging, Canada).  
3.2.10. High performance liquid chromatography (HPLC) 
 Rats whole blood was harvested by cardiac puncture and collected in EDTA-
tube. Plasma was collected after centrifugation at 2800 rpm, 4°C for 10 min. The 
serum and plasma were stored at −80°C until analysis. Plasma and serum samples 
treatment and HPLC analysis are described in Chapter 2, section 2.20 (page 56).  
 A small preliminary clinical study was done with our National University 
Hospital (NUH) collaborator, A/Professor Raymond Seet Chee Seong and the plasma 
samples were passed to me for HPLC analysis. The plasmas were stored at −80°C 
until analysis.  
3.2.11. Preparation of rotenone and 6-OHDA 
 Rotenone was dissolved in 100% DMSO (Sigma, USA) and diluted to 0.5% 
by 1 × PBS. 6-OHDA was dissolved to 1 × PBS. Both toxins were freshly prepared. 
Low serum medium (0.5% FBS) was used to dissolve rotenone and 6-OHDA to 10 
µM or 20 µM and 100 µM or 200 µM respectively.  
3.2.12. Oxidative stress staining using CellROX reagent  
 SH-SY5Y or SH-SY5Y CBSOE cells were seeded on poly-L-lysine coated 
cover slip overnight and subsequently treated with control, low or high substrates 
conditions with rotenone, 6-OHDA or OGD induced cell death. Upon the completion 
of the treatment and toxin insult, CellROX reagent (Life technologies, USA) were 
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added at a final concentration of 5 µM to the cells and incubate for 10 min at 37°C. 
Next, the medium with CellROX was removed and cells were washed three times 
with 1 × PBS. Finally cells were fixed with 4% paraformaldehyde and coverslip was 
mounted using ProLong gold antifade reagent (Life technologies, USA). Fluorescent 
images were captured using QImaging (Canada) and images captured were processed 
by Image Pro insight (QImaging, Canada).  
3.2.13. GABA transaminase assay  
 GABA transaminase assay was performed according to Salvador et al. with 
modification (Salvador et al., 1959). Rat brains were dissected into cortex, striatum, 
hippocampus, thalamus/ hypothalamus and midbrain and snap freeze in liquid 
nitrogen. Brain samples were then stored at -80°C until analysis. Rat brains were 
thawed on ice and homogenized in ice-cold 50 mM potassium phosphate buffer (50% 
w/v). Drug at various concentrations were added 10 min prior to the addition of 
substrates.  Next, substrates solution contaiinng 50 mM α-ketoglutaric acid 
(adjusted to pH 8) and 125 mM γ-aminobutyric acid (adjusted to pH 8 with 
NaOH) were added to 0.2 ml of rat homogenate (total volume 1 ml). The 
reaction mixture was incubated at 37°Cfor 1 h. Upon completion of 
incubation, reaction mixture was centrifuged at 3000 × g for 10 min at 4°C. 
Three hundred microlitter of supernatant was mixed with 0.3 ml of 0.2 M of 
3,5-diaminobenzoic acid (adjusted to pH 6 with  K2CO3) and followed by 1 h 
incubation in 60°C water bath. The fluorescence signal was measured by 
Varioskan flash multimode reader (Thermo Scientific) at excitation and emission 
wavelength at 405 and 505 nm respectively.  
3. 2. 14. Statistical analysis 
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3.3.2. Up-regulation of CBS expression following ischemic insult 
The cortex and striatum are the most affected regions following 
pMCAO in rats (Liu et al., 2009). Western blot analysis revealed that the 
truncated CBS (45 kDa), but not the full length CBS (63 kDa), was markedly 
up-regulated (about 2-fold) in the cortex at 8 h after pMCAO (Figure 3.3 A 
and C). Similarly, truncated CBS expression was up-regulated (7-fold) in the 
striatum but at a later time point of 24 h after pMCAO (Figure 3.3 B and D). 
Immunofluorescent staining (which did not distinguish the full length and 
truncated form) results were consistent with the Western blot results 
(Figure.3.4). CBS in both regions was largely expressed in astrocytes based on 
co-localization with GFAP staining (Figure 3.4). In order to validate the CBS 
up-regulation results, primary astrocytes were cultured and subjected to OGD 
over time. CBS expression in primary astrocytes was found to increase rapidly 
within 30 min after the onset of OGD and remained highly expressed for at 
least 3 h (Figure 3.5). Western blot results demonstrated the presence of both 
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Figure 3.4. Immunofluorescent staining for CBS after pMCAO. 
Immunofluorescent staining for CBS (a and b, green) post-stroke at 8 h (pMCAO 8 h) 
or 24 h (pMCAO 24 h). (A). Representative immunofluorescent staining figures from 
ipsilateral cortex and (B). representative immunofluorescent staining figures from 
ipsilateral striatum. (a & b) Merged image of the respective green and red positive 







Figure 3.5. Effects of OGD on CBS expression in primary cultures of cortical 
astrocytes. (A). Representative immunocytochemistry staining of primary cortical 
astrocytes after OGD (0.5–3 h) for CBS (green) and GFAP (red).  (B). Representative 
Western blot images showing the increased expression of both the full length CBS 
(63 kDa) and truncated CBS (45 kDa) after OGD. (C). Densitometry measurement of 
full length (63 kDa) CBS and truncated (45 kDa) CBS expression after OGD. Data 
are presented as mean ± SEM, n = 3. *p < 0.05, **p < 0.01 against no OGD treatment 
by one way ANOVA with Bonferroni post hoc analysis. 
 
3.3.3. Elevation of cys and hcy level serum or plasma of stroke patient and 
experimental stroke animal 
 Serum cys level was elevated significantly in stroke patients after 24 h 
(290.8 µM ± 13.1 µM) compared with normal healthy control (236.3 µM ± 7.3 
µM), however not significantly up-regulation at 72 h (267.0 µM ± 14.3 µM) 
was observed (Figure 3.3.5). Serum hcy level was elevated in stroke patients 
after 24 h (10.9 µM ± 1.2 µM) and 72 h (10.2 µM ± 1.0 µM) compared to 
normal healthy control (7.3 µM ± 1.4 µM). Rat plasma cys (236.1 µM ± 14.1 
µM) and hcy (6.0 µM ± 0.7 µM) level increased in pMCAO model at 8 h 
compared with normal control rat plasma cys (169.2 µM  ±  10.2 µM) and hcy 
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(3.8 µM  ± 0.2 µM) level. In tMCAO model, rat plasma hcy level significantly 
elevated after 24 h post-stroke (5.4 µM ± 0.3 µM) but no significant up-





Figure 3.6. HPLC measurement for cys and hcy level in stroke patient serum 
samples. (A). Serum cys level were measured in control, stroke patients with rtPA 
treatment at 24 h (Day 1) and 72 h (Day 3) after the onset of stroke. (B). Serum hcy 
level was measured in control, stroke patients with rtPA treatment at Day 1 and   Day 
3 after the onset of stroke. Data are presented as mean ± SEM, n = 4 for normal 
control and n = 6 for 24 h and 72 h after stroke. * p < 0.05 against control by one way 






Figure 3.7. HPLC measurement for cys and hcy level in pMCAO and tMCAO 
rat plasma samples. (A). Rat plasma cys level in control animals (CN), 3, 8 and 24 h 
after pMCAO model. (B). Rat plasma cys level in control animals (CN) and 24 h after 
tMCAO model. (C). Rat plasma hcy level in control animals (CN), 3, 8 and 24 h after 
pMCAO model. (D). Rat plasma hcy level in control animals (CN) and 24 h after 
tMCAO model. Data are presented as mean ± SEM, n = 3-4. *p < 0.05, **p < 0.01 
against normal control by independent t-test. 
 
3.3.4. CBS overexpression in SH-SY5Y cells  
SH-SY5Y cells normally express CBS at a very low level. However, 
they can be efficiently transduced with lentiviral vector to express CBS 
together with EGFP, a fluorescent reporter. Results shown in Figure 3.8 A 
confirmed that these transduced cells strongly expressed both EGFP and CBS. 
The full length 63 kDa isoform is detected by Western blot but not the 
truncated 45 kDa isoform (Figure 3.8 B). When CBS substrates (cys + hcy) 
were added to cell homogenates, H2S was produced in a concentration-
dependent manner (Figure 3.8 C). These results indicate that the CBS 
artificially expressed in these cells are fully functional. As 0.1 mM cys + 0.01 
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mM hcy are reportedly close to physiological concentrations (Singh et al., 
2009; Stipanuk et al., 2011), we used these as a low substrate condition and a 
10-fold increase as the high substrate condition in subsequent experiments. 
 
 
Figure 3.8. CBS-overexpressing (CBSOE) SH-SY5Y cells. (A). Fluorescence (left) 
and phase contrast (right) micrographs of SH-SY5Y CBSOE cells. Fluorescence 
indicates CBS-EGFP expression.  (B). Western blot results confirming that CBS was 
markedly expressed compared to non-transduced control (C) cells. Only the full 
length CBS (63 kDa) was detected but not the truncated CBS (45 kDa).  (C). H2S 
synthesizing activity of SH-SY5Y CBSOE cells measured at varying concentrations 
of cys and hcy. Data are presented as mean ± SEM, n = 3. ***p < 0.001 against no 
substrates treatment by one way ANOVA with Bonferroni post hoc analysis. 
 
 
3.3.5. Effects of H2S production on cell viability 
Cells did not show any difference in cell viability when exposure to 
high or low substrate compared with control cells (Figure 3.9 A). However, 
when cells subjected to OGD, cell viability decreased markedly regardless of 
substrate conditions. In the absence or presence of low substrates, cell viability 
fell to about 30-40% in both cell types whether or not CBS was expressed. In 
the presence of high substrates, cell viability was about 30% in the control 
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cells but about 5% in the CBSOE cells, indicating a significant increase in cell 
death. This effect was attenuated concentration-dependently by the addition of 
AOAA, a non-selective CBS inhibitor, to the cells immediately after the 
addition of substrates (Figure 3.9 C). Complete reversal was achieved at 0.5 
mM. Therefore, these data confirmed that a high level of endogenously 
produced H2S in cells would enhance cell death when the cells were subjected 
to OGD. The MTT assay outcome was confirmed in LDH assay as shown in 
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the previous study using our current CBS overexpression system, SH-SY5Y CBSOE 
cells were treated with various substrates levels to mimic elevation of H2S under 
various neurotoxic conditions (Figure 3.11). When treated SH-SY5Y CBSOE cells 
with various substrates concentration and 50 µM or 100 µM of 6-OHDA (Figure 
3.3.10 B), cell viability were reversed in a dose dependent manner. SH-SY5Y 
CBSOE cells under 8 µM cys with 0.8 µM hcy and 10 µM cys with 1 µM hcy were 
less susceptible to 6-OHDA induced cell injury (cell viability 66.2% ± 3.2% at 50 µM 
6-OHDA and 37.9% ± 4.3% at 100 µM 6-OHDA under normal media condition but 
reversed to 100.8% ± 3.2% at 50 µM 6-OHDA and 84.0% ± 7.3% at 100 µM 6-
OHDA under high substrates condition). On the other hand, when treated SH-SY5Y 
CBSOE cells with various substrates level in the presence of rotenone, cell viability 
increased as the levels of H2S increased (Figure 3.11 C). When treated with 10 µM 
rotenone, cell viability improved significantly from 59.8 % ± 1.4 % (no substrates) to 
79.7 % ± 7.0 % (0.8 mM cys + 0.08 mM hcy) and 83.3% ± 4.5% (1.0 mM cys + 0.1 
mM hcy). Furthermore, when the cells were subjected to 20 µM rotenone, cell 
viability was increased significantly in the presence of high H2S level, from 55.3 % ± 
2.6 % (no substrates) to 76.9 % ± 3.0 % (1.0 mM cys + 0.1 mM hcy). Nevertheless, 
when treated SH-SY5Y CBSOE cells with various substrates concentration and 
subjected to 24 h OGD condition without re-oxygenation, deterioration in cell 
viability was eminent as the levels of H2S increased (Figure 3.11.D). Cell viability 
was declined from 47.4 % ± 3.3 % to 2.6 % ± 0.2 % when cells were treated with 1.0 
mM cys + 0.1 mM hcy.  
 Next ROS level was detected using CellROX reagent which will be present 
as red under fluorescent microscope (Figure 3.12). Our results suggested that ROS 
level was significant increased when SH-SY5Y CBSOE cells were treated with high 
substrates condition under OGD compared with no OGD condition (Figure 3.12 A). 
Interestingly, when treated SH-SY5Y CBS OE cells with high substrates in the 
presence of 20 µM rotenone (Figure 3.12 B) or 100 µM 6-OHDA (Figure 3.12 C), 
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ROS level was remarkably reduced when compared with the respective neurotoxin 
treatment under vehicle conditioned medium. A representative normal SH-SY5Y 
cells ROS level at 20 µM rotenone (Figure 3.12 B, left panel) and 100 µM 6-OHDA 
(Figure 3.12 C, left panel) were used as a positive control for CellROX staining.   
 H2S may exert neuroprotective role by acting as an electron donar and 
facilitated electron transport chain. To proof of principle, a mitochondrial complex III 
inhibitor, antimycin was used to impede the electron transport chain.  SH-SY5Y CBS 
OE cells were treated with normal, low and high substrates under 100 µM 6-OHDA 
conditions and cell death was reversed at high substrates condition (relatively higher 
H2S condition). Interestingly, results demonstrated that the improvement of cell 
viability caused by the increase of H2S turned out abolished by 0.5 µM and 1 µM 
antimycin (Figure 3.13 A). This ascertained that H2S mediated the neuroprotective 
role via the upstream of mitochondrial complex III in the mitochondrial respiratory 
chain. In order to test the hypothesis, oxygen was replenished to the OGD condition 
by replacing a new normal medium. Results demonstrated that when we re-
oxygenated the respective cells after OGD condition, SH-SY5Y CBS OE cells 
survived better than the SH-SY5Y cells as shown in Figure 3.13 B (MTT assay) and 










Figure 3.11. Dose dependent effects of various cys and hcy concentrations on 
SH-SY5Y CBSOE cells in 6OHDA, rotenone and OGD induced cell death 
models. (A). H2S synthesizing activity increased in a dose dependent manner when 
subjected SH-SY5Y CBSOE cells to various cys and hcy concentration. Cells under 
such condition were subjected to (B) 50 µM 6-OHDA or 100 µM 6-OHDA, (C) 10 
µM rotenone or 20 µM rotenone or (D) OGD conditions for 24 h. Data are presented 
as mean ± SEM, n = 4.*p < 0.05, **p < 0.01 and ***p < 0.001 against no substrates 









Figure 3.12. ROS production after OGD, rotenone and 6-OHDA insults under 
vehicle or high substrates conditions. (A). SH-SY5Y CBSOE cells were subjected 
to normal (left) or OGD (right) with high substrates condition. (B). SH-SY5Y 
CBSOE cells  were subjected high substrates without rotenone (left), control media 
with 20 µM rotenone (centre) and High substrates with 20 µM rotenone (right) for 4 
h. (C).SH-SY5Y CBS OE cells  were subjected high substrates without 6-OHDA 
(left), control media with 100 µM 6-OHDA (centre) and High substrates with 100 µM 







Figure 3.13. Inhibition of mitochondria complex III and SH-SY5Y CBSOE cells 
cell viability in high substrates conditioned medium after oxygenation. (A). SH-
SY5Y CBSOE cells were treated with 0.5 µM or 1 µM antimycin and subjected to 
low and high substrates conditions subjected to 100 µM 6-OHDA. Data are presented 
as mean ± SEM, n = 7. **p < 0.01 and ***p < 0.001 against its respective control 
(black bar) by one way ANOVA with Bonferroni post hoc analysis. #p < 0.05 against 
SH-SY5Y CBSOE cells under normal media without 6-OHDA treated condition by 




SY5Y CBSOE cells were treated with OGD for 0, 4 or 8 h followed by 24, 20 or 16 h 
of re-oxygenation respectively at control, low or high substrates conditions. Cell 
viability were measured by MTT (B) or LDH (C) and is expressed as a percentage 
using control cells without OGD as 100%. Data are presented as mean ± SEM, n = 
4.*p < 0.05 and **p < 0.01 by independent t-test. 
 
 
3.3.7. Inhibition of CBS by saturated α-hydrazino acid analogue of cystathionine, 
reversed in vitro and in vivo stroke outcome 
A C2-symmetric,-X-Y-functionalized mimics of (L,L)-cystathionine with 
functional groups, α-hydrazino acids, α-oxamino acids and α-N-hydroxyamino acids 
(Figure 3.14) have been synthesized by Professor David B. Berkowitz and team from 
Department of Chemistry, University of Nebraska, Lincoln. The IC50 of the (L,L)-
cystathionine with functional groups were examined in 14C radioactive CBS assay 
(Figure 3.15). Results suggested that saturated hydrazine acid cystathionine analogue 
showed the best inhibition ability with an IC50 value of 132 M. The compound was 
sent to my laboratory to further examine the potential therapeutic effect on in vitro 
and in vivo acute stroke models.  
Figure 3.16A showed that saturated α-hydrazino acid analogue dose 
dependently inhibited H2S synthesizing activity in brain homogenates and the IC50 for 
inhibition was around 0.3 mM. Next, the inhibitor was tested on the SH-SY5Y 
CBSOE cells with high substrates OGD condition. Similar to AOAA, saturated α-
hydrazino acid analogue restored cell viability in a dose dependent manner (Figure 
3.16D). Similar to AOAA, no cytotoxic effect was observed at 0.1 and 0.5 mM 
concentration in the presence of control and low substrates with OGD condition. 
Moreover, i.c.v. pre-treated (30 min before occlusion) tMCAO rats with saturated α-
hydrazino acid cystathionine analogue at 1.6 µmol/kg reduced infarct volume from 
259.3 ± 47.0mm3 to 61.1 ± 25.1mm3 (24 h assessment). Next, the therapeutic window 
of saturated α-hydrazino acid cystathionine analogue in animal stroke model was 
investigated. When administered saturated α-hydrazino acid analogue (1.6 µmol/kg, 
i.c.v. administration) at 1 h after the onset of stroke (before reperfusion), the infarct 
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volume was reduced to 113.8 ± 51.1 mm3 (Figure 3.20). No significant reduction of 
infarct volume was observed at 2 h post treatment after the onset of stroke (20 min 





Figure 3.14. Design of L,L-cystathionine analogues. Three classes of C2-
symmetric, -X-Y-functionalized mimics of (L,L)-cystathionine have been 
synthesized. Further functional group transformation followed by global de-
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Figure 3.16. Saturated α-hydrazino acid cystathionine analogue inhibited CBS 
enzyme activity in ex vivo and in vitro assay. (A). Novel saturated α-hydrazino acid 
analogue dose-dependently inhibited H2S synthesizing activity in rat whole brain 
tissue homogenates. Rat brain homogenates were incubated with saturated α-
hydrazino acid analogue for 5min prior to the addition of substrates and subsequently, 
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production of H2S was measured. Data are presented as mean ± SEM, n = 3. **p < 
0.01 and ***p < 0.001 against control by one way ANOVA with Bonferroni post hoc 
analysis. (B). SHSY5Y cells were made to overexpress CBS (CBS OE) which is 
visualized by a fluorescent reporter gene (C). Western blot showed the presence of 
CBS in CBS OE cells and not the control cells (D). Cells were subjected to OGD for 
24 h under control, low or high substrates conditions in the presence of 0.1 mM or 0.5 
mM saturated α-hydrazino acid analogue. Data are presented as mean ± SEM, n = 4. 
***p < 0.01 against SH-SY5Y CBSOE cells without saturated α-hydrazino acid 
analogue treatment by one way ANOVA with Bonferroni post hoc analysis. 
 
 
Figure 3.17. Administration of saturated α-hydrazino acid analogue in tMCAO 
rats. (A). Representative of TTC stained brain slices of tMCAO with vehicle pre-
treatment (left) and  tMCAO with saturated α-hydrazino acid analogue pre-treatment 
(right). (B). The infarct volume measurement for vehicle or saturated α-hydrazino 
acid analogue (1.6 µmol/kg, i.c.v. 1.5 µl/min) pretreatment tMCAO groups. Data are 
presented as mean ± SEM, n = 7.***p < 0.01 by independent t-test. 
 
3.3.8. Saturated α-hydrazino acid analogue treated rats showed reduction of 
microglia activation in tMCAO animals 
 To examine if the reduction of infarct volume was caused by the abolishment 
of inflammatory response in CNS, microglia proliferation and activated microglia 
was quantified by Western blot (Figure 3.18). Our results indicated that saturated α-
hydrazino acid analogue reduced cortical OX-42 was reduced to 2-fold in cortex and 
 7-fold in str
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3.3.9. Saturated α-hydrazino acid analogue is a selective CBS and CSE inhibitor 
but not GABA transaminase inhibitor  
 AOAA is a general inhibitor of pyridoxal phosphate (PLP)-dependent 
enzymes by attacking at the Schiff base linkage between PLP and the enzyme thus 
forming oxime complex (Beeler et al., 1976). Therefore, it is widely used as the 
GABA transaminase (EC2.6.1.17) inhibitor. Saturated α-hydrazino acid analogue is 
not a PLP-independent CBS enzymes inhibitor, hypothetically would not inhibit 
GABA transaminase. Hence, the GABA transaminase assay for saturated α-hydrazino 
acid analogue was performed (Figure 3.19). Compared to AOAA, saturated α-
hydrazino acid analogue has a higher IC50, i.e. IC50AOAA= 0.36 µM and IC50 
saturated α-hydrazino acid analogue = 572 µM to GABA transaminase (Figure 3.19 
A). To further confirm the effect of saturated α-hydrazino acid analogue in reducing 
infarct volume was due to H2S inhibition by not GABA transaminase inhibition at 1.6 
µmol/kg concentration, saturated α-hydrazino acid analogue was administered via 
i.c.v. route and GABA transaminase activity in cortex, striatum and other brains 
regions were examined. Our results showed that saturated α-hydrazino acid 
cystathionine analogue did not inhibit GABA transaminase at 1.6 µmol/kg 
concentration, which was the effective dose used in the in vivo stroke study. 
Nevertheless, AOAA at this concentration showed remarkably inhibition in cortex 
and striatum. Both saturated α-hydrazino acid analogue and AOAA i.c.v. 
administration did not affect GABA transaminase activity in other brain regions than 
cortex and striatum (results not shown).  
 Cystathionine is the end product of both CBS and CSE. Thus, it could be a 
potent inhibitor for both CBS and CSE. Saturated α-hydrazino acid cystathionine 
analogue was further tested in CSE enzyme inhibition (Figure 3.21). Figure 3.3.22A 
showed that SH-SY5Y cells were efficiently transduced with lentiviral vector 
to express CSE together with EGFP. CSE transduced cells are strongly 
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expressing both EGFP and CSE (Figure 3.21 B). When CBS or CSE 
substrates (cys + hcy) were added to the cell homogenates, H2S was produced 
remarkably at high substrates level (results not shown) and similar to CBS OE 
cells, SH-SY5Y CSE OE under high substrate condition was more susceptible 
to OGD condition (Figure 3.21 C). Saturated α-hydrazino acid analogue could 
inhibit the SH-SY5Y CSE OE H2S production under high substrate condition in a 
dose dependent manner (Figure 3.21 D). BCA, is a selective CSE inhibitor, were used 
as the positive control in the study. Our results indicated that saturated α-hydrazino 
acid analogue is a more potent CSE inhibitor than BCA (IC50 53.2 µM versus 165.8 
µM). Similar to BCA, saturated α-hydrazino acid analogue dose dependently 
attenuated the cytotoxic effect during OGD under high substrates condition (Figure 
3.21 E).  
 
Figure 3.19. Inhibitory efficacy of GABA transaminase activity by AOAA or 
saturated α-hydrazino acid analogue. (A). The GABA transaminase inhibition 
efficacy of AOAA or α-hydrazino acid analogue in rat brain homogenates. Data are 
presented as mean ± SEM, n = 3. (B) and (C). i.c.v. injection of AOAA or α-
hydrazino acid analogue followed by GABA transaminase assay on cortex (B) and 
striatum (C). Data are presented as mean ± SEM, n = 3. **p < 0.01 and ***p < 0.01 






Figure 3.20. Post-treatment of saturated α-hydrazino acid analogue in tMCAO 
rats (A). Representative of TTC stained brain slices of tMCAO with vehicle post-
treatment (left), saturated α-hydrazino acid analogue post-treatment 2 h after onset of 
tMACO (100 min occlusion) (centre) and saturated α-hydrazino acid analogue post-
treatment 1 h after onset of tMAO (100 min occlusion) (right) (B). The infarct 
volume measurement for vehicle, saturated α-hydrazino acid analogue (1.6 µmol/kg, 
i.c.v., 1.5 µl/min) 2 h post-treatment and saturated α-hydrazino acid analogue (1.6 
µmol/kg, i.c.v. 1.5 µl/min) 1 h post-treatment. Data are presented as mean ± SEM, n 
= 5-6. **p < 0.01 and ***p < 0.001 against sham control by one way ANOVA with 









Figure 3.21. Saturated α-hydrazino acid analogue inhibition on CSE. (A). 
Fluorescence (left) and phase contrast (right) micrographs of SH-SY5Y CSE 
overexpressing cells (SH-SY5Y CSE OE). Fluorescence indicates CSE-EGFP 
expression. (B). mRNA expression to confirm CSE overexpression in SH-SY5Y CSE 
OE cells.(C). SH-SY5Y CSE OE were exposed to either no, low (0.1 mM cys + 0.01 
mM hcy) or high (1 mM cys + 0.1 mM hcy) substrate concentrations with 24 h OGD. 
Cell viability were measured by MTT and is expressed as a percentage using control 
cells without OGD as 100%. Data are presented as mean ± SEM, n = 4. ***p < 0.001 
against no substrates treatment by one way ANOVA with Bonferroni post hoc 
analysis. (D). Saturated α-hydrazino acid analogue or BCA were incubated in SH-
SY5Y CSEOE cells homogenates for 10 min prior to the addition of substrates and 
subsequently, production of H2S was measured. Data are presented as mean ± SEM, n 
= 4. **p < 0.01 and ***p < 0.001 against control (CN) by one way ANOVA with 
Bonferroni post hoc analysis.(E). CSE inhibition by saturated α-hydrazino acid 
analogue or BCA reversed the enhanced cell death in SH-SY5Y CSE OE cells 
subjected to OGD in the presence of high substrates. Cell viability were measured by 
MTT and is expressed as fraction to control without OGD. Data are mean ± SEM, n = 
4. *p < 0.05, **p < 0.01, ***p < 0.001 against its respectivevehicle treatment by one 
way ANOVA with Bonferroni post hoc analysis.  
 
3.4. Discussion  
H2S can be produced in the body by 3 key enzymes, namely CBS, CSE and 
3-mercaptopyruvate sulfurtransferase (3-MST, in combination with cysteine 
aminotransferase) (Kashfi et al., 2013). CSE is expressed predominantly in the 
cardiovascular system (Beltowski et al., 2014; Zhao et al., 2001a) but at low levels in 
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the brain and therefore generally accepted as a minor player, if at all, in H2S 
production in the brain (Abe et al., 1996). 3MST is widely present in the brain but its 
physiological relevance is not clearly understood. However, in a recent study, Zhao et 
al. reported that 3MST was down-regulated in both the cortex and striatum following 
pMCAO, hence inconsistent with an increased production of H2S under ischemic 
conditions (Zhao et al., 2013). Therefore, the focus is on CBS as the predominant 
enzyme responsible for H2S production in the brain. Such investigation is crucial in 
developing pharmacological compounds targeting at enzyme activity level thus 
potentially abrogating pathogenesis of ischemic stroke. 
First, I studied CBS cellular localization in the brain (Figure 3.2). The results 
showed that CBS is localized specifically in astrocytes, which was consistent with the 
previous observation by Enokido et al. and Lee et al. (Enokido et al., 2005; Lee et al., 
2009a). The native CBS enzyme is a tetramer consisting 4 subunits of 63 kDa (551 
amino acids). This subunit can be cleaved in its C-terminal region at Arg413 to yield 
a 45 kDa subunit which lacks the regulatory domain. Two truncated subunits form a 
dimer that is about twice as active as the tetramer (Kery et al., 1998; Majtan et al., 
2014). In primary astrocytes subjected to OGD, the expression of the 63 kDa CBS 
was clearly up-regulated (Figure 3.5) and the truncated form increased within 30 min. 
Similarly, the truncated form also increased in both the cortex and striatum within 24 
h post-pMCAO (Figure 3.3). These observations demonstrated that CBS responds 
very rapidly to ischemic insults. In contrast to the primary astrocytes, the full length 
63 kDa CBS in the cortex and striatum remained unchanged following pMCAO as 
shown by Western blot (Figure 3.3). This difference may be caused by the high basal 
expression in the cortex and striatum as opposed to very low basal level of CBS 
expression in the primary astrocytes. However, the increased level of the 45 kDa CBS 
implies an up-regulation of the expression of the 63 kDa CBS. This is supported by 
the observed increase in immunostaining for CBS (Figure 3.4). Therefore, it appears 
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that the increase of CBS expression and activation may underlie the increased 
production of H2S in ischemia (Qu et al., 2006). The mechanism that triggers the 
activation by cleavage remains to be elucidated. However, it has been reported that 
TNF-α induced CBS cleavage in HepG2 cells (Zou et al., 2003). This could be 
examined further as inflammatory cytokines such as TNF- were found to be 
increased under ischemic conditions (Zhou et al., 2013). It is possible that the 
increase of CBS truncation causes a corresponding elevation in the expression of the 
full length enzyme by a positive feedback mechanism. It is noted that the truncated 
form was not detected in the SH-SY5Y CBSOE cells indicating that in these cells 
cleavage of CBS does not occur or occurs only at very low level (Figure 3.8), perhaps 
the truncation mechanism is not in place in these cells that do not normally expressed 
CBS at a significant level. These cells can be used to investigate the factors that 
induce cleavage and the activation of CBS.  
Hyperhomocysteinemia is an independent risk factor for stroke (Perry et al., 
1995).  In addition, hcy is elevated after stroke and raised hcy adversely affect cerebral 
infarction after stroke (Spence, 2007). In animal studies, cys was found increase in 
ischemic model and the administration of cys increased the ischemic damage after 
stroke (Slivka et al., 1993; Wong et al., 2006). Thus there are ample evidences to 
suggest that in acute stroke, CBS activation is accompanied by a high availability of 
substrates for H2S production, which is most efficiently produced by β-replacement 
reaction where cys condenses with hcy to produce H2S (Chen et al., 2004; Singh et 
al., 2009). In this small cohort stroke patient study, serum cys level was elevated 
remarkably at 24 h after the onset of stroke when compared with age matched healthy 
control (Figure 3.6). Hcy level was found higher than the normal healthy control 
serum hcy level even though the difference was not significant. Hence, larger sample 
size is needed to acertain the observation in the future. In pMCAO model, cys and 
hcy level was found up-regulated in rats plasma samples at 8 h after the onset of 
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stroke (Figure 3.7). Hcy level was significantly elevated in a transient ischemic model 
at 24 h while cys level was not significantly up-regulated. Taken together, the acute 
ischemic conditions are conducive for markedly elevated production of H2S due to 
the elevation of CBS (but not 3MST) and substrates (cys and hcy) in the brain. 
Mimicking such conditions by overexpressing CBS in SH-SY5Y neuroblastoma 
cells, an increase in cell death was observed when exposing these cells to high 
substrate conditions, but not substrate concentrations that reflects the normal 
physiological conditions (Singh et al., 2009; Stipanuk et al., 2011) (Figure 3.8). 
Moreover, this effect was abolished by CBS inhibition indicating that it is mediated 
by H2S (Figure 3.9). While hcy and cys can be neurotoxic to cells at high 
concentrations (Hosoi et al., 2010; Jara-Prado et al., 2003; Koz et al., 2010; Kruman 
et al., 2000; Poddar et al., 2001; Wong et al., 2006). However the “high” 
concentrations used in the present experiments were clearly non-toxic as no effect on 
cell viability were observed in both control or CBSOE cells (Figure 3.9). In addition, 
we had similarly over-expressed CBS in HEK293 cells and observed the same (data 
not presented) indicating that the H2S-induced effects are not specific to cell of a 
neural origin.  
The mechanism by which H2S enhances cell death under ischemic conditions 
requires thorough investigations. H2S was known playing a role in inhibiting 
cytochrome c oxidase, carbonic anhydrase, monoamine oxidase, cholinesterase, and 
Na+/K+-ATPase (Szabo, 2007) and potentiate glutamate excitotoxicity (Chen et al., 
2011; Cheung et al., 2007). Using mature mouse cortical neurons expressing 
glutamate receptors, Cheung et al. reported that glultamate-induced cell death was 
exacerbated by the addition of NaHS (Asimakopoulou et al., 2013; Cheung et al., 
2007). They further reported that NaHS at concentrations less than 200 µM induced 
apoptosis, whereas at concentrations greater than 200 µM induced necrosis 
(Asimakopoulou et al., 2013). To the contrary, Kimura and Kimura (Kimura et al., 
106 
 
2004) reported that H2S at 100 µM concentration reversed cell death in immature 
mouse cortical neuron treated with 1 mM glutamate. These findings suggest that H2S 
may have neuroprotective effects at lower range of concentrations while being 
cytotoxic at a higher range of concentrations (Dorman et al., 2002). In our 
experiments, we did not observe any protective effects under the “low” substrate 
conditions (Figure 3.8). This may be due to concentrations of H2S that are still not 
sufficiently low or a difference between ischemic and excitotoxic insults.  
Understanding the underlying mechanism of how H2S induced cell death 
during OGD using the CBSOE cells is crucial. Next, I tested the CBS overexpressing 
SH-SY5Y in the presence of high substrates concentration system to rotenone and 6-
OHDA. It was previously reported that H2S was found neuroprotective in rotenone 
and/or 6-OHDA induced cell death (Hu et al., 2009; Hu et al., 2007; Tiong et al., 
2010; Xie et al., 2012). When SH-SY5Y CBSOE cells were treated with substrates at 
varying concentration, they abolished 10 or 20 µM rotenone and 100 or 200 µM 6-
OHDA induced cell death effect in a dose dependent manner (Figure 3.11). This 
implicated that the increase of H2S level reversed rotenone and 6-OHDA induced cell 
death but aggravated OGD induced cell death. On the other hand, H2S at high 
concentration was reported to be cytotoxic to various cell types, possibly acting as a 
reversible inhibitor for cytochrome c oxidase (Hu et al., 2011). In this study, due to 
the limitation of technology available to detect endogenous H2S level, I failed to 
report the actual H2S concentration in the SH-SY5Y CBS OE cells under high 
substrates concentration. At most, the high substrates concentration may still fall in 
the range of the concentration of H2S that could exert neuroprotective effect. The 
interesting observation is that H2S exerted opposite effects to different injury, at least 
in the present study. One possibility is due to the mechanistic difference rather than 
the concentration difference. Recent studies have reported that administration of 
NaHS to Chinese hamster ovary cells (CHO) cells that overexpressing succinate-
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coenzyme Q reductase (SQR) coenzyme resulted in an increase in cellular oxygen 
consumption and ATP production. As such, this led to the speculation that H2S could 
be a potential electron donor as well as inorganic source of energy in mammalian 
cells (Goubern et al., 2007; Lagoutte et al., 2010). Furthermore, Morris et al. has 
demonstrated that 3-mercaptopyruvate (3-MP) stimulated mitochondria function and 
ATP generation in cell culture. Silencing of 3-MST or SQR reduced the basal 
bioenergetic parameters and abolished the effect of 3-MP (Modis et al., 2013). In the 
study, Modis and colleagues suggested that 3-MST-derived H2S maintains 
mitochondrial electron flow and supports cellular bioenergetics by serving as electron 
donar at SQR of mitochondrial electron transport chain. It has been known that 
rotenone and 6-OHDA exerted the neurotoxic effects via inhibition of complex I of 
electron transport chain. Furthermore, 6-OHDA was known to be capable of 
increasing the production of ROS (Blum et al., 2001; Sherer et al., 2003). I 
hypothesized that when complex I was blocked by rotenone or 6-OHDA, exogenous 
supply of H2S could serve as the electron donar at SQR (which is located at the 
downstream of complex I in electron transport chain). However, during OGD 
condition, where oxygen was deprived and anaerobic glycolysis was halted, electron 
transport chain would be disrupted. As such, H2S, which is a bioenergetic electron 
donar at SQR, could attribute to the accumulation of more reactive oxygen or reactive 
nitrogen species, eventually enhance cell death when electron leakage occurs. To test 
hypothesis, CellROX reagent was used to trace ROS in SH-SY5Y CBS OE cells 
under high substrates condition and during OGD condition. These cells appeared to 
have stronger CellROX staining (Figure 3.12). However, when subjected these cells 
to rotenone or 6-OHDA condition under high substrates condition, cells appeared to 
have significantly fewer Cellrox staining than SH-SY5Y CBS OE cells in normal 
medium under OGD condition. These results provided more new evidences that when 
treated SH-SY5Y CSE OE cells with high substrates (more H2S was generated), cells 
reversed the cell death by reducing ROS burden.  Moreover, when impeded the 
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electron transport chain at the complex III using antimycin, the neuroprotective effect 
of H2S was abolished (Figure 3.11 A). This further supports the hypothesis that H2S 
exerts its neuroprotective effect in 6-OHDA and rotenone induced injury via the 
facilitating electron flows in the electron transport chain hence provides more energy 
to survive under cytotoxic condition. In order to ascertain if H2S exerts neurotoxic 
effect via overloading the electron burden under OGD condition where oxygen is 
deprived, we replenished the OGD treated cells with normal medium. Interestingly, 
re-oxygenation prevented more SH-SY5Y CBSOE cells from OGD induced injury 
when compared with control SH-SY5Y (Figure 3.13 B and C), hence suggests that 
when cells were subjected to anaerobic condition, H2S worsened cell injury by 
overloading the electron burden; in contrast, facilitated electron transport chain under 
aerobic condition and thus enhanced cell survival. The proposed H2S mechanism of 









































Figure 3.22. Proposed mechanism of action and outcome that H2S plays a role as 
a electron donor during aerobic and anaerobic condition. Figure re-adapt and 
modified from Modis et al. (Modis et al., 2013). 
 
 
 Inhibition of H2S by non-selective CBS inhibitors, AOAA and 
hydroxylamine (HS), CSE inhibitors, propargylglycine (PAG) and β-cyanoalanine 
(BCA) dose dependently reduced infarct volume in pMCAO model (Qu et al., 2006). 
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Among all the inhibitors, AOAA was the most potent CBS inhibitor that reduced 
pMCAO induced infarct volume. However, AOAA is a PLP-dependent inhibitor that 
can also inhibit GABA transaminase (Loscher, 1981) and glutamic acid 
decarboxylase (Hamel et al., 1982). Therefore, the existing side effects such as 
inhibition of GABA transaminase activity or glutamic acid decarboxylase cannot be 
ruled out. More importantly, inhibition of GABA transaminase has shown to improve 
ischemic stroke outcome (Grabb et al., 2002), potentially due to the inhibition of 
excitotoxicity during stroke (Louzada et al., 2004). Hence, a selective CBS inhibitor 
is highly warranted.  
To develop a CBS inhibitor, we first understand the mechanism involved in 
condensation of cys and hcy to form H2S. Cystathionine is the end product of the cys 
and hcy condensation reaction. CBS consists of a binding pocket for cystathione, 
upon the binding of hcy at the aminoacrylate intermediate, release cystathione as the 
end product of the reaction. To selectively target at non-PLP binding sites, a 
compound that can covalently compete with cystathionine is developed. Therefore, a 
mimic of cystathionine could be a selective candidate for CBS inhibition. In this 
study, three classes of C2-symmetric, -X-Y-functionalized mimics of (L,L)-
cystathionine have been synthesized.  These are outfitted with specific side chain 
recognition elements for the CBS active site and with X-Y functional groups 
designed to engage the active-site cofactor in stable hydrazone, oxime or a nitrone 
linkages. Further functional group transformation followed by global de-protection 
has yielded nine CBS inhibitor candidates (Figure 3.14).  The saturated hydrazine 
acid inhibitor has shown to be the best inhibitor with  IC50 values of 132 M in the 
14C CBS radioactive assay (Figure 3.15). Thus the following experiments for CBS 
inhibition in stroke has be performed on saturated hydrazine acid cystathionine 
analogue in our ex vivo, in vitro and in vivo assay.    
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Saturated hydrazine acid analogue of cystathionine dose dependently 
inhibited CBS enzyme activity in brain homogenates. 3MST together with CAT, was 
known as the main H2S producing enzymes in the brain (Shibuya et al., 2009a). 
Therefore, by selectively inhibiting CBS in brain may not completely abolish H2S 
production when cys was used as a substrate in the assay. As expected, inhibition of 
CBS by saturated hydrazine acid analogue of cystathionine at 1 mM reduced H2S 
production up to 60% (Figure 3.16 A). This also indicates that CBS, as important as 
3MST, in synthesizing H2S in the brain. Next, SH-SY5Y CBSOE was used to 
examine the selective inhibitory function of the novel saturated hydrazine acid 
analogue of cystathionine on CBS. The results showed that the novel CBS inhibitor 
under the high substrates condition, dose dependently reversed cell death against 
OGD insult (Figure 3.16 D). This implicated the inhibition of endogenous H2S during 
ischemic stroke could potentially reverse cell injury. Next, i.c.v. injection pre-treated 
tMCAO animals with the novel CBS inhibitor demonstrated a reduction of infarct 
volume significantly up to 80% when compared to vehicle treated control (Figure 
3.17). Higher efficacy was seen when animals were treated with novel CBS inhibitor 
when compared with our previous reports of AOAA treatment on pMCAO rats (Qu et 
al., 2006). In the study, AOAA at 0.05 mmol/kg reduced pMCAO infarct volume by 
40% compared with vehicle treated control. Comparison for the efficacy of AOAA 
and cystathionine analogue cannot be determined since the experimental designs were 
different. For example, cystathionine analogue was administered 30 min via i.c.v. 
injection which drugs can effectively cross blood brain barrier and exert the highest 
bioavailability to CBS enzymes. In contrast, i.p. injection of AOAA was done, even 
at relatively low concentration, was able to reduce infarct volume with a lower 
bioavailability of drugs to brain CBS. Secondly, animal models used in both studies 
are different. For example, the effect of the novel cystathionine analogue was 
examined in transient ischemic model, whereas the AOAA was tested on pMCAO 
model which is well characterized with tissue necrosis. Hence, the efficacy of the 
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novel CBS inhibitor was incomparable to AOAA at this stage. Nevertheless, a well-
designed experiment should be done to validate the potency of both drugs.  
Ischemic stroke was characterized by stimulation of inflammatory responses 
thus endangers brain tissues and eventually aggravates cell death (Danton et al., 
2003; Dirnagl et al., 1999a). In the present study, we further validated the effect of 
novel cystathionine analogue on CNS inflammatory responses as the secondary 
damage induced by pro-inflammatory cytokines. Hence, microglia activation after 
novel inhibitor treatment was examined (Figure 3.18). Our results showed that the 
novel CBS inhibitor reduced microglia proliferation by reducing OX-42 staining 
which was markedly elevated after transient ischemic attack. Furthermore, the 
amount of activated microglia was significantly reduced after pre-administering novel 
CBS inhibitor. ROS triggers microglia activation during ischemic stroke. Alleviating 
microglia activation as the outcome after CBS inhibition indicated that inhibiting H2S 
during ischemic stroke condition might reduce ROS production during the 
progression of ischemic stroke pathogenesis.  
Finally, we examined the selectivity of the novel CBS inhibitors on GABA 
transaminase and CSE enzyme activity. Current available CBS inhibitors were mostly 
targeting PLP binding site, in contrast saturated hydrazine acid analogue of 
cystathionine was designed to avoid the binding of PLP binding sites so as to improve 
the selectivity for CBS inhibition. Our results showed that the IC50 for the novel CBS 
inhibitor for GABA transaminase was 572 µM. When compared with AOAA, it is 
almost 1000 times less potent than AOAA. AOAA, on the other hands, has an IC50 of 
0.36 µM thus indicating that the previous report of AOAA as a neuroprotective agent 
against pMCAO might be due to the inhibition of both CBS and GABA transaminase. 
Next, to rule out the possibility that the protection effect observed was simply due to 
GABA transaminase inhibition, administration of the novel CBS inhibitor at 1.6 
µmol/kg was done and GABA transaminase activity was examined at 1 h after 
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administration. Our in vivo results indicated that the novel CBS inhibitor did not alter 
GABA transaminase in all regions of the brain (Figure 3.19). As a positive control, 
AOAA administration inhibited GABA transaminase enzyme assay significantly in 
both cortex and striatum.  
The selectivity of novel CBS inhibitor was further investigated in CSE 
enzyme assay. By overexpressing CSE in SH-SY5Y cells (Figure 3.19), we used the 
system as an in vitro system to study the novel CBS inhibitor inhibition efficacy on 
CSE. Our results showed that the novel CBS inhibitors could inhibit CSE in a dose 
dependent manner (Figure 3.19 D) and reversed cell death in the presence of high 
substrates and OGD condition (Figure 3.19 E). BCA, a selective CSE inhibitor was 
used as a positive control in the experiments. Unfortunately, selective CBS inhibitor 
was yet to be found and the current saturated hydrazine acid cystathioine analogues 
could be used as a H2S inhibitors targeting CBS and CSE. Despite CSE is a low 
abundant enzyme in CSN, we are not certain that the effect of saturated hydrazine 
acid cystathionine analogue was fully from CBS inhibition.  
The therapeutic window of saturated hydrazine acid cystathionine analogues 
was examined at 1 and 2 h after middle cerebral artery occlusion (Figure 3.20). Post 
treatment of saturated hydrazine acid cystathionine analogue reduced infarct volume 
significantly when administered at 1 h post-MCAO but not at 2 h post-MCAO. This 
could be due to two reasons. Firstly, saturated hydrazine acid cystathionine anlaogue 
could have a relatively shorter therapeutic window which could only alleviate stroke 
outcome when administered before 1 h after the onset of stroke. Secondly, it could be 
due to the re-oxygenation was performed after 100 min occlusion. Inhibition of H2S 
during reperfusion of cerebral blood flow could potentially disturbed electron 
transport chain in which H2S functions as an electron donors when electron transport 
chain remained intact. Study has shown that NaHS at 0.85 mg/kg reduced infarct 
volume and improved neurological deficit in mice tMCAO model (Wang et al., 
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2014), which is contradict with the previous study that NaHS at 1.8 mg/kg increased 
infarct volume in pMCAO animals (Qu et al., 2006). Different from the present 
study, Wang et al. has administered NaHS at 3 h after reperfusion of cerebral blood 
flow when H2S served as an electron donor in the presence of oxygen. This suggested 
that the inhibition of H2S in the presence of oxygen during reperfusion could inhibit 
H2S functions as an electron donor thereby aggravate stroke outcome. The idea is so 
far remains speculative and more investigations should be carried out to further 
elucidate the possibility.  
Preferably, endogenous H2S level should be determined in the study. 
However, the current methods used was the colorimetric assay adapted from  
Stipanuk (Stipanuk et al., 1982) and further modified by Abe (Abe et al., 1996). It is 
an indirect method to detect background levels of sulfur and not specifically H2S. 
Other H2S detection methods include of the use of H2S-sensitive fluorescent probes 
which can allow detection location concentration of H2S and of the sites of release in 
real time (Lippert et al., 2011; Qian et al., 2011) or monobromobimane methods 














Chapter 4: Inhibiting NF-κB by andrographolide benefits acute ischemic stroke 
outcome  in experimental models  
4.1. Introduction 
Andrographolide is an active constituent of Andrographis paniculata Ness (A. 
paniculata), which is also known as the king of bitters (Lim et al., 2012). A. 
paniculata contains multiple kinds of flavanoids, labdane diterpenoids, stigmasterols 
and xanthones. Labdane diterpenoids can be isolated in free and glycoside forms and 
it includes of andrographolide, 14-deoxy-11, 12-didehydroandrographolide, 
neoandrographolide and 10 other compounds with unknown functions. Structurally, 
andrographolide contains of two double bonds and three hydroxyls at C-3 
(secondary), C-14 (allylic) and C-19 (primary) (Figure 4.1). Both ends of 
andrographolide are polar. It is soluble in methanol and ethanol. Experimental 
evidences indicated that andrographolide exerted several therapeutic actions 
including as a immunosuppresant (Burgos et al., 2005; Iruretagoyena et al., 2006), 
inhibiting inflammatory responses (Abu-Ghefreh et al., 2009; Bao et al., 2009; Wang 
et al., 2007b) and thrombus formation (Li et al., 2009), potent antioxidant (Akowuah 
et al., 2009) and can be served as and anti-diabetic (Zhang et al., 2009), antibacterial 









Figure 4.1: Chemical structure of andrographolide. Figure adapated from Lim et 
al. (Lim et al., 2012) 
NF-κB is known as one of the key regulators for inflammation, oxidative 
stress and inflammation. In the canonical NF-κB pathway (Figure 4.2), it consists of 
p50 and p65 (RelA) subunits, form heterodimers (Harari et al., 2010). NF-κB dimers 
normally retain in cytosol until activated by stimuli for example TNF-α, IL-1β, C40 
or lipopolysaccharide (LPS), thereby released from its inhibitor IκB subunits and 
translocate into nucleus (Gerondakis et al., 2014; Harari et al., 2010). Other important 
inducers for NF-κB activity including ionizing radiation, UV light, oxidative stress 
and hypoxia (Ridder et al., 2009). NF-κB dimers facilitate gene transcription by 
binding to its targeted DNA. Phosphorylation of IκB plays an important role in 
determining the activation NF-κB signalling. The phosphorylation of IκB is regulated 
by the inhibitor of kappaB kinase (IKK). The IKK complex consists of two subunits 





Figure 4.2: Canonical NF-κB signaling pathway. Cerebral ischemic injury triggers 
the activation of IKK complex (NEMO, IKKα and IKKβ) and phosphorylate IKKβ. 
Phosphorylated IKKβ thereby activate the NF-κB complex, by phosphorylated IκB at 
Ser32 and Ser36. The phosphorylation of IκB leads to p50/p65 heterodimers release. 
The heterodimers, p65/p50 translocates from cytosol to nucleus and eventually 
functions to regulate the transcription of NF-κB-dependent gene transcription. NF-κB 
dependent genes include of iNOS, COX-2, ICAM-1, Nox-2 and TNF-α etc. Figure 
readapted from Viennois et al. 2013 (Viennois et al., 2013). 
 
The idea for the association of NF-κB with stroke was first suggested when 
RelA and p50 expression was found on stroke patient brain tissues (Terai et al., 
1996). RelA and p50 were also detected in macrophages in the infarct areas and 
predominantly in the ischemic penumbra (Terai et al., 1996). Subsequently, RelA 
expression in nucleus, which indicated translocation activation, was found in the post-
mortem ischemic brain samples (Nurmi et al., 2004). The translocation of RelA was 
observed mainly in necrotic infarct core (Nurmi et al., 2004). Experimentally, there 
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are ample evidences suggested that NF-κB signalling activation attributes to the 
detrimental outcome to ischemic stroke. For instance, in mouse permanent and 
transient ischemic stroke model, a κB-dependent β-globin reporter gene was found 
increased (Schneider et al., 1999). Moreover, mice deficient of NF-κB p50 subunit 
showed smaller infarct volume in MCAO model (Nurmi et al., 2004). In addition, 
selectively inactivation of NF-κB signalling by mutation of IKK phosphorylation 
sites, showed improvement in both histological and neurological outcome in a mouse 
MCAO model (Davoli et al., 2002). Experimental stroke animals with RelA 
conditional deletion was shown to have improvement in stroke outcome (Inta et al., 
2006). The progression of cerebral ischemia is also characterized by the activation of 
several pro-inflammatory mediators regulated by NF-κB signalling. These mediators 
include of TNF-α and IL-1 β. Several pro-inflammatory mediators that was found to 
have deleterious role to ischemic stroke including TNF-α, IL-1 α & β, IL-6, iNOS, 
ICAM-1, MMP-9, cPLA2 and prostaglandin E are genes (Herrmann et al., 2005; 
Ridder et al., 2009; Wang et al., 2007a).  
Xia and colleagues reported that andrographolide bind covalently to the 
reduced cys62 of the NF-κB p50 subunit. In the reporter assay, andrographolide 
specifically inhibited the luciferase activities of NF-κB activated by TNF-α in a dose 
dependent manner. Andrographolide could also prevent the binding of NF-κB  
oligonucleotide to the nuclear protein. In addition, andrographolide reacts covalently 
with p50 and prevents the binding of the NF-κB probe to p50. Supporting with mass 
spectroscopy analysis, Xia et al. showed the direct binding of andrographolide to p50 
thus confirm the binding specificity of andrographolide to NF-κB p50 subunit (Xia et 
al., 2004). Andrographolide is a selective NF-κB inhibitors targeting multiple cascade 
in the cerebral ischemic pathogenesis. We hypothesize that andrograhpolide could be 
a potential therapeutic agent against acute ischemic stroke. In the present study, the 
effect of andrographolide was investigated by using both in vitro and in vivo 
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approach. By testing andrographoilde in our cell culture system, it provides more 
information for the potential neuroprotective mechanism of action exerted by 
andrograhpolide. Moreover, andrographolide effect was tested on an animal stroke 
model and finally the underlying mechanism was studied in detail.  
4.2. Materials and methods 
4.2.1. Primary culture of rat cortical astrocyte  
Primary astrocyte cultures were prepared from the cerebral cortices of 1-2 
day old Sprague-Dawley rat pups. Materials and methods are described in Chapter 2, 
section 2.11 (page 48).  
4.2.2. Neuroblastoma SH-SY5Y cell line  
 Materials and methods are described in Chapter 2, section 2.12 (page 49).  
4.2.3. Cell treatment  
 Primary astrocytes were seeded into 96 well plate or 6 well plate (GSH assay) 
and incubated overnight. One h before the treatment, the cell medium was replaced 
with low serum medium (0.5% FBS/DMEM). Cells were pre-treated with vehicle 
(0.5% DMSO) or andrographolide (1 µM or 5 µM) and followed by 200 µM of H2O2 
treatment for 2 h. For GSH assay and reactive oxygen species experiments, H2O2 
treatment was reduced to 1 h. SH-SY5Y neuroblastoma was pre-incubated with 
vehicle, 1 μM and 5 μM andrographolide for 2 h and followed by 10 μM sodium 
dithionite treatment for 24  h.  
4.2.4. Cell viability assay  




4.2.5. Total GSH assay  
GSH assay was performed according to the manufacturer instruction (Sigma, 
USA). Briefly, primary astrocytes were scrapped and re-suspended in 1 × PBS, 
centrifuged at 1000 rpm to obtain the cell pellets. Five percent of SSA solution was 
added to the cell pellets (3:1 ratio) followed by repeated freezed/thawed in liquid 
nitrogen. Next, cells were spun at 10,000 g for 10 min. Ten microlitre of supernatant 
was added to 150 µl working mixture (GSH reductase and DTNB solution) and 
incubated for 5 min at room temperature. Finally, NADPH solution (50µl) was added 
into the mixture. Absorbance value was measured at 412 nm determined by kinetic 
measurement. Total GSH level was achieved by conversion of absorbance through a 
standard curved obtained by known GSH level.  
4.2.6. Reactive oxygen species (ROS) measurement  
 Primary astrocytes were seeded in a black 96 well plates. After 
andrographolide treatment, cells were incubated in 2', 7'-dichlorofluorescin diacetate 
(DCFH-DA) dye at a final concentration of 50 µM in dark. ROS oxidizes DCFH-DA 
to form a fluorescent product, fluorescent 2', 7'-dichlorofluorescein. After 45 min of 
incubation, astrocytes were rinsed twice with PBS solution and the fluorescent signal 
can be detected at an EX at 490 nm/ EMat 520 nm by Varioskan flash multimode 
reader (Thermo Scientific). 
 
4.2.7. pMCAO model  
Materials and methods are described in Chapter 2, section 2.2 (page 39). 
4.2.8. Drug administration for animals study 
 Andrographolide was dissolved in 1% DMSO (in sasline) and 1 h post 
administrated at 0.01 mg/kg, 0.1 mg/kg and 1 mg/kg via i.p. injection. 
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4.2.9. Behavioural assessment  
 Materials and methods are described in Chapter 2, section 2.7 (page 44). 
4.2.10. Infarct volume assessment  
 The brains were harvested at 24 h post-stroke. Next, the whole brain were cut 
into 2 mm coronal sections and further stained by 1% Tetrazolium Blue Chloride 
(TTC, Sigma, USA) for at 37ºC for 30 min. Brain sections with TTC staining then 
post-fixed in 4% paraformaldehyde (Sigma, USA) overnight at room temperature. 
The infarct volume measurement with brain oedema correlation are described in 
Chapter 2, section 2.9 (page 45).  
 
4.2.11. Immunohistochemistry  
 Materials and methods are described in Chapter 2, section 2.14 (page 50) 
except perfusion buffer used was Ringer buffer and followed by 2% 
paraformaldehyde. Primary antibodies used in the study were anti- ED-1 (1:100, 
Serotec, Oxford, UK) and anti-OX-42 (CD11b; 1:100, Serotec).  
4.2.12. Recipe for cytoplasmic and nuclear proteins extraction 




HEPES (mM) 10 20 
MgCl2 (mM) 1.5 1.5 
KCl (mM) 10 - 
NaCl (M) - 0.42 
EDTA (M) - 0.2 
Glycerol (%, v/v) - 25 
pH 7.9 7.9 
 
Table 4.1. Ingredients and final concentration of lysis buffer and extraction buffer for 




 Cerebral tissues were homogenized in cold lysis buffer containing inhibitor 
cocktails (Roche, Germany). The lysates were centrifuged at 10,000 × g for 20 min. 
The supernatant were further re-suspended in the extraction buffer containing 
protease inhibitor cocktail (Roche, Germany) for 30 min. Finally, nuclear fraction 
was retrieved from supernatant after centrifugation for 5 min at 20,000 × g.  
 
4.2.13. Western blot analysis  
 Materials and methods were described in Chapter 2, section 2.15 (page 51). 
Primary antibodies used were p65 protein (1:1000, Cell Signalling Technologies) and 
β-actin (Cell Signalling Technologies, Beverly, MA, USA) at 4°C overnight  
 
4.2.14. Cytokines (TNF-α and IL-1β) and chemokines (PGE2) level measurement  
 Total proteins of ipsilateral or contralateral rat brain hemispheres were 
extracted using celLytic MT Cell Lysis Reagent (Sigma, USA). The levels for 
cytokines and chemokines were detected by using the commercial immunoassay kit 
for TNF-α (R&D systems, USA) and IL-1β (R&D systems, USA) and PGE2 
(Amersham, UK). Microplate reader (Sunrise, Tecan, USA) was used to quantified 
the total cytokines and chemokines level. The final total cytokines and chemokines 
level were normalized to respective protein level.  
 
4.2.15. Data analysis  
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4.3.4. Andrographolide post-treatment reduced infarct volume and improved 
neurological deficits.  
 Andrographolide at 1 h post-treatment reduced the pMCAO infarct volume 
(226 ± 25 mm3) by around 50% as presented at 0.1mg/kg concentration. Furthermore, 
andrographolide at 0.1 mg/kg improved neurological score of pMCAO animals 
significantly from a score of 3.5 ± 0.3 (vehicle control pMCAO) to 1.7 ± 0.3 (0.1 
mg/kg andrographolide treated pMCAO).   
 
 
Figure 4.8. Andrographolide effect to pMCAO stroke rats. (A), Representative 
TTC staining of pMCAO rat brain sectioned at 24 h after the onset of stroke. (B), 
Quantification of vehicle, 0.01, 0.1 and 1 mg/kg andrographolide (Andro) treated 
pMCAO rats' brain infarct volume. N=6, **p < 0.01; ***p < 0.001 against the vehicle 
group by one way ANOVA, post hoc analysis by Bonferroni. Error bars represent 



























1 0 0 2 0 
2 0 1 4 2 
3 3 5 0 4 
4 3 0 0 0 
Mean±SEM 3.5±0.3 2.8±0.2 1.7±0.3* 2.7±0.3 
 
 
Table 4.1. Neurological score of andrographolide treated rats. Table represents 
the number of rats that scored at various category of neurological deficits 
(neurological scores 1-4). N = 6. χ2 = 24.7, d.f. - 9 and p < 0.005. *p < 0.01 against 
vehicle treated pMCAO rats analysis by Kruskal-Wallis test.   
 
 
4.3.5. Andrographolide against microglia activation 
Both OX-42 and ED-1 immunopositive staining were observed in cortex and 
striatum (Figure 4.9 and 4.10). Resident microglia (OX-42 positive cells) appeared in 
both ipsilateral and contralateral hemispheres as ramified star like cells characterized 
of inactive micrgolia (Figure 4.9.Aa, Dd). Among MCAO rats, OX-42 
immunopositive microglia cells in the peri-infarct and infarct core appeared to be 
activated and characterized as rounded amoeboid morphology with retracted or 
degenerated processes. In contrast, microglia activation was not observed in 
contralateral hemispheres (Figure 4.9. Bb, Ee) and andrographolide treated rats 
appeared to have fewer activated microglia (Figure 4.9. Cc, Ff). To confirm the 
observation, a semi quantitative approach was employed to count OX-42 positive 
immunostaining cells in a blinded manner and our quantitative results assures that 
andrographolide was found significantly reduced the total number of microglia 
positive cells in both infarct core and peri-infarct regions (Table 4.2). ED-1 stained 
for macrophages including phagocytic microglia. Consistent with the results obtained 
from OX-42 immunostaining, ED-1 immunopositive cells were observed only in the 
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ipsilateral hemisphere of MCAO rats (Figure 4.10. Bb, Ee) and andrographolide 
treatment reduce the ED-1 positive staining. Quantitative cell counts showed that the 
reduction was statistically significant in the peri-infarct region, but not in the infarct 
core (Table 3), indicating that microglia activation was significantly reduced by 
andrographolide only in the peri-infarct regions.  
 
 
Figure 4.9. Immunohistochemistry staining of OX-42 in pMCAO rats peri-
infarct cortex.  Representative immunofluorescent staining figures from -1.8 m from 
bregma. Images were taken from both ipsilateral and contralateral peri-infarct cortex 
of sham control rats (A, D, a and d), vehicle treated pMCAO rats (B, E. b and e) and 
0.1mg/kg ANDRO treated pMCAO rats (C, F, c and f). A-F are images taken under 
lower magnification (4 ×). a-f are images taken under higher magnification (40 ×). 
Scale bar = 0.5 mm (A-F) and 0.05 mm (a-f). Red arrows indicated ramified or un-
activated microglia while red arrow heads indicated activated microglia with 





















Table 4.2. OX-42 positive staining semi-quantification. Three region of interested 
(ROI) of 0.2, -1.8 and -2.7 mm from bregma were chosen in a randomly selected 
areas of 0.25 mm2 and were counted by a blinded approach. OX-42 positive cells 
were quantified in both infarct cortex and peri-infarct cortex of the ipsilateral vehicle 
treated pMCAO (MCAO) and 0.1 mg/kg Andrograhpolide treated pMCAO 
(Andrographolide treated) rat brains.  N=3. *p < 0.05. Independent t-test. Error bars 










ROI (from bregma)  infarct region  MCAO    Andrographolide treated  
0.2 infarct core 238.0 ± 17.6 131.3 ± 9.9 * 
 peri infarct 153.0 ± 2.4 73.7 ± 14.3 * 
-1.8 infarct core 198.0 ± 26.5 110.7 ± 6.4 * 
 peri infarct 100.0 ± 7.0 75.0 ± 6.1 * 
-2.7 infarct core 238.7 ± 3.5 165.3 ± 14.4 * 




Figure 4.10. Immunohistochemistry staining of ED-1 in pMCAO rats peri-
infarct cortex.  Representative immunofluorescent staining figures from -1.8 m from 
bregma. Images were taken from both ipsilateral and contralateral peri-infarct cortex 
of sham control rats (A, D, a and d), vehicle treated pMCAO rats (B, E. b and e) and 
0.1mg/kg ANDRO treated pMCAO rats (C, F, c and f). A-F are images taken under 
lower magnification (4 ×). a-f are images taken under higher magnification (40 ×). 
microglia with amoeboid morphology. Co, cortex; St, striatum. Scale bar = 0.5 mm 











Table 4.2. ED-1 positive staining semi-quantification. Three region of interested 
(ROI) of 0.2, -1.8 and -2.7 mm from bregma were chosen in a randomly selected 
areas of 0.25 mm2 and were counted by a blinded approach. ED-1 positive cells were 
quantified in both infarct cortex and peri-infarct cortex of the ipsilateral vehicle 
treated pMCAO (MCAO) and 0.1 mg/kg Andrograhpolide treated pMCAO 
(Andrographolide treated) rat brains.  N=3. *p < 0.05. Independent t-test. Error bars 
represent SEM.  
 
 
4.3.6. Andrographolide reduced the IL-1β and TNF-α elevation in pMCAO rat 
brains 
Both IL-1β (Figure 4.11) and TNF-α (Figure 4.12) levels were found remarkably up-
regulated in ipsilateral rat hemisphere after pMCAO when compared to sham 
ipsilateral and its respective contralateral hemisphere. Andrographolide post-
treatment at 0.1 mg/kg 1 h after pMCAO signficantly reduced both IL-1β and TNF-α 
levels drastically. Interesting to note that, andrographolide post-treatment abolished 
the TNF-α elevation completely back to normal physiological concentration   
ROI (from bregma) infarct region  MCAO    Andrographolide treated 
0.2 infarct core 72 ± 10 43 ± 8 
 peri infarct 65 ± 3 14 ± 4 * 
-1.8 infarct core 139 ± 11 113 ± 13 
 peri infarct 155 ± 9 45 ± 13 * 
-2.7 infarct core 240 ± 50 109 ± 38 * 




Figure 4.11. Andrographolide at 0.1 mg/kg 1 h post-stroke treatment reduced 
the elevation of IL-1β in pMCAO ipsilateral hemisphere. Commercial 
immunoassay kit was used to measure IL-1β level in sham operated (sham), vehicle 
treated pMCAO and 0.1 mg/kg andorgrapholide treated pMCAO (0.1mg/kg Andro) 
rat hemisphere. The IL-1β level was normalized relative to Sham. Data are presented 
as mean ± SEM, n=3-5. ***p < 0.001 against Sham by one way ANOVA with 




Figure 4.12. Andrographolide at 0.1 mg/kg 1 h post-stroke treatment reduced 
the elevation of TNF-α in pMCAO ipsilateral hemisphere. Commercial 
immunoassay kit was used to measure TNF-α level in sham operated (sham), vehicle 
treated pMCAO and 0.1 mg/kg andorgrapholide treated pMCAO (0.1mg/kg Andro) 
rat hemisphere. The TNF-α level was normalized relative to Sham. Data are presented 
as mean ± SEM, n=3-5. ***p < 0.001 against Sham by one way ANOVA with 





4.3.7. Andrographolide treatment reduced PGE2 level in pMCAO rat ipsilateral 
hemisphere.  
Similar to IL-1β and TNF-α level, PGE2 level was found significantly increased in 
pMCAO rat hemisphere selective to ipsilateral site of the brain (Figure 4.13). 
Andrographolide 1 h post-treatment at 0.1 mg/kg attenuated the PGE2 level back to 
physiological concentration as such reduced the pro-inflammatory responses 
significantly.  
 Figure 4.13. Andrographolide at 0.1 mg/kg 1 h post-stroke treatment reduced 
the elevation of PGE2 in pMCAO ipsilateral hemisphere. Commercial 
immunoassay kit was used to measure PGE2 level in sham operated (sham), vehicle 
treated pMCAO and 0.1 mg/kg andorgrapholide treated pMCAO (0.1mg/kg Andro) 
rat hemisphere. The PGE2 level was normalized relative to Sham. Data are presented 
as mean ± SEM, n=3-6. ***p < 0.001 against Sham by one way ANOVA with 
Bonferroni post hoc analysis; §§p < 0.01 against the vehicle control by independent t-
test.  
 
4.3.8. Effect of andrographolide on p65 subunit translocation  
Activation of NF-κB promotes nuclear translocation of p50 and p65 subunits. 
In the present study, we observed a marked p65 subunit translocation at 24 h after 
pMCAO and the effect was abolished by andrographolide treatment (Figure 4.14), 




Figure 4.14. Andrographolide at 0.1 mg/kg 1 h post-stroke treatment inhibited 
p65 subunit translocation to nucleus. (A). Representative Western blot results of 
p65 subunit in nuclear and cytosolic fraction in ipsilateral sham hemisphere (Sham), 
vehicle treated pMCAO rat ipsilateral hemisphere (pMCAO) and Andrograhpolide at 
0.1 mg/kg post-treated rat ipsilateral hemisphere (pMCAO + ANDRO). (B). 
Densitometry measurement of p65 subunit expression in ipsilateral sham hemisphere 
(Sham), vehicle treated pMCAO rat ipsilateral hemisphere (pMCAO) and 
Andrograhpolide at 0.1 mg/kg post-treated rat ipsilateral hemisphere (pMCAO + 
ANDRO). Protein level of p65 subunit in nuclear fraction was normalized against 
histone; while protein level of p65 subunit in cytosolic fraction was normalized 
against β-actin. Protein expression was finally normalized relative to Sham control 
(Sham). Data are presented as mean ± SEM, n=4. *p < 0.05 against Sham by one way 
ANOVA with Bonferroni post hoc analysis; +p < 0.05 against the pMCAO by 
independent t-test.  
 
 
4.4. Discussion  
In the preliminary data, I showed that andrographolide ameliorated H2O2 
induced cell death in primary astrocytes via the inhibition of ROS (Figure 4.5) and 
the up-regulation of GSH (Figure 4.6). Astrocytes are important in GSH synthetic 
machinery in the brain. Consistent with the current results, previous studies revealed 
that pre-treatment with andrographolide protected the cardiomyocytes against 
hypoxia/ reoxygenation injury and up-regulated the cellular-reduced GSH level as 
well as antioxidant enzyme activities (Woo et al., 2008). In addition, Woo and 
colleagues further showed that andrographolide time-dependently up-regulated the 
glutathione and the cardioprotective action of andrographolide was completely 
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abolished by γ-glutamate cysteine ligase inhibitor, the butathionine sulfoximine (Woo 
et al., 2008). Results suggested that andrographolide facilitates neuroprotective 
function in H2O2 induced primary astrocyte cell death via the enhancement of GSH 
synthesis and the reduction of ROS production. As such, andrographolide could bring 
beneficial effect against stroke condition.  
Next, as a preliminary study, sodium dithionite was used to mimic the stroke 
condition as it is known as a oxygen scavenger. The present results showed that when 
treated SH-SY5Y neuroblastoma cells with sodium dithionite at 10 µM, significantly 
reduced cell viability to around 50% (Figure 4.7). Andrographolide at 5 µM reversed 
cell death markedly as shown in the MTT assay. I proceed the experiment by testing 
andrographolide in an experimental animal stroke model. The current results showed 
that andrographolide dose dependently reduced infarct volume (Figure 4.8) and 
improved neurological deficit (Table 4.1). Furthermore, using immunochemistry, 
significant reduction of microglia proliferation (Figure 4.9) as well as activation 
(Figure 4.10) were observed mainly in the peri-infarct cortical regions. This 
suggested that andrographolide exerted its effects mainly in the energy rich 
phosphates preserved region during ischemic stroke injury where the energy is still 
temporary reserved (Back 1998). The neuroprotective effects of andrographolide 
perhaps not surprising given the fact that it has been reported to function as anti-
inflammatory (Abu-Ghefreh et al., 2009; Bao et al., 2009), anti-oxidative stress 
(Akowuah et al., 2009) and anti-oedematogenic (Lin et al., 2009) agent, which could 
serve as a protective shield against ischemic injury.   
 Elevation of OX-42 stained cells (Table 4.2) and activated cells (Figure 4.9 B 
and b) were observed in the ipsilateral brain, but not in the contralateral side after 
pMCAO insults. This results is consistent with the previous findings that OX-42 
immunoreactivity is increased within hours after pMCAO (Stoll et al., 1998). 
Schroeter suggested that immunoreactive phagocytes are mainly derived from 
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resident microglia, while the macrophages were recruited from the blood stream only 
in the delayed stages (Schroeter et al., 1997). Immunostaining of ED-1 demonstrated 
ramified resident microglia, upon activation, changed into amoeboid phagocytic cells. 
Activation of microglia thereby caused the release of a variety of cytotoxic and 
cytoprotective substances (Wood, 1995). Activated microglia may serve as 
scavengers in inflammation and/or deleterious factors in ischemic injury (Gunther et 
al., 2005; Yrjanheikki et al., 1999; Zhang et al., 2005). Consistent with the findings 
on infarct volume and neurological score, treatment with andrographolide markedly 
reduced the number of microglia in both the infarct core and the peri-infarct region, 
while attenuating microglia activation in the peri-infarct region. This is also 
consistent with a previous finding that andrographolide attenuated LPS-induced 
microglia activation. In the present data, andrographolide suppressed the 
transformation of microglia into phagocytes that exacerbate cytokine secretion thus 
implied that andrographolide may reduce cytokine up-regulation after stroke. 
Furthermore, andrographolide down-regulates IL-1β (Figure 4.11) and TNF-α (Figure 
4.12). Both IL-1β and TNF-α are well-studied cytokines that related to inflammatory 
responses in stroke and the up-regulation appear to exacerbate ischemic damage 
(Barone, 2009; Yamasaki et al., 1995). Previous evidences had suggested that down-
regulating of IL-1β or TNF-α expression appeared to reduce infarct volume in stroke 
animals (Garcia et al., 1995b; Yang et al., 1998). Similar results were obtained for 
PGE2.  Much smaller increase of PGE2 level was observed after pMCAO than IL-1β 
or TNF-α expression (Figure 4.13). Upstream pathway of PGE2 is COX-2. COX-2 
was found up-regulated in post-mortem specimens from ischemic stroke patients 
(Iadecola et al., 1999). Such clinical evidence supports the data that ischemic stroke 
animals and patients both showed increase in COX-2 level. Moreover, COX-2 
inhibition has been shown to be beneficial in neurological outcome after stroke and 
COX-2 exerts its aggressive actions via its downstream product including PGE2 
(Kawano et al., 2006; Sasaki et al., 2004). COX-2 deficient mice was reported to 
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have smaller brain injury produced by MCAO (Iadecola et al., 2001). All these 
supporting evidences suggested that COX-2 mediated inflammation caused by the 
onset of brain ischemic attack, has a significant role in stroke, so does its downstream 
products, PGE2. Interesting, Wang was previously reported that andrographolide 
reduced the production of pro-inflammatory mediators including ROS, TNF-α, NO 
and PGE2 in microglia culture with LPS as inflammatory stimulator (Wang et al., 
2004). This study supports our observation of andrographolide neuroprotective effect 
on the in vivo animal stroke study.  
 NF-kB is well recognized in the regulation of inflammation and is a key 
regulator of many genes involved in cell survival and inflammation (Clemens et al., 
1997; Schneider et al., 1999), where cerebral ischemia activated several transcription 
factors including of NF-kB as one of the crucial factors regulate the outcome of 
cerebral ischemia. Pro-inflammatory NF-kB targets genes including TNF-α, IL-1α 
and β, iNOS, COX-2 and ICAM-1 (Wang et al., 2007a). These mediators contribute 
to ischemic damage. Targeting NF-kB is one of the potential therapeutic approach 
with reverse genetic evidences that mice deficient in the p50 subunit of NF-kB and 
specific inhibition of NF-kB by pyrolidinedithiocarbomate (PDTC) show reduction in 
infarct size in both permanent and transient stroke model (Nurmi et al., 2004; 
Schneider et al., 1999). In the current study, I found that andrographolide exerted its 
anti-inflammatory effects probably via the inhibition of p65 subunit of NF-kB 
translocation. This may suppress the expression of the above cytokines and 
inflammatory factors, which in turn suppress microglia activation. However, it could 
be possible that the suppression of inflammatory cytokines by andrographolide 
treatment is simply a results of diminished infarction, although this is unlikely 
considering dramatic suppression of pro-inflammatory responses were observed after 
treatment in stroke model. A direct inhibition of andrographolide in animal brain 
using both in vivo and ex vivo approach should be done to further elaborate the data. 
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Chapter 5: The potential roles of 5-lipoxygenase and leukotriene B4 in the 
pathology of ischemic stroke 
5.1. Introduction  
5.1.1. Leukotrienes (LTs) and leukotriene B4 (LTB4) 
 Leukotrienes (LTs) originally confirmed in asthma. However, the 
implications of these findings have been extended to atherosclerosis recently (De 
Caterina et al., 2004). It is a class of eicosanoids, known as the key players in pro-
inflammatory process. Among all the eicosanoids, LTB4 is a known as the most 
potent pro-inflammatory lipid mediator that activates and recruits leukocytes to the 
site of injury. LTB4 was previously known to involve in the production of cytokines 
(Heesen et al., 2002), stimulation of NF-κB (Sanchez-Galan et al., 2009), increase 
production of IL-2, IFN-γ and interleukin-5 (IL-5) by T cells, increase expression of 
MCP-1 and IL-8 (Nair et al., 2014). At nanomolar concentration, LTB4 serves as a 
chemotaxis of neutrophils whereas at micromolar concentration, LTB4 stimulates the 
release of lysosomal enzymes (Hafstrom et al., 1981). Previous studies reported that 
Apolipoprotein E knockout (APOE-/-) mice with double knockout of LTB4 receptor 
type I (BLT1 receptor), displayed a decrease in monocyte infiltration and decrease of 
lesion size in atherosclerosis model (Heller et al., 2005). Moreover, Clinical study has 
reported the expression of LTB4 receptors (BLT1 and BLT2 proteins) was found in 
macrophage rich areas within the human atherosclerotic lesion (Back et al., 2005). 
This suggested that LTB4 may exert detrimental role in atherosclerosis.  
5.1.2. Biosynthesis of LTB4 
 Metabolites of AA, COX and LOX contribute to detrimental effects of stroke 
via post-ischemic brain inflammation and circulatory disorders. Particularly, the 
metabolites of COX-2 pathway were more widely studied in brain ischemia. 
Synthesis of leukotrienes is initiated when the translocation of cytosolic 
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phospholipase A2 (cPLA2) to the nuclear envelope and of 5-lipoxygenase (5-LO) 
from the cytosol or nulcear matrix to nuclear envelope occur (Figure 5.1). AA is 
subsequently revealed by cPLA2 from membrane phospholipids. Acting as a 
scaffolding protein, 5-LO activating protein (FLAP) facilitates the transfer of AA 
from cPLA2 to 5-LO. 5-LO is a non-heme iron dioxygenase catalyzing the first two 
steps of AA to generates leukotriene A4 (LTA4). First step includes lipoxygenation of 
C5 of AA to generate 5-hydroperoxy-eiocosatetraenoic acid (5-HPETE). Next, 5-LO 
facilitates the dehydration of 5-HPETE to form LTA4. LTA4 hydrolase (LTA4H) is 
the key enzyme that specifically converts LTA4 into LTB4. On the other hands, 
leukotriene C4 (LTC4) and subsequently leukotriene D4 and E4 (LTD4 and LTE4 
respectively) were formed when LTA4conjugates with glutathione (GSH) via LTC4 
syntheses (LTCS4) (Peters-Golden et al., 2007). 
 
 
Figure 5.1. Leukotriene biosynthesis. 1. Upon stiumulation, arachidonic acid (AA) 
releases from cellular membranes by cytosolic phospholipase A2 (cPLA2). Free AA is 
presented to 5-lipoxygenase activating protein (FLAP) and 5-lipoxygenase (5-LO) 
thereby convert to 5-hydroperoxy-eiocosatetraenoic acid (5-HPETE). 5-HPETE 
further de-hydrated by 5-LO to form leukotriene A4 (LTA4). 3. Leukotriene A4 
hydrolase (LTA4H) catalysed LTA4 to form leukotriene B4 (LTB4) whereas 4. 
leukotriene C4 synthase associates (LTC4S) LTA4 with glutathione to form 
leukotriene C4 (LTC4) and subsequently produce leukotriene D4 (LTD4) and 






5.1.3. 5-LO and LTB4 in cardiovascular diseases 
 Lipid mediators are important in facilitating inflammatory responses. They 
are active in low nanomolar range and are capable of activating a series of cellular 
pro-inflammatory responses. For instances, LTB4 is one of the most potent 
chemoattractants whereas, CysLTs are potent in provoking smooth muscle 
constriction in bronchitis airways. Several human diseases which involve 
inflammatory responses were found to have some sort of connection with 5-LO 
pathways, for example, asthma, rheumatoid arthritis, inflammatory bower disease, 
atherosclerosis, myocardial infarction, ischemic stroke and cancer (Charo et al., 2011; 
Peters-Golden et al., 2007).  
 5-LO pathways in pathogenesis of asthma has been studied widely however 
much attention have been shifted to cardiovascular diseases recently. It was arise 
from clinical evidences that LTB4 production was found in human atherosclerotic 
plaques (De Caterina et al., 1988). This was followed by the study done by Allen and 
colleagues that 5-LO, FLAP and LTA4H were found expressed in human 
atherosclerotic coronary artery (Allen et al., 1998). Not much attention has been paid 
on the role of leukotriene in cardiovascular disease until genetic evidences suggested 
that the mutation of 5-LO gene is associated with the risk of atherosclerosis and 
myocardial infarction (Dwyer et al., 2004). Since then, more research groups devoted 
in searching for the potential role of LTB4 in atherosclerosis. Studies for example 
performed by Qiu et al. showed high mRNA levels of 5-LO, FLAP and LTA4H in 
human atherosclerotic lesion as compared to healthy controls (Qiu et al., 2006). More 
interestingly, the mRNA level of 5-LO and LTA4H was shown to be correlated with 
clinical signs of plaque instability (Qiu et al., 2006). ApoE-/- and low density 
lipoprotein receptor (LDLR) null mice were always used as a murine atherosclerotic 
model to recapitulate human atherosclerosis. BLT1 antagonist was found to reduce 
vascular lesions and macrophage number in APOE-/-  and LDLR-/- mice (Aiello et al., 
142 
 
2002). Moreover, genetic deletion of BLT1 in ApoE-/- mice also showed significant 
reduction in lesion formation (Subbarao et al., 2004). Taken together, both genetic 
studies and pharmacological studies on animal models emphasized the importance of 
LTB4 in atherosclerosis formation.  
 Several evidences have suggested that leukotriene pathway confers risk for 
myocardial infarction and ischemic stroke. For instance, ALOX5AP is known as the 
gene that encodes FLAP. Helgadottir et al. from DeCODE group identified a 4-
marker single nuclear polymorphism (SNP) termed HapA in the ALOX5AP gene 
locus that confers a 1.67 greater risk of myocardial infarction and stroke (Helgadottir 
et al., 2004). The finding was successfully replicated in different populations 
including Scottish (Helgadottir et al., 2005), German (Lohmussaar et al., 2005), 
Chinese (Ji et al., 2011; Sun et al., 2011; Zhang et al., 2006a), white American 
(Kaushal et al., 2007), Japanese (Yamada et al., 2008), British (Bevan et al., 2008), 
Spanish and Portuguese (Domingues-Montanari et al., 2010). The subsequence 
genetic association studies have reported other LTs pathway mutations associated 
with ischemic stroke. Several mutations include of 581_582 ins A polymorphism in 
the ALOX5AP gene promoter region (Ji et al., 2011), Hap A variants (defined by 
SG13S25, SG13S114, SG13S89 and SG13S32) and Hap B variants (defined by the 
SNP at SG13S377, SG13S114, SG13S41 and SG13S35) (Helgadottir et al., 2005), 
single mutation of SG13S114 and SG13S100 on ALOX5AP gene (Lohmussaar et al., 
2005) and the addition and deletion allele of 5-LO promoter of ALOX5 gene (Dwyer 
et al., 2004) were reported. These studies marked the genetic association of LTs 
pathway with the increase risk of ischemic stroke. Furthermore, gain of function 
mutation that led to the acceleration of LTs pathway was reported to have strong 
association with ischemic stroke. For instance, Helgadottir and colleagues 
demonstrated that neutrophils from myocardial infarction cases with the at-risk 
haplotype produced more LTB4 than controls when stimulated by calcium ionophore 
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ionomycin (Helgadottir et al., 2005). Domingues-Montanari and colleagues showed 
that SG113S114 SNP led to the increase of mRNA level of FLAP in ischemic stroke 
cases than control (Domingues-Montanari et al., 2010). A study was done in North 
Chinese Han population showed that serum LTB4 concentration of the carrier of II 
genotype of 581_582 Ins A was significantly higher than carrier of DD genotype, in 
which only carrier with II genotype 581_582 Ins A was found to be significantly 
associated with ischemic stroke of large artery atherosclerosis and undetermined 
etiology (Ji et al., 2011).  
5.1.4. LTB4receptors  
 Eicosanoids including 5-HETE, 12-hydroperoxyeiocosatetraenoic acid (12-
HETE), 15-hydroperoxyeiocosatetraenoic acid (15-HETE) and several derivatives of 
LTB4 for instances, 12-oxo leukotriene B4 (12-oxo-LTB4) and 20-oxo leukotriene B4 
(20-oxo-LTB4), same as LTB4 and posses of chemoattractant activity (Broughton 
Pipkin et al., 1980; Powell et al., 1996; Turner et al., 1975; Yokomizo et al., 1993; 
Yokomizo et al., 1996). However when compare the above chemoattractants with 
LTB4, higher concentration is required to exert their activities (Ford-Hutchinson et 
al., 1980). The differences in relative potencies was then determined the classification 
of the specific receptors. LTB4 had not been identified until 1997. In 1997 and 2000, 
two types of LTB4 receptors has been discovered such as LTB4 receptor type I (BLT1) 
and LTB4 receptor type II (BLT2) (Yokomizo et al., 1997; Yokomizo et al., 2000). 
5.1.4.1. BLT1 receptor  
 The human BLT1 receptor was identified as a putative seven transmembrane 
receptor with 352 amino acids (Nakamura et al., 2011). In human BLT1 is expressed 
in inflammatory cells including neutrophils, eosinophils, dendritic cells, 
macrophages, B- cells and T-cells (Nakamura et al., 2011). BLT1 expression is 
enhanced in IL-5 treated eosinophils, IFN γ-stimulated macrophages and greatly 
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enhanced when naive T-cells differentiate into CD4+ T-cells or D8+ T-cells in vitro 
(Back et al., 2006; Di Gennaro et al., 2014; Goodarzi et al., 2003; Huang et al., 1998; 
Ott et al., 2003; Tager et al., 2003). Other than myeloid cells, non-myeloid cells such 
as vascular smooth muscle, endothelial cells, skeletal muscle satellite cells and neural 
stem cells also express functional BLT1 (Nakamura et al., 2011).   
5.1.4.2. BLT2 receptor  
 BLT2 receptor gene is highly homologous to BLT1, with the amino acid 
identities of 45.2% to human and 44.6% to mouse (Ramirez et al., 1990). It was 
reported to function as a low affinity receptor for LTB4. Human BLT2 expression is 
quite distinct from BLT1 and express exclusively in leukocytes (Yokomizo et al., 
1997). BLT2 is a low-affinity receptor if compare to BLT1, in term of LTB4 binding 
(Kamohara et al., 2000; Yokomizo et al., 2000).     
5.1.5. Hypothesis and specific aims  
 Inflammation accounts for acute progression as well as secondary injury of 
ischemic stroke (Wang et al., 2007a). Cessation of cerebral blood flow leads to 
energy failure and eventually necrotic neuron death, which triggers immune 
responses and inflammatory cell activation and infiltration (Dirnagl et al., 1999a; 
Wang et al., 2007a). Stroke, is a multi-factorial disease, caused by complicated 
mechanisms including atherosclerosis and neuronal cell death due to deprivation of 
energy. Despite the compelling clinical data and crucial inflammatory role of LTB4, 
the role of LTB4 in ischemic stroke pathogenesis has not been investigated. In a pilot 
clinical study, our collaborators from National University of Singapore have recruited 
29 consecutive patients with ischemic stroke. The plasma LTB4 level was analysed 
and correlated with patients stroke recovery outcome. Deducing from this pilot study, 




5.2. Material and Methods  
5.2.1. Plasma isolation 
 A small pilot clinical study was done with our National University Hospital 
(NUH) collaborator, A/Professor Raymond Seet  Chee Seong. Briefly, patients whole 
blood was collected in EDTA-tube and followed by centrifugation at 2800 rpm, 4°C 
for 10 min. Plasma was collected and preserved with 15 µM indomethacin and 40 µM 
butylated hydroxytoluene to prevent artifactual oxidation during storage. The plasmas 
were stored at −80°C until analysis.  
5.2.2. Sample preparation for gas chromatography-mass spectrometry 
 20ng LTB4-d4 was added on each sample as an internal standard. Solid-phase 
extraction was performed by using Agilent Bond Elute Certify II cartridges. Sodium 
formate (100 mM, 1 ml) was added into the sample and vortex briefly. The pH was 
adjusted to 3.0 with 20 μl 2 N formic acid. Samples were eluted through the 
conditioned column and wash with 1 ml of water followed by elution with 1ml of 
ethyl acetate. Ethyl acetate was completely evaporated under ultra-high purity 
(99.9%) nitrogen gas. Samples were then incubated with 15 μl DIPEA (10% v/v 
acetonitrile) and 30 μl PFBBr (10% v/v acetonitrile) at room temperature for 30 min 
and dried under nitrogen gas. To the dried samples, 20 μl of acetonitrile and 40 μl of 
BSTFA with 1% TMCS were added and incubated at 40°C for an hour for silylation 
of the LTB4. The samples were dried down and reconstituted in 35 μl isooctane. 
 
5.2.3. Gas chromatography-mass spectrometry (GCMS) 
 Samples were injected into an Agilent 7890A GC coupled with 5975°C mass 
spectrometer.  The stationary phase used was Agilent DB1701 capillary column 30 
m, 0.25 μm thick. Whereas the mobile phase used was helium at a flow rate of 
1ml/min in a negative chemical ionisation mode. LTB4 was quantified by monitoring 
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the M-PFB ion at m/z 479 for LTB4 and corresponding ion at m/z 483 for the d4-
LTB4 using the selected ion monitoring (SIM) scan mode. 
5.2.4. Embolic stroke model  
 Materials and methods are described in Chapter 2, section 2.4 (page 41).  
5.2.5. Transient middle cerebral artery occlusion model  
 Materials and methods are described in Chapter 2, section 2.3 (page 40).  
5.2.6. Immunofluorescence 
Rats were anaesthetized and perfused with 0.1 M phosphate buffer saline 
followed by 4% paraformaldehyde through the heart. Detailed for Materials and 
methods are described in Chapter 2, section 2.14 (page 50). Primary antibodies used 
were 5-LO (1:4000, BD Bioscience), LTA4-hydrolase (1:400, Abcam) and MPO 
(1:200, Novus Biologicals ).  
5.2.7. Thionin staining  
Brains were sectioned on a cryostat (Leica 3050S, Germany). Sections (30 
µm) were mounted on glass slides (Matsunami, Japan) and stained in 0.25% thionin 
(Sigma Aldrich) for 2 min, followed by stepwise exposure to an increasing 
concentration of ethanol from 50% to 100% for dehydration. The final ethanol was 
replaced with histoclear (Sigma Aldrich) and the slides were cover slipped with 
mounting medium.  
5.2.8. Western Blot 
Materials and methods are described in Chapter 2, section 2.15 (page 51). 
Primary antibodies used were 5-LO (1:1000, BD Bioscience) at 4°C 4 h incubation, 
GFAP (1:5000, Sigma, USA), ED-1 (1:1000, Serotec), OX-42 (1:1000, Serotec) and 
β-actin (Cell Signalling Technologies, Beverly, MA, USA) at 4°C overnight  
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5.2.9. Statistical analysis 
Material and methods are described in Chapter 2, section 2.21 (page 58). 
5.3. Results  
5.3.1. Stroke patient plasma LTB4 level and MRS score 
 Patients presented within 3 h following the onset of their symptoms were 
reviewed and treated with intravenous rtPA. After obtaining the written informed 
consent, patients' blood samples were collected before rtPA treatment and repeated 1 
and 7 days later. Functional status was determined using the modified Rankin scale 
(MRS) at 90 days post-stroke and dichotomized as favourable (MRS, 0-2) and poor 
(MRS, 3-6). The mean age of the patients was 62.9 years (SD 13.5) and 59% of the 
trials' patients are men. Median NIHSS was 16.4 (range 9-20) (Table 5.1). Compared 
with normal control subjects which was published previously by our group (Loke et 
al., 2012), stroke patients had 4-fold increased in plasma LTB4 level. These levels 
increased further at 24h later. Plasma LTB4 level was found attenuated to control 
level on day 7 post-stroke. Interestingly, patients with favourable functional recovery 
were found to have lower levels of plasma LTB4 compared to those with poor 









General information    
Mean age   62.9 years (SD 13.5)  
Gender (men)  17 (59%)  
Risk factor     
Dyslipideia  26 (90%)  
Hypertension   19 (67%)  
Artrial fibrillation   12 (41%)  
Coronary artery disease  11 (38%)  
Diabetes mellitus   10 (35%)  
Active cigarette smoker  2 (7%)  
Stroke subtype (%)    
Large atherothrombosis   19 (66%)  
Cardioembolism  28% 
Lacunar   2 (7%)  
Recanalization status at 24 h    
Yes  9 (31%)  
No  18 (62%)  
NA  2 (7%)  
Modified Rankin Scale at 90 days   
0-2  17 (59%)  
3-6 10 (35%)  
 
Table 5.1.  Coronary risk factors, stroke subtypes, recanalization status at 24 h, 








Figure 5.2. Stroke patient LTB4 level before and after rtPA treatment and 
correlation of LTB4 level to MRS score. (A). Plasma LTB4 level before rtPA 
treatment (Before TPA) while sending to the hospital, Day 1 after the onset of stroke 
symptoms (Day 1) and Day 7 after the onset of stroke symptoms (Day 7). (B). 
Correlation study of stroke patient LTB4 level and MRS scores. MRS score from 0-6, 
where 0-2 suggest better function stroke outcome while 3-6 indicated bad clinical 
stroke outcome. n = 29. **p < 0.01 by independent t-test. Pilot clinical study was 
done by our collaborator from National University Hospital (NNUH) by Associate 





5.3.2. Expression of 5-LO was increased after embolic stroke 
The protein level of 5-LO, ED-1, OX-42 and GFAP were measured by 
western blot at 3, 24 and 72 h in infarcted cortex and striatum. Analysis showed that 
ipsilateral (ipsi) 5-LO was increased spontaneously after embolic stroke at 3 h and 
maintained up to 72 h when compared to sham control (sham) or contralateral control 
(contra) respectively (Figures 5.2C and 5.3C) in both infarcted cortex (Figure 5.3) 
and striatum (Figure 5.4). Interestingly, CNS inflammatory markers, ED-1 (a marker 
for activated microglia, Figures 5.3D and 5.4 D), OX-42 (a marker for microglia, 
Figures 5.3E and 5.4E) and GFAP (a marker for gliosis, Figures 5.3F and 5.4F) were 
found up-regulated with a similar trend to 5-LO up-regulation after embolic stroke in 






Figure 5.3. Time course and expression of 5-LO, ED-1, OX-42 and  GFAP after 
embolic stroke in rat infarcted cortex. (A), Representative thionin staining of ES at 
24 h, red indicated protein for western blot was extracted from this region. (B), 
Representative western blots of 5-LO, ED-1, OX-42 and GFAP for sham and embolic 
stroke (ES) rats at 3, 24 and 72 h after operation. Ipsi indicated ipsilateral 
hemisphere; contra indicated contralateral hemisphere. (C), (D), (E) and (F) are 
densitometry for 5-LO, ED-1, OX-42 and GFAP protein level. n = 3-5 per group for 
western blots. *p < 0.5 vs ipsilateral sham by one way ANOVA with Bonferroni post 













Figure 5.4. Time course and expression of 5-lipoxygenase (5-LO), ED-1, OX-42 
and  GFAP after embolic stroke in rat infarcted striatum. (A), Representative 
thionin staining of ES at 24 h, red indicated protein for western blot was extracted 
from this region. (B), Representative western blots of 5-LO, ED-1, OX-42 and GFAP 
for sham and embolic stroke (ES) rats at 3, 24 and 72 h after operation. Ipsi indicated 
ipsilateral hemisphere; contra indicated contralateral hemisphere. (C), (D), (E) and 
(F) are densitometry for 5-LO, ED-1, OX-42 and GFAP protein level. N = 3-5 per 
group for western blots. *p < 0.01 vs ipsilateral sham by one way ANOVA with 
Bonferroni post hoc analysis.   
 
5.3.3. Expression of LTB4 synthesizing enzymes LTA4 hydrolase increased after 
embolic stroke at 24 h and overlapped with MPO staining 
LTB4 synthesizing enzymes, LTA4 hydrolase brain expression and 
localization, was examined by immunofluorescence staining. The present results 
showed that LTA4 hydrolase (green) was up-regulated significantly in ipsilateral 
(Ipsi) cortex (Co) and striatum (St) when compared to contralateral (Contra) cortex 
and striatum and sham control (results not shown) (Figure 5.5 B). 5-LO, which is the 
enzyme for leukotrienes production was found increased markedly in the 
immunofluorescence staining results (red), with a trend similar to LTA4 hydrolase 
upregulation at 24 h after embolic stroke (Figure 5.5 B). Next, double 
immunofluorescence staining for MPO (a marker for neutrophils) was done with 5-
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LO or LTA4 hydrolase. MPO was found up-regulated in ipsilateral cortex and 
striatum at 24 h after embolic stroke (results not shown). The up-regulation of MPO 
was observed in vasculatures (Figure 5.6 C) indicating that neutrophils infiltration 
occurred after ischemic attack. Double immunofluorescence staining results showed 
that 5-LO positive staining was co-localized with MPO positive staining in ipsilateral 
cortex (Figure 5.6A) and striatum (Figure 5.6B). Similarly, LTA4 hydrolase positive 
staining was co-localized with MPO positive staining in ipsilateral cortex (Figure 
5.6D) and striatum (Figure 5.6E).  
 
 
Figure 5.5. Immunofluorescence staining of 5-LO and LTA4 hydrolase after 
thromboembolic stroke. (A), Representative thionin staining for 24 h embolic 
stroke. Small boxes represented images taken from these specific regions, Co: Cortex 
or St: Striatum. (B), Representative immunofluorescence staining of 24 h embolic 
stroke ipsilateral (ipsi) or contralateral (contra) hemispheres for 5-LO (red) or LTA4 
hydrolase (green). Co or St indicated images taken from respective regions of interest 





Figure 5.6. Immunofluorescence double staining for 5-LO, LTA4 hydrolase and 
MPO in ipsilateral cortex (Co) or striatum (St) at 24 h embolic stroke. (A) and 
(B), Representative immunofluorescent double staining of MPO (green) and 5-LO 
(red) in ipsilateral cortex (A) or ipsilateral striatum (B) respectively. C, 
Representative immunofluorescence double staining of MPO (green) and 5-LO (red) 
for vasculature in ipsilateral cortex. (D) and (E), Representative immunofluorescence 
double staining of LTA4 hydrolase (green) and MPO (red) in ipsilateral cortex (D) or 
ipsilateral striatum (E) respectively. Yellow indicated co-localization of MPO 
positive staining with 5-LO or LTA4 hydrolase positive staining. Right panels for (A-
E) indicated merged image of DAPI (blue), MPO and 5-LO or LTA4 hydrolase. Scale 
bar equals to 50 µm. 
 
 
5.3.4. LTB4 level increased in peripheral/ circulatory system and ipsilateral 
cortex after embolic stroke 
 
GCMS was used in this study to measure plasma and brain LTB4 level. 
Results showed that plasma LTB4 level was up-regulated significantly at 24 h 
embolic stroke (4.5  ±  0.98 ng/ml) when compare to baseline level (2.4 ± 0.26 ng/ml) 
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Figure 5.8. Increase LTB4 in tMCAO model. (A), Representative TTC images for 
tMCAO with vehicle infusion and tMCAO with 50 ng LTB4 pre-administration. (B), 
Percentage of infarct volume of vehicle control or 50 ng LTB4pre-administered at 24 
h after tMCAO induction. N = 5-6, ***p < 0.001 against vehicle control by 
independent t-test.  
 
 
5.4. Discussion  
 
 Mounting genetic association evidences suggested leukotriene pathway 
confers risk for myocardial infarction and ischemic stroke (Bevan et al., 2008; 
Domingues-Montanari et al., 2010; Helgadottir et al., 2005; Helgadottir et al., 2004; 
Kaushal et al., 2007; Lohmussaar et al., 2005; Yamada et al., 2008; Zhang et al., 
2006a). To confirm the pilot clinical data, an experimental stroke animal model was 
used. Thromboembolic stroke model is the closer model that could recapitulate the 
pathophysiology of human ischemic stroke than other available animal stroke model 
(Zhang et al., 1997a). Results showed significant increase of 5-LO expression in the 
ipsilateral infarct cortex and striatum. Same results was achieved by Zhou and 
colleagues that 5-LO was significantly elevated after reperfusion at 12 h at mRNA 
level and 24 h at protein level (Zhou et al., 2006). Furthermore, in human autopsied 
brain, up-regulation of 5-LO was shown in neurons, glial cells and mononuclear 
leukocytes during focal ischemic damage (Tomimoto et al., 2002).  In consistent with 
5-LO, inflammatory markers in CNS including microglia marker (OX-42), activated 
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microglia markers (ED-1) and astroglia (GFAP) were found increased in the 
ipsilateral infarct cortex and striatum. The increase of 5-LO was seen at 3 h after 
embolic stroke and up-regulated up to 72 h in a time dependent manners. These 
results indicated permanently deprivation of cerebral blood triggered the increase 
proliferation of local inflammatory cells in the brain and stimulated the activation of 
microglia. Similar to my previous findings that at 24 h permanent middle cerebral 
artery occlusion (pMCAO) model, both OX-42 and ED-1 immunopositive staining 
were found elevated significantly in infarct core regions (Chan et al., 2010).  
LTA4, can be either metabolized by LTA4 hydrolase to form LTB4 or 
conjugated with to yield LTC4, LTD4 and LTE4. LTC4, LTD4 and LTE4 has been 
collectively known as cysteinyl or peptidyl leukotrienes (CysLT). CysLT has been 
known to its functions in mediating vascular permeability, bronchoconstriction, 
mucus secretion, edema and smooth muscle cells contraction was reported to be one 
of the important candidates to ischemic stroke (Capra et al., 2013; Funk, 2001). For 
instance, production of CysLTs in the brain increased after ischemia or ischemia 
reperfusion (Ohtsuki et al., 1995; Ste-Marie et al., 2000), increased expression of 
CysLT receptor-1 (Fang et al., 2006) and CysLT receptor-2 (Fang et al., 2007; Zhao 
et al., 2011a) was found in the brain after focal ischemia stroke (Zhang et al., 2006b), 
CysLT receptor antagonists Montelukast (Yu et al., 2005b; Zhao et al., 2011b)  and 
Pranlukast (Chu et al., 2006; Yu et al., 2005a) were reported to have protective 
functions against focal cerebral ischemia in animal stroke models. Ingelssson and 
colleagues have done a nationwide cohort study involved approximately 7 million 
person using Montelukast and found an association of Montelukast use with a lower 
risk for recurrent stroke (Ingelsson et al., 2012). This study provides paramount 
clinical evidences that inhibiting CysLT could be the secondary prevention for 
cardiovascular disease including ischemic stroke. Despite CysLT function in 
ischemic stroke has been widely studied, the role of LTB4 in ischemic stroke remains 
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unclear. The present study focused on deciphering the detrimental effect exerted by 
LTB4 and hypothesized that it may be more important in the LOX pathway than 
CysLT. It is because, GSH is highly consumed during ischemic stroke (Cojocaru et 
al., 2013; Salemi et al., 2009) and hence this could potentially direct the LTA4 
metabolic pathways predominantly towards LTB4 conversion. Double 
immunofluorescent staining suggested that 5-LO together with LTA4 hydrolase 
elevated strikingly at 24 h embolic stroke (Figure 5.6) in ipsilateral infarct cortex and 
striatum when compared with its respective contralateral regions. Leukotriene was 
predominantly expressed in neutrophils (Dahinden et al., 1988; Daryadel et al., 
2009). Results showed both 5-LO and LTA4 hydrolase were co-localized with 
neutrophils (shown as MPO immunopositive cells in Figure 5.6). Results showed 
MPO immunopositive cells infiltration process in the cerebral vasculature, which 
provided evidence that neutrophils entered brain potentially via disrupted blood brain 
barrier (BBB) from peripheral circulatory system after ischemic stroke injury. 
Furthermore, LTB4 increased in plasma and ipsilateral infarct cortex after 24 h 
(Figure 5.7) but not at 3 h after embolic stroke. This further indicated that injured site 
signalled and recruited neutrophils to the infarct cortex. The expression of 5-LO and 
LTA4 hydrolase in neutrophils were elevated upon stroke stimuli, eventually 
increased LTB4 level in the brain. Secretion of LTB4 to the peripheral circulatory 
system by activated neutrophil thereby caused the increase of LTB4 level in the 
embolic stroke animal’s plasma. Jatana and team reported that 5-LO elevated in a rat 
transient ischemic model at 24 h after the onset of stroke (Jatana et al., 2006). Similar 
to current results, 5-LO increased in the ipsilateral hemisphere. However, Jatana et al. 
results showed that 5-LO immunopositive cells were also merged with NSE and RCE 
(neuronal and microglial markers respectively) (Jatana et al., 2006). Two studies 
demarcated that reperfusion could potentially stimulate the local inflammatory cells, 
microglia to increase 5-LO expression.     
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Both plasma and ipsilateral cortical LTB4 level was markedly elevated after 
embolic stroke at 24 h (Figure 5.7). The results advocated that after ischemic damage, 
BBB was disrupted and caused the chemokines secretion. These eventually increased 
leukocyte infiltration to the brain and increased secretion of LTB4 level in the 
ipsilateral hemisphere. On the other hands, we have shown the high of LTB4 level 
correlated with high MRS scores. In order to validate the emerging data, we infused 
50 ng LTB4 to the brain and observed the histological outcome of ischemic stroke. 
The LTB4 infused animals showed larger infarct volume when compared to the 
vehicle group (Figure 5.8). This  provides direct evidence that increase of LTB4 in the 
brain worsened ischemic stroke outcome.   
The strength of the present study is GC/MS was used to analyse LTB4 level 
in both plasma and brain. To my knowledge, ELISA kit is more widely used in 
laboratories for LTs research despite it always reports higher analytes concentration. 
The fact is antibodies used in immunoassays sometimes recognize not only single 
target but also structurally related molecules. GC/MS provides accurate measurement 
for LTB4, thus confirm the previous reports regarding the up-regulation of LTB4 in 
coronary disease human plasma using ELISA immunoassay (Nair et al., 2014). In 
contrast, the weakness of this study is the genetic background on ALOX5AP, 
ALOX5 or LTA4H were not determined in the pilot clinical study. The overall LTB4 
level could be affected by different carriers of genetic variants thereby potentially 
contribute to the unwanted variations in the LTB4 data. Previously, several groups 
have reported conflicting findings, for instance, there was no genetic and risk of 
stroke association was reported in other American, Swedish and Italian cohorts 
(Wang et al., 2011). In Easten Chinese Han population, ALOX5AP rs10507391 and 
rs12429692 revealed the decreased risk of stroke (Wang et al., 2011). It was 
concluded that the discrepancy of the results could be due to the complexity of 
difference ethnic groups were involved in one study. Singapore population contains 
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diverse ethnicity. The genetic association of LOX pathway with ischemic stroke is 
therefore highly demanded for further confirmation of our clinical observation. 
 Our group has previously investigated the roles of 5-LO and LTB4 among 
cigarette smokers and patients with dengue infection. Results suggested a significant 
elevation of 5-LO and LTB4 level was found in patient subjects (Loke et al., 2012). In 
these studies, we observed the level of 5-LO and LTB4 correlated significantly with 
the burden of inflammation and disease severity. Similar to the current study, 
Inflammation plays an important role in the pathogenesis of ischemic stroke. 
Furthermore, it has been known that, stroke patients with systemic inflammation 
exhibit clinically poorer outcome. Therefore, LTB4, as a lipid mediator that was also 
known as a chemoattractant that recruits inflammatory cells to the site of 
inflammation, could be a potential candidates that attribute to the detrimental effects 

















Chapter 6: The role of modulator of apoptosis (MOAP-1) in acute ischemic 
stroke 
 
6.1. Introduction  
 Modulator of apoptosis 1 (MOAP-1) is a mitochondria-enriched molecule 
with 39.6 kDa molecular weight (Tan et al., 2005). It was first identified as a novel 
Bax-associating protein in a yeast two-hybrid screen (Tan et al., 2001). MOAP-1 is 
located at genetic locus 14q32 and is a negatively charged protein that consists of 351 
amino acid residues in human (www.ncbi.nlm.nih.gov/gene/64112). At pH7.0, it has 
an isoelectric point of 4.939 (Ensembl protein ID: ENST00000298894). MOAP-1 is 
highly conserved in chimpanzee (Pan troglodytes), rat (Rattus norvegicus) and mouse 
(Mus msculus) with the coding sequence contains of a single exon in both mouse and 
human (Law et al., 2012). It was previously named as MAP-1, contains a putative 
BH3-like domain and induces caspase-dependent apoptosis in mammalian cells when 
overexpressed (Tan et al., 2001). Moreover, it is ubiquitously expressed at moderate 
levels under normal cellular condition. The regulatory mechanism of MOAP-1 
remains unknown, however it is possible that the expression changes of MOAP-1 
may be caused by promoter specific methylation for instances by existing micro RNA 
or by the alteration of MOAP-1 protein stability due to the ubiquitin-directed 
proteolysis (Law et al., 2012). However, there is no micro RNA has been identified 
for MOAP-1 transcriptional regulation up to now. Post-translational modification of 
MOAP-1 protein expression by ubiquitination and degradation by proteasomal 
degradation machinery therefore become plausible. Trim39 was identified as MOAP-
1 degradation inhibitor (Lee et al., 2009b). It is a member of the tripartite motif 
(TRIM) family (Orimo et al., 2000). MOAP-1 was reported to be degraded during G1 
by anaphase-promoting complex (APC/Cdh1) ubiquitin ligase (Huang et al., 2012). As 
a novel APC/Cdh1 regulator, Trim39 directly inhibits APC/Cdh1-mediated protein 
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ubiquitylation thus facilitates MOAP-1 downstream apoptotic event (Huang et al., 
2012).  
 
 MOAP-1 is required to execute both the intrinsic and extrinsic apoptotic 
pathways which requires Bax translocation from cytosol to the mitochondria and 
facilitates the release of apoptogenic facors (Law et al., 2012). MOAP-1 normally 
appears as "closed" conformation through an intra electrostatic interaction. Whereas, 
RASS1A, prior to death receptor association, loses its ability to homodimerize and is 
released from the association with 14-3-3. Upon stimulation by TNF-α or TRAIL, 
death receptors via a basic sequence (336EEEEA) at its C-terminal end recruited 
MOAP-1 by binding to its N-terminal cys-rich (C1) domain. RASSF1A thereby 
causes a conformational change in MOAP-1 and exposes its BH3-like domain. The 
association of MOAP-1 with RASSF1A involves the sequence 202KRRR of MOAP-1 
and 312EEEE of RASSF1A. The "open state" of MOAP-1 thereby induces Bax 
conformational change and enables Bax translocation from the cytosol to the 
mitochondria. Insertion of Bax to the mitochondrial membrane eventually promote 
the release of cytochrome c and its downstream caspase dependent pathways 
subsequently resulted in cell death. Moreover, MOAP-1 demonstrates its association 
to RASSF6, a second RASSF family members. The association of RASSF6 and 
MOAP-1 was reported to be enhanced by K-Ras. RASSF6 is also known to be 
capable to facilitate apoptosis. The mechanism of RASSF6 associates with MOAP-1 
thus activates apoptosis is yet to be investigated and is speculated to be similar to the 









Figure 6-1. MOAP-1 and its binding domains. Schematic diagram of MOAP-1 
with indicated areas of contact with respective proteins documented including Bax, 
RASSF1A, Trim 39 and TNFR-1. Several binding domains were previously reported 
on MOAP-1 was indicated together with the interactive regions. Figure re-adapted 















Figure 6.2. Schematic diagram of MOAP-1 dependent apoptotic pathway. 1. 
Upon death stimuli TNF-α binds to TNF-R1 and facilitates the translocation from cell 
membrane into cytosolic compartment. 2. In response to death receptor stimulation, 
MOAP-1 is recruited to the receptor and form a complex. 3. RASSF1A associated 
with MOAP-1/receptor complex and 4. thereby induce MOAP-1 conformational 
change from closed state MOAP-1 to open state MOAP-1. 5. The open state MOAP-1 
exposes its BH3-like domain which is required for Bax association. This stimulates 
the interaction between MOAP-1 and Bax and induces a conformational change in 
Bax. 6. Bax becomes activated and this enables active Bax to translocate and insert 
into the mitochondrial outer membrane subsequently resulting in the release of 
cytochrome c and apoptogenic factors, leading to apoptosis. Figure readapted from 
Foley et al. (Foley et al., 2008). 
 
 Bcl-2 family proteins, including Bax and Bak, govern mitochondrial 
cytochrome c release by triggering oligomerization at the mitochondrial outer 
membrane. MOAP-1/TNF-R1/RASSF1A complex was found to be selectively 
promoting Bax insertion into mitochondria membrane upon death stimulation but not 
cappase-8 (Foley et al., 2008). To support the statement, Foley and colleagues 
showed that the association of DISC components that include of FADD, TRADD and 
caspase-8 was not lost in RASSF1A or MOAP-1 shRNA knockdown cells. This 
indicated that signalling complex composed of MOAP-1, TNF-R1 and RASSF1A 
may thereby activate Bax but not Bid. Bax and Bak are central but redundant 
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regulators of apoptosis signalling (Lindsten et al., 2000; Wei et al., 2001). It was 
previously reported that Bax and Bak knockouts in murine embryonic fibroblasts 
(MEFs) showed dramatic resistance to diverse apoptotic stimuli (Danial et al., 2004). 
Compare to Bak, Bax appears to exert dominant functions in term of apoptotic 
signalling events (Putcha et al., 2002). Apoptotic stimuli causes the unfolding of N 
and C termini of Bax thus facilitates structural changes and eventually leads to the 
translocation of Bax from cytosol to mitochondrial (Goping et al., 1998; Nechushtan 
et al., 1999; Suzuki et al., 2000). Bax was also shown to interact with VDAC and 
adenine nucleotide translocator that constitutes mitochondrial permeability transition 
pore (MPTP) (Marzo et al., 1998; Shimizu et al., 1999). It was speculated that Bax 
might function in mitochondria by activating the opening of MPTP thereby lead to 
mitochondrial swelling, rupture of the outer membrane. This eventually causes the 
release of cytochrome c from mitochondria to the cytosol. Therefore, MOAP-1, 
which is the regulator for Bax dependent apoptotic pathway, will play a crucial role in 
cell death.  
 Apoptosis is the fundamental for development of the central nervous 
system (Roth et al., 2001). It contributes to normal brain morphogenesis by inducing 
cell death in response to physiological stimuli (Roth et al., 2001). Defective apoptotic 
processes have been identified in several human diseases including Alzheimer's 
disease, Parkinson's disease and stroke (Mattson, 2000). Apoptosis contributes to the 
progression of these diseases by elimination of functional neurons subsequently 
leading to a gradual loss of brain functions (Mattson, 2000). Inhibiting apoptosis 
event after ischemic stroke becomes a potential therapeutic approach for stroke 
treatment; on the other hand, understanding the underlying mechanism of apoptosis 
remains crucial in developing a pharmacological agent for stroke therapy.  
 The role of MOAP-1 in facilitating apoptosis via the activation of BAX 
has been studied at the molecular biology level, however its physiological roles is yet 
to be discovered. Ischemic stroke triggers several cell death pathway which includes 
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of intrinsic as well as extrinsic apoptotic pathway hence became a well established 
model for the physiological role of MOAP-1 in the CNS. In the present study, a 
MOAP-1 knockout mice have been used to provide further information about MOAP-
1 dependent apoptotic function by an in vivo approach. 
 
6.2. Materials and Methods 
 
6.2.1. Cell culture  
 Neuroblastoma SH-SY5Y cell line was obtained from American Type 
Culture Collection (ATCC). Materials and methods are described in Chapter 2, 
section 2.12 (page 49).  
 
6.2.2. Construction of MOAP-1 lentiviral expression vectors  
  MOAP-1 (NM_022323) cDNA with Myc-DDK-tagged was purchased 
from Origene (Catalogue no. MR205352). MOAP-1 cDNA was amplified and and 
subcloned into a lentiviral vector with an insertion of a IRES-EGFP reporter cassette. 
Materials and methods are described in Chapter 2, section 2.16 (page 54).  
 
6.2.3. Primary cortical neuron culture   
 Cultures of wild-type (C57BL/6) and MOAP-1 KO mice embryonic day 
15-16 cortical neurons were prepared as described in Chapter 2, section 2.10 (page 
46).  
 
6.2.4. Oxygen glucose deprivation (OGD) 
 OGD was achieved by incubating the SH-SY5Y cells with vector or LV-
MOAP-1 overexpression or wild-type (C57BL/6) and MAOP-1 KO primary neurons 
in glucose free DMEM medium (Gibco, Invitrogen) supplemented with 1% 
stretomycin/penicillin in a hypoxia chamber (5% CO2/ 94% N2) for 1, 2 and 4 h with 
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23, 22, or 20 h replenished of DMEM/F12 complete medium or neurobasal medium 
respectively at 37ºC in a humidified incubator.  
 
6.2.5. Generation of MOAP-1 deficient mice  
 Heterozygous MOAP-1 mice (129 × C57BL/6) were crossed to generate 
homozygous MOAP-1 deficient mice. Materials and methods are described in 
Chapter 2, section 2.6 (page 44). Genotypes of the mice were confirmed by PCR.  
 
6.2.6. Genotyping  
 Routine genotyping was done to ensure littermates genetic integrity. 
Briefly, tail snipping was carried out on wild-type and MOAP-1 KO mice followed 
by incubation in lysis buffer (50 mM Tris, pH 8.8; 100 mM NaCl; 100 mM EDTA; 
1% SDS) in the presence of proteinase K (Sigma-Aldrich) at 55ºC overnight. After 
tail digestion, saturated NaCl solution was added and continuously shaked for 5 min, 
followed by centrifugation at 14,000 rpm at 4ºC for 20 min. Isopropanol was added to 
the supernatant and samples were centrifuged for 12 min. DNA was extracted and 
further re-suspended in 70% ethanol. Dried DNA pellet was then incubated at 37ºC 
for 30 min. Both quality and quantity of the final DNA product was measured by 
NanoDrop Spectrometer (Thermo scientific, USA) and stored at -20ºC.  
 
6.2.7. Gene expression analysis  
 DNA product was PCR using primer (for wild-type: 5'-
ATCCATCCCATCCGCTGACG-3' and 5'-GACTCTTGCTCGCTTGCAGG-3'; 
MOAP-1 KO: 5'-ATCCATCCCATCCGCTGACG-3' and 5'-
AGTAGAAGGTGGCGCGAAGG-3') and Qiagen HotStarTaq Master Mix Kit 
(Qiagen, USA) under the following conditions: Initial incubation at 95ºC for 15 min, 
followed by 40 cycles of amplification (95ºC for 40 sec, 58ºC for 40 sec and 72ºC for 
2 min), ending with a final extension step of 72ºC for 5 min. Equal amount of PCR 
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product was then loaded to 1% agarose gel with SafeviewTM (Applied Biological 
Materials, Canada) and finally visualized by Gel Doc XR+ system (Biorad, USA).  
 
6.2.8. Transient middle cerebral artery occlusion model 
 Materials and methods are described in Chapter 2, section 2.5 (page 43).  
 
6.2.9. Infarct volume assessment  
 The mice were euthanized at 24 h after tMCAO. The whole brains were 
cut into 1 mm coronal sections and immediately stained with 2% tetrazolium chloride 
(TTC, Sigma Aldrich, USA) for 15 min. The infarct volume was measured using 
Image-J (NIH, USA) with correction for brain oedema. Materials and methods are 
described in Chapter 2, section 2.9 (page 45). 
 
6.2.10. Rota-rod assessment  
Materials and methods are described in Chapter 2, section 2.8 (page 45).  
 
6.2.11. Western Blot  
 Brain tissues from control, sham-operated and tMCAO (1, 3 and 8 h) 
mice were lysed with RIPA buffer (Cell Signalling) supplemented with protease 
inhibitor and phosphotase inhibitor cocktail (Roche, Manheim, Germany). Total 
protein was determined by BCA protein assay kit (Pierce, ThermoScientific, 
Rockford, USA). Materials and methods are described in Chapter 2, section 2.15 
(page 51). Primary antibodies used were MOAP-1 (Sigma Aldrich, USA), RASSF1A 
(Abcam, UK), Trim39 (Sigma Aldrich, USA), Bax (Cell signalling technologies, 
USA), NeuN (Millipore Corporation, Billercia, MA, USA), TNR-1 (BD Bioscience, 





6.2.12. Measurement of TNF-α level  
 Cortical brain lysate was collected from sham or tMCAO mice at 1, 3 and 8 h 
for total TNF-α analysis using commercial immunoassay kit (R&D Systems, 
Minneapolis, MS, USA). Protein band intensity was measured by a microplate reader 
(Sunrise, Tecan, Research Triangle Park, NC, USA) and normalized to respective 
protein level.  
 
4.2.13. Immunofluorescent staining 
 Mice were anesthetized and perfused with 0.1 M phosphate buffer saline. 
Brain were harvested and post-fixed with 4% paraformaldehyde at 4ºC overnight. 
Paraformaldehyde fixed brains were further cryoprotected in 10% sucrose and 
eventually 20% sucrose at 4ºC until use. Coronal sections (20 µm) were made using a 
cryostat and mounted onto glass slides (Matsunami, Japan). Materials and methods 
are described in Chapter 2, section 2.14 (page 50). Primary antibodies used were 
MOAP-1 (1:200, Sigma, USA), MAP-2 (1:200, Sigma, USA) and NeuN (1:400, 
Chemicon, Millipore).  
 
4.2.14. Statistical analysis  
Methods are described in Chapter 2, section 2.21 (page 58). 
 
6.3. Results  
6.3.1. MOAP-1, RASSF-1A, Trim39, TNF-R1 and Bax are highly expressed in 
cortical cortex and specifically expressed in neuronal cells 
 MOAP-1 was first reported highly expression in the brain (Takaji et al., 
2009). Upon death stimuli, TNF-α allows the recruitment of MOAP-1 by death 
receptor TNF-R1 therefore activate the binding of MOAP-1 to RASSF-1A and 
leading to the activation of Bax, cytochrome c release and stimulation of the 
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downstream caspase dependent apoptotic pathway (Foley et al., 2008). Our results 
showed that MOAP-1, RASSF-1A, Trim 39 and TNF-R1 expressed mostly in cortical 
cortex than other brain regions for instant striatum, hippocampus, thalamus and 
midbrain (Figure 6.3). Among all, MOAP-1 and RASSF-1A were also highly 
expressed in cerebellum (Figure 6.3). MOAP-1 and RASSF1-1A expression in 
cerebellum was similar to cortical cortex. Bax, on the other hand, was ubiquitously 
expressed in all brain regions. Cortical cortex and striatum are the two most affected 
regions after transient middle cerebral artery occlusion induction in rodent model. 
Compare to striatum, the cortical expression of MOAP-1, RASSF-1A, Trim39, TNF-
R1 and Bax are higher. Therefore, we focused our following study mainly in cerebral 
cortex than other regions of the brain. Next, we examined the cellular expression of 
MOAP-1 in the brain. Our results indicated that MOAP-1 was specifically expressed 
in neuronal cells that can be detected with NeuN antibody (Figure 6.4). Hence, SH-



















































Figure 6.4. Immunofluorescent  staining of MOAP-1 in cerebral cortex of 
C57/B6 mice. (A). MOAP-1 positive staining. (B). NeuN positive staining. (C). 
Overlapping of MOAP-1 and NeuN. (D). Overlapping for MOAP-1, NueN and DAPI 
staining. Scale bar = 50µm 
 
 
6.3.2. MOAP-1 overexpressing SH-SY5Y cells were more susceptible to OGD 
condition 
 MOAP-1 was reported mainly localized in cytoplasm of neuron (Takaji et 
al., 2009). In order to test the hypothesis that MOAP-1 could be detrimental to stroke 
due to its function in modulating the extrinsic apoptosis pathway, the MOAP-1 
overexpressing SH-SY5Y cell line was created (Figure 6.5). OGD was used as an in 
vitro approach to examine the effect of MOAP-1 in response to acute ischemic 
condition. Lentiviral vector that consists of CMV-MOAP-1-GFP with a blasticidin 
resistance gene was transduced into SHSY5Y to create a stable MOAP-1 
overexpressing cell line (Figure 6.5). Results suggested that the transgene was 
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successfully expressed in the cell line as shown under fluorescent microscopy with 
GFP expression (Figure 6.5 A) and increased expression as shown in the Western blot 
results (Figure 6.5 B). When subjected the MOAP-1 overexpressing SH-SY5Y cells 
to OGD condition, MOAP-1 overexpressing SHSY5Y cell was found to be more 
susceptible to OGD condition compared to vector control SH-SY5Y cells (Figure 6.5 
C). When subjected cells to OGD condition for 8 h (with 16h reperfusion), 67.3% ± 
3.4% of vector control SH-SY5Y survived whereas only 26.2% ± 1.9% of MOAP-1 
overexpressing SH-SY5Y cells survived (Figure 6.5 C).  
 
Figure 6.5. MOAP-1 overexpressing SH-SY5Y and cell viability under OGD 
condition.(A). Representative images of MOAP-1 overexpressing SH-SY5Y cells 
(MOAP-1 OE) GFP expression. Left panel is the phase contrast image of image taken 
under fluorescent microscope. (B). Representative western blot image of MOAP-1 
overexpressing SH-SY5Y (MOAP-1 OE) cells and vector control of SH-SY5Y cells 
(vector ctrl) MOAP-1 and β-actin protein expression. (C). Percentage of cell viability 
of MOAP-1 overexpressing SH-SY5Y cells (closed bar) versus vector control SH-
SY5Y cells (open bar) at 24 h after 1, 2, 4 and 8 h OGD condition with 23, 22, 20 and 
16 h replenish of DMEM/F12 medium. N = 4, ***p < 0.001. Independent t test. Error 






6.3.3. MOAP-1 knockout primary cortical neurons were more resistant to OGD 
condition 
 Next, we have created the MOAP-1 knockout mice in order to investigate 
the role of MOAP-1 in the in vivo model. Genotyping was done to validate a 
complete knockout of MOAP-1 routinely (results not shown). Both wild type mice 
and MOAP-1 knockout mice primary cortical neurons were prepared and 
immunostained with MAP-2 and GFAP to confirm the 90% purity of primary cortical 
neurons (Figure 3A and 3B). MOAP-1 knockout mice primary cortical neuron was 
found to be more resistant to OGD condition and survived significantly better at 4 h 
followed by 20 h reperfusion after OGD (56.1% ± 1.5%) than wild type mice primary 








Figure 6.6.  Wild type and MOAP-1 KO primary cortical neurons subjected to 
OGD condition. (A). Purity of mouse primary cortical neurons at Day 9. 
Representative image of MAP-2 and GFAP immunofluorescent staining. Left is 
micrograph that was taken from lower magnification while right panel was taken 
from high magnification under fluorescent microscope. (B). Wild type (closed bar) 
and MOAP-1 KO (open bar) primary cortical neuron survival rate after 1, 2 and 4 h 
OGD insult with 23, 22 and 20 h complete neurobasal medium replacement. N = 4, 
*p < 0.05. Independent t test. Error bars represent SEM.  
 
 
6.3.4. MOAP-1 knockout reversed stroke outcome by reducing infarct volume 
and improve functional outcome  
 Wild type mice and MOAP-1 knockout mice were subjected to transient 
middle cerebral artery occlusion (tMCAO) for 24 h (90 min occlusion with 22.5 h 
reperfusion). Results showed that MOAP-1 knockout tMCAO induced mice had 
smaller infarct volume (57.8 ± 8.9 mm3) (Figure 6.7 B and 6.7 C) than wild type 
tMCAO induced mice (128.9 ± 9.6 mm3) (Figure 6.7 A and 6.7 C). Motor function 
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1/RASSF1A/Bax pathway after MOAP-1 deletion (Figure 6.8). Induction of tMCAO 
increased TNF-α expression at 1 h after tMCAO however returned to normal when 
reperfusion was established at 3, 8 and 24 h (Figure 6.9 A and B). Up-regulation of 
MOAP-1, Trim39 and Bax level were similar to TNF-α elevation after stroke (Figure 
6.9 A, C, D and F). This indicated that MOAP-1, Trim39 and Bax expression were 
modulated by TNF-α. In contrast, RASSF-1A level was not increased significantly at 
1 h after occlusion but increased when reperfusion was established. Interestingly, in 
MOAP-1 KO animals when subjected to tMCAO, Trim-39 level up-regulated less 
significantly when compare to wild type animals (Figure 6.9 D). RASSF-1 expression 
in MOAP-1 KO animals were found drastically up-regulated and even higher than the 
elevation observed in wild type animals (Figure 6.9 E). The downstream candidate of 
MOAP-1/RASSF-1A/Bax apoptotic pathway, Bax was increased strikingly at 1 h 
tMCAO in wild type mice but not in MOAP-1 knockout mice (Figure 6.9F). The 
neuron expression of wild type tMCAO mice were reduced to 90% relative to normal 
control whereas MOAP-1 knockout mice neuron expression was only reduced to 30% 
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Figure 6.9. TNF-α, MOAP-1, Trim39, RASSF-1A, Bax and NeuN protein level 
after tMCAO in both wild type and MOAP-1 KO C57BL/6 mice cerebral cortex. 
(A). Representative Western blot images of MOAP-1, Trim39, RASSF-1A, Bax, 
NeuN expression in wild type or MOAP-1 KO ipsilateral cortical cortex in normal 
control (CN), sham operated (Sham), 1, 3 and 8 h after tMCAO. (C), (D), (E) and (F). 
Densitometry measurement of MOAP-1, Trim39, RASSF-1A and Bax in wild-type 
(closed bar) or MOAP-1 KO (open bar) ipsilateral cortical cortex of normal control 
(CN), 1, 3 and 8 h after tMCAO respectively. (B). TNF-α fold of change of tMCAO 
1, 3 and 8h normalized to normal control (CN) of wild type (closed bar) or MOAP-1 
KO (open bar) ipsilateral cortical cortex. (H). Densitometry measurement of NeuN 
expression in wild-type and MOAP-1 KO ipsilateral cortical cortex of normal control 
(CN), 1, 3 and 8 h after tMCAO. N = 3. ***p < 0.001, *p < 0.05, by one way 
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ANOVA compare to control, post hoc analysis by Bonferroni; #p < 0.05, ##p < 0.01, 
Independent t test. Error bars represent SEM. 
6.4. Discussion  
 MOAP-1 is an effector for Bax (Tan et al., 2005). Stimulation of TNF-R1 
facilitates the binding of MOAP-1 to RASSF-1A and thus causes the activation of 
Bax, subsequently to a series of caspase dependent apoptosis (Baksh et al., 2005; 
Foley et al., 2008; Tan et al., 2005). By far, MOAP-1 apoptotic functions were 
studied only in the in vitro artificially system while its physiological role remains 
unknown. It was previously reported that MOAP-1 was highly expressed in brain, 
heart and testis (Takaji et al., 2009). High expression in brain may suggest a role of 
MOAP-1 in regulating brain development or other functions. MOAP-1 was initially 
discovered consists of a BH (BH1, BH2, BH3) domain and subsequently paramount 
evidences about MOAP-1 role in apoptosis were reported. Using an animal stroke 
model, we aim to investigate the importance of MOAP-1 in the mechanism of cell 
death.  
 First, MOAP-1, RASSF1A, Trim39, TNF-R1 and Bax expression level 
were measured in wild-type C57BL/6 mice brain homogenates. The results 
demonstrated the regional distribution of these target proteins are mainly expressed in 
cerebral cortex. These results are consistent with the previous study done by Takaji 
and colleagues. Takaji found that MOAP-1 mRNA expressed highly in primary 
somatosensory area, temporal area, area 46, primary visual area, primary motor area 
and cerebellum of African green monkey (Takaji et al., 2009). Moreover, MOAP-1 
was highly expressed in cerebrum and cerebellum of adult mouse, rats and human 
brain (Takaji et al., 2009). Trim39 mRNA was previously detected ubiquitously 
distributed in all tissues in human notably mostly expressed in brain, heart kidney, 
liver, skeletal muscle, spleen and testis (Lee et al., 2009b). Again, consistent with the 
present results, Trim39 protein expression was found in mouse brain. The expression 
was found mainly in cerebral cortex and cerebellum. The expression of Trim39 
180 
 
correlates with MOAP-1 brain distribution indicated that Trim39 might possibly play 
an important role in regulating MOAP-1. Similar to MOAP-1, this implicated that 
Trim39 plays an important role in regulating MOAP-1. This provides crucial 
evidences of Trim39 protein expression in the mouse brain. However, the biological 
role of Trim39 in CNS remains uncertain.  
 Overexpression of MOAP-1 is unlikely to induce apoptosis in SH-SY5Y 
human neuroblastoma cells (Fu et al., 2007; Takaji et al., 2009). Takaji and 
colleagues reported that overexpression of MOAP-1 did not trigger apoptosis in 
Neuro2a mouse neuroblastoma cells (Baksh et al., 2005). Similar to the reported 
studies, we did not observe significant cell growth deficiency in the stable MOAP-1 
overexpressing SH-SY5Y cell line. An in vitro deprivation of oxygen and glucose in 
the cell based experiment, OGD has been commonly used as a tool to study potential 
drug candidate for stroke treatment (Endres et al., 2002). When primary cortical 
cultures were exposed to OGD, TACE/ADAM17 pathway will be stimulated and thus 
resulting in overproduction of TNF-α (Hurtado et al., 2002). TNF-α was known to 
involve in necrosis, regulation of caspase and apoptotic factors (Watters et al., 2011). 
These results demonstrated that MOAP-1 overexpressing SH-SH5Y neuroblastoma 
cell is more susceptible to OGD induced cell death (Figure 6.5). Results suggested 
that MOAP-1 enhanced cell death perhaps by modulating apoptotic pathway. Next, to 
study the role of MOAP-1 in depth, we created a MOAP-1 knockout mice. Primary 
cortical neuron was prepared for the following experiments because MOAP-1 
expression was found mainly in cerebral cortex (Figure 6.3) and selectively expressed 
in neuronal cells (Figure 6.4). When exposing the MOAP-1 KO primary cortical 
neuron or wild type primary cortical neuron to OGD treatment, MOAP-1 knockout 
primary cortical neurons were more resistant to OGD condition (Figure 6.5). 
Interestingly, we did not observe any phenotypic difference between wild type or 
MOAP-1 knockout primary cortical neuron. In addition, RASSF-1A, Trim39, Bax 
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and TNF-R1 level remain unchanged after MOAP-1 knockout (Figure 6.8). These 
evidences suggested that MOAP-1 deficit did not affect physiological functions 
distinctly.  
 MOAP-1 KO mice had smaller infarct volume after tMCAO induction 
when compared with wild type tMCAO mice (Figure 6.7). MOAP-1 KO tMCAO 
mice were found to have better neurological outcome than wild type tMCAO mice 
(Figure 6.7D). Consistent with primary cortical neuron research, deletion of MOAP-1 
gene was more resistant to cell death. This highlighted the role of MOAP-1 as a 
modulator of apoptosis and crucial in facilitating program cell death during ischemic 
injury.  
 Next, ipsilateral cortex from both wild type and MOAP-1 KO mice were 
extracted at 1, 3 and 8 h after tMCAO. Results demonstrated that an increase of TNF-
α, MOAP-1 and Trim39 were found in cerebral cortex after ischemic injury with 
similar pattern (Figure 6.9 B, C and D). TNF-α was increased significantly at 1 h after 
tMCAO but reduced back to normal at 3 and 8 h. MOAP-1 knockout did not reversed 
the effect of TNF-α after tMCAO model indicated that the upstream mechanism of 
MOAP-1/RASSF-1A/Bax did not change. We demonstrated that MOAP-1 and 
Trim39 protein level elevated in the wild type and knockout animals (for latter) at 1 h 
after tMCAO model (Figure 6.9 C and D). This provides in vivo evidence to support 
the previous in vitro observation that Trim39 stabilized MOAP-1 by inhibiting 
APC/Cdh1-mediated protein ubiquitylation of MOAP-1 for degradation (Huang et al., 
2012). Trim39 in MOAP-1 knockout mice was found significantly up-regulated after 
ischemic stroke. This further elaborated that the upstream pathway of MOAP-
1/RASSF-1A/Bax pathway was not disturbed after ischemic stroke. 
 Surprisingly, RASSF-1A level was not significantly increased at 1 h after 
tMCAO but at 3 and 8 h after tMCAO. Interestingly, RASSF-1A level was found 
markedly increased in MOAP-1 knockout tMCAO animals at 8 h after tMCAO. The 
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elevation of RASSF-1A in the late phase of tMCAO model at 3 and 8 h may not have 
direct effect on MOAP-1/RASSF-1A/Bax dependent apoptotic pathway. Instead, 
previous study has shown that RASSF-1A is an important regulatory element to 
restrict NF-κB activity (Gordon et al., 2013). Unrestricted NF-κB will significantly 
contribute to poor recovery in inflammatory induced injury (Gordon et al., 2013). 
Ischemic stroke was characterized by elevation of excitotoxicity, inflammatory 
responses, reactive oxygen species and apoptosis. Results indicated that MOAP-1 KO 
animals showed to have a significant elevation of RASSF-1A at 8 h tMCAO than 
wild type animals. Increase of RASSF-1A would restrict NF-κB activation which was 
observed during ischemic stroke injury. As a speculation, with higher RASSF-1A 
expression after ischemic stroke, MOAP-1 KO mice would have improved stroke 
outcome due to the enhance restriction of NF-κB activation. As expected, we could 
see the NeuN expression in MOAP-1 KO group was higher than wild-type group at 8 
h tMCAO (Figure 6.9F) suggested that RASSF-1A inhibit NF-κB activation thus 
resulted in improvement of stroke outcome.  
 Bax level was found elevated significantly after tMCAO at 1, 3 and 8 h. 
However, Bax level of MOAP-1 KO animals remained unchanged after tMCAO 
induction. These results suggested that knockout of MOAP-1 negatively regulated 
Bax elevation after tMCAO model. It is speculated that MOAP-1  function in 
regulating the elevation of Bax upon death stimuli. The mechanism of action how 
MOAP-1 regulates Bax translational expression remained to be investigated. MOAP-
1 mainly expressed in neuronal cells. Therefore,  measuring neuron level could 
support the neurodegenerative function of MOAP-1 upon ischemic attack. Results 
showed that neuron level of MOAP-1 knockout mice were significantly higher than 
wild type tMCAO mice at 8 h after tMCAO (Figure 6.9 G). This implicated that 
MOAP-1 facilitate neuron death after ischemic injury and removal of MOAP-1 
reversed the MOAP-1/RASSF-1A/Bax induced cell death.  
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In summary, at pathophysiological level, MOAP-1 plays an important role in 
modulating programmed cell death. Inhibiting MOAP-1 in an experimental stroke 
model, reversed stroke outcome. At molecular level, inhibiting MOAP-1 showed 
neuroprotective effect via the inhibition of apoptotic event, by inhibiting Bax/Bcl-2 
ratio elevation during stroke. Ideally, measurement of anti-apoptotic markers for 
stroke should be determined to confirm the importance of MOAP-1 dependent 
























Chapter 7: Concluding remarks and future prospects 
In this thesis, I have investigated the roles of several novel molecules in the 
pathogenesis of stroke.  
In Chapter 3, I have provided strong evidence that endogenously H2S 
production enhanced cell death under ischemic conditions. Moreover, H2S exerted 
opposite effects in rotenone or 6-OHDA and OGD induced cell death. This was 
proven as described in Chapter 3 that H2S functions as an electron donor in the 
mitochondrial electron transport chain. Therefore, the presence or absence of oxygen 
determined the role of H2S in exerting neuroprotective or neurotoxic function. The 
present results supported the idea that CBS is a viable therapeutic target and CBS 
inhibition may hold promise as a treatment of ischemic stroke. Next, a novel H2S 
inhibitor cystathionine analogue was developed and showed to bring beneficial 
outcome to animal stroke models. As such, current study explained the biology of the 
previous clinical observation that high cys is detrimental to ischemic stroke and H2S, 
which is the downstream metabolites of cys, is the culprit in worsening stroke 
outcome.  
In Chapter 4, I have demonstrated that andrographolide produced 
neuroprotective effects against cerebral ischemia with accompanying inhibition of 
microglia activation, possibly caused by the suppression of NF-kB activation, leading 
to a reduction in the production of cytokines and pro-inflammatory factors. These 
findings indicated that andrographolide or other andrographolide-like drugs are 
another viable therapeutic approach against acute ischemic stroke. Multiple clinical 
evidences showed that NF-κB activation was found in stroke patients samples, 
therefore targeting NF-kB in stroke can be a potential approach for stroke treatment. 
The present study provided direct evidences that andrographolide is a safe 
pharmacotherapy compound that can alleviate stroke outcome as tested in 
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experimental stroke animals. These contribute to future development of 
andrographolide as a potential neuroprotective compound for the treatment of stroke.  
In chapter 5, I presented evidence that the plasma LTB4 levels increased in 
stroke patients. More interestingly, the high LTB4 level correlated with stroke 
severity and clinical outcome (90 days) based on Modified Rankin Score (MRS). 
Furthermore, the results achieved from the small cohort of the clinical works were 
consistent with the results obtained from the rat thromboembolic stroke model. As 
such, the rat thromboembolic model could be used to study the underlying 
mechanism of LTB4 related pathway as this stroke model recapitulates the clinical 
stroke pathological process. Furthermore, inhibiting LTB4 production by selective 5-
LO inhibitor, LTA4 hydrolase  inhibitor, BLT1 and BLT2 receptor antagonists will be 
extremely interesting in the future pre-clinical trials using thromboembolic stroke 
animal model.   
Last, I presented evidences supporting the involvement of the MOAP-1 as a 
modulator in cell death pathway in stroke. Using genetically modified mice, MOAP-1 
was found neuroprotective via the inhibition of BAX elevation. The facilitation of 
apoptosis by MOAP-1 appears to involve in the formation of MOAP-1/RASSF-
1A/TNF-R1 complex. As MOAP-1 knockout mice are more resistant to ischemic 
stroke injury, this suggested that the activation of extrinsic apoptotic pathway 
triggered MOAP-1 dependent apoptosis is one of the important apoptotic pathways 
stimulated during the ischemic injury. It remains to be unravelled that the inhibition 
of the MOAP-1 pathway is feasible as a potential strategy for stroke treatment.  
In conclusion, I have found that by inhibiting CBS or H2S level thereby 
restored mitochondrial electron transport chain function, inhibiting NF-κB activation 
by andrographolide, inhibiting arachidonic acid pathway by selectively targeting 
LTB4 elevation and the deletion of MOAP-1 improved ischemic stroke outcome in 
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both in vitro cell based experiment and in vivo experimental animal stroke models 
(Figure 7.1).  
 
 
Figure 7.1. Summary of the thesis. My research study found that inhibiting 
mitochondrial proton gradients collapse, NF-κB activation, leukotriene pathway, a 
novel apoptotic pathway reversed stroke outcome in cell based study and 
experimental animal stroke models.    
 
  For future study,  selectively inhibition of CBS for instance using transgenic 
animals, by in vivo RNA interference (RNAi) approach or by highly selective 
pharmacological agent should be performed to confirm that the inhibition of CBS is 
beneficial to acute ischemic stroke. Moreover, the direct effect of andrographolide in 
brain was not determined in the study and this suggested that andrographolide could 
exert its neuroprotective effects through a completely different pathways. As such, 
locally injecting andrographolide in animal brain should be performed in the future. 
In Chapter 5, the correlation of CysLTs pathway to ischemic stroke patients outcome 
have not been studied yet. Future works should also focus on comparing the 
importance of LTB4 pathways and CysLTs pathway in ischemic stroke. For future 
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translational study, therapeutic window of the potential pharmacological compounds 
should be further examined. Animals with other co-morbidity (e.g. diabetesand 
hypertension) should be used to better resemble stroke patients. The combinary 
therapy by administration of a cocktail of multiple potential pharmacological 
compounds or with rtPA should be tested in animal study. This aims to exert the 
maximal effects of the pharmacological compounds as the potential ischemic stroke 
therapy. Finally yet importantly, the advanced multimodal imaging tools such as MRI 
should be used to probe the drug effects in the salvageable penumbra or as a tool to 
recruit stroke patients that match with the stroke pathogenesis of animal models for 
future pre-clinical study.  
 Overall, the current study provides deep understanding of several pathways in 
ischemic stroke pathophysiology, however it is still too speculative to conclude that 
such treatment could bring beneficial outcome to stroke clinically. It is envisaged that 
stroke treatment will one day adopt a multiple modality approach as more effective 
drugs targeting different pathways become available. Researchers are still hopeful 
that the future drugs will be developed soon by better revisits of strategies or an 
evolutionary approach that could change the completely pharmacological perspective 
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